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CHAPTER! 
INTRODUCTION 
Patients suffering from a certain disease generally differ greatly regarding the course 
of their disease. The identification of factors from which much of this variability 
between patients can be explained may be of great importance. The study of such pro-
gnostic factors in clinical medicine is usually done for a variety of reasons which to 
some extent may overlap each other. One of the reasons may be to better understand 
how the disease is likely to behave. It is hardly ever possible nowadays to study the 
pure natural history of a disease because usually some form of treatment will have 
been undertaken. The treatment often will be curative in intent, but may also be 
directed towards the relief of symptoms or avoiding or delaying these in case no 
curative treatment is available. It is known from their natural history that certain 
illnesses do not require treatment at all because they are self-limited processes. 
Knowledge about prognostic factors in such cases will make it possible to provide 
information to the patient about the probable duration and course of the disease. 
Knowledge of factors which are related to the outcome of disease may be helpful to 
physicians in understanding the mechanism of the disease. Such better understanding 
may assist in modifying treatment protocols, searching for new treatments or fonnula-
ting strategies for the optimal use of expensive medical tests. Sometimes knowledge 
of prognostic factors may be of use to alter the course of disease by remedial action. 
This will particularly be so if these factors are elements of lifestyle such as diet, 
exercise or habits. For instance, patients with alcoholic liver cirrhosis who stop taking 
alcohol appear to have a better prognosis regarding survival as compared to those 
who continue drinking alcohol [Borowsky et ai, 1981]. Such scientifically based facts 
may be helpful in encouraging patients to change their drinking habits. 
Knowledge of prognostic factors often will be of importance in planning therapeutic 
trials. It may be desirable to evaluate certain therapies only in patients who belong to 
certain prognostic categories. Also the number of patients required in a randomized 
clinical trial depends on the distribution of prognostic factors among patients to be 
included in the study. 
A fundamental dictum of all scientific experimentation is that in analysing experiments 
one has to account for all known factors which may influence the results. To adhere to 
this principle in randomized clinical trials it is usual to stratify on a few important 
prognostic factors, particularly if the size of trial is relatively small. This will guarantee 
that the treatment groups will be comparable regarding these factors. In the phase of 
analysis additional other factors may be taken into account to obtain more precise 
estimates of the treatment effects. Non-randomized studies to compare interventions, 
e.g. studies with historical control groups, can be of value only when all major 
prognostic factors are known and taken into account at analysis [Armitage & Gehan, 
1974]. In analysing such studies it is essential that comparisons are made within groups 
of patients who are comparable with respect to such factors. Nevertheless, great care 
is still needed in the interpretation of the outcomes of such studies [Byar, 1980]. In 
this respect it is worth mentioning that the use of statistical tests to assess the 
comparability of groups is improper [Dales and Ury, 1978]. Large imbalances in 
unimportant variables will not matter much in studies using historical controls, but 
even small imbalances in important ones may severely bias treatment comparisons. 
Although in randomized studies the distribution of prognostic factors will tend to be 
equal in the various randomized groups, it is nevertheless of great value to take 
account of them in the analysis. The treatment effects will be estimated with much 
greater precision if the various known sources of variation are adequately taken 
account of in the analysis. In the last decades, sophisticated and powerful statistical 
models have been developed which deal with this issue. 
A major challenge in analyzing clinical studies is to recognize the possibility that some 
patient subgroups may benefit more from a certain treatment than others. However, 
searching for such so-called treatment-factor interactions raises great statistical pro-
blems though. Because of the usually large number of ways the patients studied can 
be divided into subgroups, it is likely that by chance alone some apparent treatment-
factor interactions will arise. Special caution is required in drawing conclusions from 
such findings [Peto et aI, 1976]. The general solution to this problem is to limit the 
special comparisons to only a few prespecified subgroups. 
There are many kinds of prognostic factors depending on the type of the disease 
studied. In the field of cancer Byar (1983) classified these into three categories: 
hostfactors (e.g. age, comorbidity), tumour characteristics (e.g. histopathological 
parameters, extent of surgical removal of the tumour), and effects of the tumour on 
the host (e.g. weightloss, performance status). 
For a variety of diseases there are formal disease classification systems which are 
strongly related to prognosis. Well known systems for instance are the TNM-clas-
sification for cancer patients [UICC, 1992], the Child-Pugh classification for liver 
disease [Conn, 1981] and the APACHE-score [Knaus et aI, 1986] for use in intensive 
care medicine. 
The TNM-classification system is a system based upon experts opinions and is based 
on three separate entities: the anatomical extent of the primary tumor (T), the 
condition of the regional Iympnodes (N) and the presence/absence of metastases(M). 
Combinations of these three components lead to a prognostic stage grouping of the 
cancer concerned. 
The Child-Pugh score is based upon clinical experience and involves three biochemi-
cal variables (serum bilirubin and albumin level, and prothrombin time) and the two 
clinical characteristics absence/presence of ascites and encephalopathy. Each of these 
variabeles is given one to three points, leading to a total score with a minimum of 5 
and a maximum of 15 points, with the latter indicating a very bad liver function and 
poor prognosis. Although originally utilized to predict prognosis after surgical 
treatment [Pugh et aI, 1973], the classification has proven to be useful for patients 
with liver cirrhosis in general. 
The Apache-score combines many variables, mostly physiological, by attaching a 
weight to each of the separate items. The score, when evaluated at entry into the 
intensive care unit, is capable of providing probabilities of dying on the intensive care 
unit. The weights of the various features in this prognostic index have been derived 
using multiple logistic regression [Cox, 1970]. 
The description of the patterns of events, e.g. relapse or death, along time under 
specified conditions, and the relation thereof with various factors such as manifestati-
ons of disease, characteristics of the patients or interventions, is a major goal in many 
clinical studies. The question of prognosis need not solely be asked at the time of 
diagnosis. Also an update of prognosis during follow-up on the basis of the latest 
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observations on patients will be valuable. Prognostic estimates are expected to be 
most accurate when based on a careful analysis of data of sufficient good quality. 
When clinical data have been gathered rigorously, preferably in a prospective manner, 
adequate statistical methods are required to derive optimal estimates of patient outco-
mes. The statistical aspects of the identification and evaluation of prognostic factors is 
the subject of the present thesis. 
In the following chapters frequent use is made of the terms death and failure to 
denote the event determining prognosis. The methods described, however, will equally 
be useful in case the event considered is favourable, e.g. the achievement of remission 
of disease. 
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CHAPTER 2 
EVENT HISTORY ANALYSIS 
The prognosis of an individual patient can be characterized by whether or not a 
properly defined event of interest will occur, e.g. death, and the time it takes to do so. 
Unfortunately, any prognostic statement about individual patients will nearly always be 
imprecise and, usually large, uncertainties will remain. Practice demonstrates that 
predictions of future events can only be made in probabilistic terms in the vast 
majority of cases. In this chapter statistical methods are reviewed to evaluate patient 
characteristics regarding their ability to reduce probabilistic uncertainties in estimating 
prognosis. 
1. Characterisation of event occurrence. 
If for an individual patient from some population, T denotes the time until the 
occurrence of the event, e.g. death, measured from some time "zero", there arc several 
ways to describe the pattern of events along time for the population. Time "zero" is 
defined as the time corresponding to the entrance into the population, e.g. diagnosis, 
initiation of treatment, the timepoint at which remission of disease was established, 
etcetera. Time "zero" (t=O) marks the point in time from which prognosis is to be 
made. A descriptor of the pattern of events along time in a population which is most 
often used is the "survival function" S(t). This function denotes at each time point t 
the fraction of the patients in the population which did not experience the event at or 
before that time. Expressed in another way, it gives for an arbitrary subject in the 
population the probability that T exceeds t, i.e. 
S(t) = Pr(T>I} (l.l) 
Another measure, which in practice is seldom used and mainly serves in theoretical 
developments, is the probability density function f(t), which is defined as: 
j(t) = _ d S(t) 
dt 
(1.2) 
The quantity f(t)dt indicates the unconditional probability for the event to occur 
within the small interval (t,t+dt). A third measure to characterize the pattern of 
events along time is the hazard rate function )..(t). This measure, depending on the 
definition of the event, is also called failure rate, death rate or incidence rate. The 
hazard rate function is defined as: 
).(t) d S(t)/dt 
S(t) 
(1.3) 
)..(t) can be interpreted as a conditional probability density function of failure: )..(t)dt 
gives the probability of the event to occur in the small interval (t,t+dt) among those 
patients still at risk for the event at time t. The hazard rate function in many cases is 
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more informative than either the probability density function f(1) or the survival 
function S(I). 
There are a number of relations between MI), f(1) and S(I), 
because either one of them determines the other two: 
100=M (I.~ 
S(I) 
and 
1(1) = -d log S(I)/dl 
in which log denotes the natural logarithm, 
and 
S(I) =e -A(f) 
in which i\(1) denotes the cumulative hazard nA(t)dt. 
(1.5) 
(1.6) 
As 1.(1) represents the rate of failure among that part of the population still at risk for 
the event at time t, it is better capable of describing the intensity of the failure 
process at time t as compared to the survival function S(I). In some cases it is possible 
on biological grounds to predict whether the hazard rate will be increasing or 
decreasing along time. For instance, in the period shortly after a surgical hernia repair 
one might expect that the instantaneous recurrence rate will decrease due to healing 
and strengthening of tissues. After some time, when the patients resume their daily 
activities, possibly including hard labour, a rise of the relapse rate may be anticipated. 
The survivor function S(I) is related to 1.(1) only through its cumulative function i\(1) 
(see 1.6). As is evident from relation (1.5), however, much of the information about 
1.(1) can be read from graphing the survival function S(I) on a logarithmic scale. If the 
slope of the curve thus obtained increases along some time interval of the time axis, 
the instantaneous failure rate A(t) will also increase during the same interval. An 
interval on which the slope of the logarithmically transformed survival function does 
not change, i.e. log 8(t) is a linear function of t, indicates a hazard rate function which 
is constant within the interval. This device of plotting survival functions on a loga-
rithmic scale is especially appropriate for comparing two or more groups. If the curves 
thus obtained run parallel on some interval on the time axis, one can conclude that 
the failure rates within that interval do not differ between the groups. In figure 1 this 
is demonstrated for two arbitrary populations by showing hypothetical failure rates 
and their corresponding survival functions. It is clear from the figure that an increa-
sing or decreasing failure rate can be more easily recognized in the logarithmically 
transfonned survival function as compared to its linear representation. 
Another more fundamemal advantage in using the failure rate function A(t) in 
describing the pattern of events along time holds when the population of interest 
exists only a limited period of time, with the length of the period possibly differing 
from individual to individual. As an example one may consider a study of the 
occurrence of the Sleep Deprivation Syndrome (Schwab, 1994) in patients admitted to 
an intensive care unit. At the time of discharge from the unit, the patient leaves the 
population and can not be considered to be at risk anymore. Other examples are 
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Figure 1. Two hypothetical failure rates (panel A) and their corresponding survivor 
functions (panel B: linear vertical axis, panel C: logarithmically transformed vertical 
axis). 
studies of the occurrence of some viral infection during dialysis while patients are 
waltmg for a kidney transplant or patients getting bedsores as long as they are 
bedridden. In these cases patients can be considered to leave the population at the 
time when the high-risk period ceases. In these circumstances the failure rate function 
has a clear interpretation and discribes the probability function of failure at time t 
among those patients still belonging to the population of interest at that time. No such 
clear interpretation is possible for the function S(t)= exp(-A(t)). It should especially be 
noted that its complement I-S(t) under these circumstances can not be considered to 
quantify the risk of the event to occur before time t while belonging to the population. 
If the latter probability is needed, it has to be calculated according to the formula: 
I: !.(T)G(T)dT (1.7) 
Here G(T) denotes the probability of being at risk for the event at time T, i.e. the 
probability of population membership at time T without having experienced the event 
of interest before. Equation (1.7) is used in chapter 5 to assess the lifetime risk of 
recurrent dysphagia in patients operated for oesophageal carcinoma. 
2. Parametric survival functions 
In the previous section survival distributions were considered in a general framework. 
Practical applications may require selection of a particular statistical model. Some 
often used survival functions are shown in table 1. Each of them is characterized by 
one or more parameters defining the survival distribution within its class. 
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Table 1. Some well-known survival functions Set) and corresponding hazard rate 
functions A(t) 
Distribution Set) A(t) 
Negative exponential exp(-at) a 
Weibull exp(-(at) ') a8(at)'-1 
Gompertz exp«a/8)(I-e ")) ae 61 
Rayleigh exp(-at-V,8t2) a+8t 
Log-logistic 1/(1 + (ta) ') MB-1a'/(1 + (ta)') 
Other important distributiol15 are the lognormal distribution and the gamma-distribu-
tion. Both these distributions are not included in the table because they do not have a 
closed form expression. 
The negative exponential distribution, which is characterized by a constant hazard 
rate, was used by Zelen (1966) in a study of survival times in an animal leukemia 
model. A remarkable feature of the negative exponential failure time distribution is its 
"lack of memory". If this distribution applies, the future lifetime of an individual does 
not depend on the lifetime already achieved. If the constant hazard rate is denoted by 
a, the mean and median lifetime are lIa and log(2)/a, respectively . The negative 
exponential function Set) reduces to a straight line when plotted on a logaritlunic 
scale. Metcalf (1974) has shown by extensive examples that for patients with various 
types of cancer, when survival is studied in patient groups that are relatively homo-
geneous with regard to prognosis, the survival data can often fairly well be described 
by the negative exponential distribution. 
The Weibull distribution is determined by two parameters, a and 8. Because 8 
determines the shape of the hazard function, it is referred to as the shape parameter. 
The parameter a generally is called the scale parameter. The hazard rate increases 
with time when the shape parameter 8 is greater than I, and decreases when 8 is less 
than 1. The Weibull distribution reduces to the negative exponentional distribution in 
case 8 equals one. The Weibull model was used by Peto et al (1972) to analyze 
carcinogenesis experiments. 
The Gompertz distribution is often used to model mortality from natural causes in old 
age. Albertsen et al (1995) used this distribution to model expected survival in 
prostate cancer patients. The Rayleigh distribution, also called the linear exponential 
distribution, is an extension of the negative exponential distribution. It is characterized 
by a linearly increasing or decreasing hazard rate. The model was used by Carbone et 
al (1967) in the study of survival of myeloma patients. 
The log-logistic distribution is the only distribution of those given in Table 1 whose 
hazard function does not necessarily monotonically increase or decrease along time. 
The hazard function ,-(t) has a single maximum for values of 8 greater than I, while it 
is monotonically decreasing along time if 8 < 1. The log-logistic distribution was used 
by Pocock et al (1982) to model mortality for patients with breast cancer. 
The lognormal distribution applies when the logaritlun of the survival time follows a 
normal distribution. The associated hazard function is initially increasing with time to 
a maximum, and is decreasing thereafter. Feinleib and MacMahon (1960) used the 
lognormal distribution for the discription of survival of patients with chronic lympho-
cytic leukemia. 
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Cox and Oakes (1984) showed that the negative exponentional, Weibull, gamma, 
lognomlal and log-logistic distributions can all be put in the framework of the single 
parametric family of the generalized F-distribution. This property may be of use in 
discriminating between various candidate distributions in applications. 
Other less used parametric survival distributions are discussed by Gross and Clark 
(1975) and Lee (1980). 
All the failure time models described above are of the "proper" type, i.e. the survival 
function approaches zero for increasing values of t. This means that all members of 
the population ultimately will experience the event of interest. However, in many 
cases this will not apply. The distributions described so far may be useful in such 
applications if not the whole time-axis is to be considered, but only the first part of it. 
Alternatively, the models can be adapted to situations in which only a fraction of the 
population is due to experience the event ultimately. This leads to a characterization 
of the population through a mixture of distributions. An (unspecified) fraction of the 
population will not experience the event of interest, while for the remaining group a 
particular distribution of times until the event is assumed to apply. Boag (1949) used 
this approach in investigating cure rates of cancer patients using a lognormal distribu-
tion of survival times for non-cured patients. Farewell et al (1977) estimated the 
lifetime risk of developing breast cancer and assumed that in those patients develo-
ping the disease the age distribution followed a Weibull distribution. 
If a population can be considered to be a mixture of populations, while each subpo-
pulation can be characterized by its own hazard function, the hazard function for the 
population as a whole can be obtained. For instance, if a population is a mixed 
population with a fraction p of cases having a constant hazard rate A,. If the remai-
ning subpopulation has a constant hazard rate 1." then it is easy to show that the 
resulting hazard rate for the whole population can be written as 
(pA,exp( -A, t) + (l-p )1.,exp( -1.,0 )/(p exp( -A,t) + (l-p )exp( -1.,0). 
This function will be a decreasing function with advancing time t, and after sufficient 
time the function will approach a constant level. This level will equal the smallest of 
the two values A, and 1.,. This is shown in figure 2 where the hazard rate function is 
shown for a mixed popUlation for some arbitrary chosen parameters p, A, and 1.,. The 
decreasing hazard rate for the mixture can be explained by selection: the cases with 
the highest hazard rate will leave the population at a high rate, and ultimately only 
the group remains with the lowest hazard rate. This example demonstrates that an 
observed decreasing failure rate for a population is not necessarily due to an intra-
patient decreasing activity along time of the biological mechanism which leads to 
failure. It may even be that each individual's relapse rate increases along time, but 
that the heterogeneity among individuals is great enough so that the relapse rate of 
the population as a whole appears to decrease. If one would inappropriately assume 
that the popUlation is homogeneous in such instances, conclusions may be obtained 
which are wrong quantitatively as well as qualitatively. If interest focusses on the 
behaviour of the hazard rate along time, it is imperative to take account of prognostic 
factors which determine any heterogeneities. 
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Figure 2. Hazard rate function for a mixed population. The fraction of cases with 
hazard rate Al = 1 is denoted by p; the hazard rate of the remaining subpopulation 
equals A,=2. 
3. Estimation of parametric survival distributions 
Due to time limitations or for other reasons in clinical studies, the full time period 
until the event of interest will often not be available for some patients at the time of 
analysis. For such patients the event did not occur during the period they were on 
study, and the actual failure time is (right) censored. Such censored event times occur 
particularly in clinical trials in which analysis starts relatively soon aner entry into the 
study of the last patient. 
Another source of such incomplete follow-up data is caused by patients who drop out 
of the study after varying periods of time and who therefore are no longer available 
for further follow-up. It may also happen that some patients still participate in the 
follow-up regarding clinical aspects, but are no longer available, possibly due to 
refusal, to perform the tests which are necessary to assess whether the event of 
interest occurs. It is obvious that such sources of incomplete observations are potenti-
ally hazardous with regard to correct interpretation of results. Their presence may 
lead to biased results in case the mechanism of censoring is in some way related to 
the probability of experiencing the event thereafter. To perform a meaningful survival 
analysis in case of such incomplete data, it is required that the censoring mechanism is 
non-informative, meaning that at all times t the patients still under observation can be 
regarded as a representative sample of the patients in the population about which 
inferences are to be made. 
If this condition applies, the likelihood L of the sample with n, failures and n, 
censored lifetimes with total sample size n=n, +n" can be written as the product of 
the probability density functions for patients having experienced the event, and the 
survival probabilities for patients whose lifetimes were censored. If 0, is an indicator 
which equals 1 in case the lifetime ~ for the i-th patient was actually observed, and 
equals 0 in case that lifetime was censored, the likelihood L becomes 
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" 
L = IIro,)" S(d -', (3.1) 
1",1 
which can also be written as 
L = II }(t,m S(lj) (3.2) 
u , 
Here the products nu and n, denote the products over the uncensored and censored 
lifetimes respectively. Another way of writing the likelihood is 
" L= II ACt,) II S(t) 
u 1",1 
(3.3) 
in which the second product concerns all patients in the study. irrespective of whether 
they had died or not. If the parametric distribution of lifetimes is characterized by a 
vector Jl consisting of p elements whose values are to be estimated, an estimate J1 can 
be obtained by maximizing the likelihood function L. Equivalently. the maximum of 
the logarithm of the likelihood function can be deternlined. The latter function can be 
written as 
" 
log L(P)= L log W,.P)+ L log S(t,.P) (3.4) 
u i"l 
Finding il such that L(fi) reaches its maximal value is equivalent to finding the solution 
il of the p likelihood equations 
alogL(JJ) =0 
ap 
(3.5) 
Unfortunately. this equation can generally not be solved analytically. An explicit 
estimate of II is not available in those cases and an iterative procedure is required to 
estimate the beta-parameters. The mostly used iterative method is the Newton-
Raphson procedure: starting from an initial guess il'. after each cycle the updated 
estimate of II is obtained from: 
pl" =p/_[ a'logL(P')]-' alogL(p/) 
ap' ap 
(3.6) 
Iteration stops when the difference between the estimate of 8 and its updated version 
differs less than some prespecified limit. Using the Newton-Raphson method one also 
obtains an estimate of the covariance matrix of the estimate il from the inverse of the 
sample information matrix. which is given by 
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_[a'logL(P)] 
ap' 
(3.7) 
The estimator of II can be treated as approximately multivariately normally distributed 
with mean value II and covariance matrix equalling the inverse of (3.7). Standard 
errors of the components of Ii are obtained by taking the square root of the diagonal 
elements of the estimated covariance matrix. 
In case the lifetimes follow a negative exponential distribution with the constant 
hazard rate 'J.., an analytic solution for Ii is obtained. If one reparametrizes 'J.. to e', the 
loglikelihood function (3.4) can simply be written as 
log L(fJ) = fJd-eP'£t, (3.8) 
in which d represents the number of observed failures. Substitution in the likelihood 
equation (3.5) leads to the estimate of the hazard rate e'=d/Et,. From (3.7) it then 
follows that the standard error of Ii equals IIVd. Two-sided (l-a)·confidence limits for 
'J.. are obtained from 
(3.9) 
Here Zp denotes the 100pfu percentile from the standard normal distribution. 
The reparametrisation used has the advantage that the estimator of II approaches a 
normal distribution more rapidly than the estimator of 'J.. itself due to the restriction to 
positive values for A. 
The confidence limits (3.9) are approximate and are derived from asymptotic normali-
ty properties. Exact confidence limits are available in cases where there is no censo-
ring or censoring is of the kind which is so·called Type II [Miller, 1981]. Type II 
censoring occurs for instance in experiments with animals which are put on test 
simultaneously and testing is stopped after a prespecified number of animals have 
developed the event of interest. 
For purposes of illustration of the foregoing, survival data of 174 patients operated for 
kidney cancer are used here (these data are more fully discussed in chapter 3). 
Assuming an exponential survival distribution, the (constant) death rate was estimated 
to be 0.011 deaths/month, which value corresponds to a mean survival time of 90 
months. It appeared however that the assumed negative exponential model did not fit 
the survival data very well. In comparing the estimated survival curve arising from the 
assumed negative exponential model with the observed survivor curve which can be 
obtained without making any assumptions about the parametric form (to be discussed 
in section 5 below), both curves do not seem to agree very well. This is shown in 
figure 3. 
In fitting the Weibull model to the data, it appeared that the hazard rate decreased 
along time as shown by the shape parameter 6=0.75, which is significantly smaller 
than 1 (p<O.OI; likelihood-ratio test). However, this finding does not imply that the 
risk of dying for individual patients decreases along time. As will be shown in chapter 
3, the patient group appears to be rather heterogeneous with respect to various 
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Figure 3. Estimed survival curve assuming a negative exponential survival function 
(curve A) and non-parametric estimate (Kaplan-Meier estimate: curve B). 
important prognostic factors. For patients with a similar prognosis it is demonstrated 
in section 8 that the hazard rate is rather constant along time. The decreasing hazard 
rate for the group as a whole should be explained by the selection mechanism already 
described. High risk patients die relatively soon whereas patients with lower risk 
remain in the cohort. 
4. Testing a known distribution against sample data. 
Sometimes there is knowledge about a specific survival distribution So(t) , possibly 
derived from the Iitterature, and one may need to test obtained survival data against 
that specified survival distribution. A test which focuses on the maximal distance 
between the non-parametric survival curve and the postulated curve, is available 
[Koziol, 1980]. A more powerful test is obtained if testing occurs against special 
alternatives. If it is assumed that the hazard function describing the data can be 
written as A(t)=e'A,(t), where the hazard rate function A,(t) corresponds to the 
survivor function So(t) , then it follows, from equation (1.6) that S(t) follows the so-
called Lehmann-alternative: S(t)=S,(t)'. [Lehmann, 1953] The loglikelihood (3.4) can 
then be written as 
(4.1) 
Here 1: denotes the sum over all patients in the study. Maximizing this likelihood gives 
e'=d/1:A ,(t,). The score test for testing 6=0 is based on the ratio of the first and the 
negative of the second derivative of the loglikelihood function, both evaluated at 6 =0 
[Cox and Hinkley, 1974]. This leads to the so-called one-sample logrank test statistic 
[Harrington and Fleming, 1980]: 
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T= _d-=E=A:::::,G=-t,) 
J EA.(O (4.2) 
which follows approximately the standard normal distribution. 
If A,(I) is allowed to differ between individuals, for instance in comparing observed 
survival of a patient group with expected survival according to vital statistics of a 
group matched for age and sex from the national population, then the estimate of e" 
represents the standardized mortality rate [Breslow and Day, 1987]. 
5. Nonparametric estimates of survival distribution 
In cases where there is insufficient information about the parametric form of the 
survival distribution, the estimator of S(t) which is generally used, is the Kaplan-Meier 
estimator. This estimator is also called the product-limit estimator [Kaplan and Meier, 
1958]. If among the n patients studied there are k different observed ordered failure 
times t, < t, < ... < t, and at each timepoint ti (i = i, ... ,k)there are ri patients still at risk 
(Le. they all have an observation period of at least til, of whom the number of patients 
who died is given by m" the Kaplan-Meier estimate of the proportion surviving t is 
given by 
(5.1) 
Here the product runs over all observed failure times t, up to t. If the largest observa-
tion time corresponds to a censored value, the estimator of the survival function is not 
defined beyond that time. The estimate is a step function with constant levels between 
the observed failure times and jumps at the recorded failure times. The Kaplan-Meier 
estimator is asymptotically unbiased and approaches a normal distribution [Breslow 
and Crowley, 1974]. The estimated variance of S(I) is given by 
(5.2) 
and is conunonly referred to as Greenwood's formula (1929). 
For the purpose of confidence interval construction it is to be preferred [Kalbfleisch 
and Prentice, 1980] to base that interval on the asymptotic variance of 10g(-log(S(t», 
which reads 
(5.3) 
Apart from the improved adequacy of the normal approximation, using this variance 
estimate will avoid impossible values for the confidence limits outside the range [0,1]. 
Alternative confidence limits have been proposed by Thomas and Gruokemeyer 
(1975). 
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Brookmeyer and Crowley (1982) have described a very simple graphical device to 
determine confidence limits for the median survival time. The lower limit corresponds 
to the smallest value of t at which the confidence interval for S(t) includes the 50% 
survival probability. The upper limit corresponds to the smallest value of t greater 
than the median for which the confidence interval for S(t) fails to include the 50% 
probability. Gill (1980) has developed confidence bands for the whole survival 
function on some fixed interval [O,tJ. 
An alternative estimator of the survival function is Nelson's estimator (Nelson, 1969). 
This estimator is given by 
8(1)= exp{-A(I)} (5.4) 
in which the estimator of the cumulative hazard rate is given by the step function 
(5.5) 
There will be no large differences between the Kaplan-Meier estimate and Nelson's 
estimate if the number of deaths at each time point is relatively small in comparison 
with the numbers at risk. The minor difference between the two estimators of survival 
for the kidney cancer survival data already discussed, is shown in figure 4. The solid 
line denotes the Kaplan-Meier curve, while the dotted line is corresponding to Nel-
son's estimate. Both estimates are hardly distinghuisable; they differ at most 0.4%. 
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Figure 4. Kaplan-Meier (solid curve) and Nelson (dotted curve) estimates of survival 
for operated renal cell carcinoma patients. 
6. Comparisons of survival curves 
In comparing failure time data between two or more groups, various powerful 
distribution-free test statistics are available. A test statistic which considers the 
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maximum difference between two survival curves has been described [Fleming et al. 
1980]. The two tests mostly used. however. are the logrank test and a generalized Wil-
coxon test. 
In the following the logrank test and a generalized Wilcoxon test are described for the 
comparison of two groups. Extension to a comparison of more than two groups. 
including a test for trend in case of ordered alternatives. is straightforward [Thomas et 
al. 1977]. 
If in the two groups (A and B) combined there are k different observed failure times. 
these can be denoted by t, <t,< ... <t,. 
mlA denotes the number of events observed. and rIA denotes the number of patients at 
risk at time t, (i=I ..... k)in group A. Further. m, and r, (i=I ..... k)denote the respective 
numbers in both groups combined. The logrank test and the generalized Wilcoxon test 
can both be written as 
k 
T" LIV,(III,.. -1II,r ,../r,) 
1=1 
(6.1) 
T represents a weighted sum of the differences between the observed number of 
deaths in sample A and the conditionally expected number under the hypothesis of 
equal survivorship. 
If this hypothesis holds. the variance of T is a weighted sum of hypergeometric 
variances, which can be written as 
(6.2) 
In this formula riB denotes the number of patients at risk for the event at time point t, 
in group B. 
The test statistic TN"' follows approximately a standard normal distribution. 
By taking weights w,= 1 for all i. the logrank test is obtained. If the weights are taken 
to be 
IV,= IH(rj -lIIj + 1)/(rj + I)} }"1 
(6.3) 
a generalized Wilcoxon test is obtained [Prentice and Marek. 1979]. The weights (6.3) 
correspond closely to the value of the single Kaplan-Meier survival curve at t, when 
both groups are combined. 
The logrank test is demonstrated [Mantel. 1966] to be an adaptation of the Mantel-
Haenszel procedure [Mantel and Haenszel. 1959] for censored survival data. The 
logrank test is most powerful in cases where the hazard rate functions in the various 
groups are proportional to each other [Peto. 1972]. When there are no censored 
lifetimes. the generalized Wilcoxon test reduces to the well-known Wilcoxon rank-sum 
test. Small-sample properties of the logrank-test and generalized Wilcoxon test have 
been investigated by Keller and Chmelevsky (\983). 
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7. Parametric survival time regression models 
For a heterogeneous sample of patients, of which the heterogeneity can be expressed 
by a number p of covariates Zl!~'''' ,Zp, it is needed to assess the relation between 
these covariates and the time to the occurrence of the event of interest. 
One of the earliest models used, although only for uncensored survival data and one 
covariate z" was the negative exponential model [Feigl and Zelen, 1965]. The relation 
between the expected survival time and the covariate was expressed as a linear model: 
(7.1) 
Using the method of maximum likelihood the parameters 90 and fi, can be estimated 
from the data. Zippin and Armitage (1966) described procedures to follow for this 
linear model in case censored event times were present. The multiple linear model, 
I.e. allowing for more than one covariate in (7.1), was discussed by Mantel and Myers 
(1971). Alternative models for the univariate case suggested by Feigl and Zelen (1969) 
were 
(7.2) 
and 
(7.3) 
Models (7.2) and (7.3) can also be interpreted as models in which the hazard rate is 
associated with z, in terms of linear and log linear functions of z,. Both models (7.1) 
and (7.2) suffer from the disadvantage that, unless precautions are taken in the 
procedure when estimating the parameters, non-permissible negative estimated values 
for the mean lifetime may occur at extreme values of z,. This can not happen with 
model (7.3). 
The multiple version of model (7.1), allowing for various covariates, was used to 
evaluate survival in prostatic cancer patients [Byar et ai, 1974]. As already noted, 
model (7.3) allowing for multiple covariates, can be written as: 
(7.4) 
In this fannula z denotes a column vector of p covariates and B denotes a roW vector 
of p associated regression coefficients. This model was used by Prentice (1973) in 
evaluating survival of lungcancer patients. Prentice (1973) also noted that a greater 
flexibility could be achieved if the constant term 90 in model (7.4) was allowed to 
depend on time. This leads to the Weibull model 
(7.5) 
Other functions of time for the leading term in model (7.5), for instance a polynomial 
of a certain degree [Taulbee, 1979], may be more appropriate. 
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An important property which models (7.4) and (7.5) share is that the covariates act 
multiplicatively on some "baseline" hazard function. This baseline hazard function 
corresponds to the hazard function of the patients whose covariate values all take the 
value zero. 
Another model which may be appropriate in applications is the linear lognormal 
model in which the expected value of the logarithm of the survival time is a linear 
function of the components of the covariate vector z: 
(7.6) 
Random deviations of 10g(T) from the expected value follow a normal distribution 
with mean zero and standard deviation 9,. 
Models (7.5) and (7.6) belong to a larger class of so-called accelerated failure time 
models [Kalbfleish and Prentice, 1980J. These can be characterized by the property 
that the covariates have a multiplicative effect on T in stead of a multiplicative effect 
on the hazard rate. If an independent censoring mechanism applies, the regression 
coefficients can be estimated by maximizing the likelihood of the observations. It is 
allowed that the censoring mechanism depends on z. What is required is that, condi-
tionally on z, the censoring is unrelated to the future risk of the event. 
If the sample size equals nand t, (i = 1, ... ,n) denotes the individual observation times 
and z, denotes the individual covariate vectors, the likelihood can be written as 
" , 
UP)" IIW,;z"fi) J S(t,;z,'!) 
i=1 
(7.7) 
Here 0, indicates that t, represents a complete failure time (0,= 1) or a censored one 
(0,=0). The vector II is taken to represent not only the regression coefficients asso· 
ciated with the various covariates, but the vector includes also other parameters 
indicating the chosen parametrisation such as 90 and 9, in model (7.5). 
Estimates of fl, as described before for the case without covariates, can be obtained by 
solution of the likelihood equations using the Newton·Raphson procedure. Variances 
and covariances can be obtained by using the inverse of the observed matrix of second 
partial derivatives of the loglikelihood function. These can be used for the constructi-
on of confidence limits for individual parameters or for functions thereof. For testing 
hypotheses about subsets of parameters in a multiple model, which may be useful in 
reducing the dimensionality of the model by eliminating variables which are of lesser 
importance considering the presence of other variables in the model, three commonly 
used tests are available: Wald's test, Rao's score test and the likelihood ratio test [Cox 
and Hinkley, 1974J. 
If II is written as (IIA , II.), in which II. denotes the vector of the subset of parameters 
for which the hypothesis 11.=0 applies, the Wald test is based on the estimate of II. of 
the full model including IIA and its estimated covariance matrix. For a single para-
meter Wald's test reduces to the ratio of the square of the estimate of II. and the 
square of the standard error of the estimate of II •. 
The score test is based on the value of the first derivative of the loglikelihood function 
and the observed information matrix, both evaluated at 11.=0. 
The likelihood ratio test evaluates the difference between the loglikelihood of the full 
model and the restricted model, Le. the model with 11.=0. 
17 
If the dimension of Jl. equals v, and the hypothesis Jl.=O is true, all three test 
statistics follow approximately a Chi-square distribution with number of degrees of 
freedom equalling v. All three test statistics are asymptotically equivalent. There is 
general agreement, however, that in moderately sized studies the likelihood-ratio test 
is to be preferred. 
Goodness of fit of a chosen parametric model can be graphically evaluated by using 
generalized residuals [Cox and Snell, 1969]. If Slt"z"il) denotes the estimated survival 
function based on the model for the i'" patient evaluated at tl , then, if the model is 
correct, the values S,(t"z"il) should approximately behave as an uniform distribution on 
the interval [0,1]. Therefore, the residuals -log S,(t"z"il), which equal the estimated 
cumulative hazards H,(t"z"il), should behave approximately as a sample from the 
negative exponential distribution with mean one. The residuals corresponding to 
censored survival times are themselves censored residuals. By calculating the Kaplan-
Meier curve of the residuals and plotting the curve on a logarithmic scale versus the 
residuals, approximately a straight line must emerge with a slope equal to -1 (an 
example is shown in figure 7 of the next section). In case of continuous covariates, the 
residuals can be plotted against the covariates. Here the expected remaining value of 
1 for the standard negative exponential distribution can be added to the residual in 
case the residual is a censored one. 
The evaluation of adequacy of fit for a particular model as a special case of a larger, 
more general, family of models is described by Farewell and Prentice (1977). 
8. Cox regression 
Since the use of hazard rates is basic in many applications and conceptually simple, 
the modeling of the hazard rate 1.(t;z) as a function of time and covariates seems 
attractive. Various parametric models already discussed were of this type. A disadvan-
tage of these parametric models, however, is that the functional relation with time has 
to be specified in detail lip to a few parameters which may be estimated. 
This disadvantage had led Cox (1972) to formulate the model: 
(8.1) 
The remarkable characteristic of this model is that I.o(t) is completely left unspecified. 
The model (8.1) is the one mostly used in practice. The term exp(zO) in the model, 
however, may occasionally need to be replaced by another function of z and O. 
Generally the model is referred to as the proportional hazards model, because the 
covariates affect the so-called reference hazard rate function 1.0(1) in a multiplicative 
manner. 
The fact that there is no need to specify the reference function 1.0(1) gives the model 
an extreme flexibility. With the introduction of partial likelihood [Cox, 1975] it 
became possible to estimate the p elements of the column vector of unknown 
regression coefficients B associated with the covariate vector z=(Zt,Z:2,,,,,zp)The partial 
likelihood function can be used in the same manner as ordinary likelihoods for 
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asymptotic inference on II. The method also allows for the estimation of the reference 
hazard rate function Ao(t). This function, also known as the baseline hazard rate 
function, can be thought to apply if all covariates take the value of zero. Using 
survival functions, the model can equivalently be expressed as 
S&;z) = SJ!)' ., (8.2) 
where So(t) denotes the reference survival function corresponding to the covariate 
vector 11= O. 
Suppose there are K patients who experienced the event, and these patients all had 
different event times t, < t, < ... < tK; for each t,(i = 1, ... ,K) the set of patients still under 
observation at time t, will be represented by R(t;). The partial likelihood can then be 
written as 
K 
L(Pl = fI{e~,PI E e'IP} (8.3) 
i=l jeR(tl) 
The product runs over the K event times and the term z(Q in the numerator denotes 
the covariate vector of the patient who experienced the event at time t;. Several 
generalisations of (8.3) have been proposed to accomodate tied failure times [Kalb-
fleisch and Prentice, 1980]. These resulting likelillOods, however, are rather complica-
ted. In practice therefore use is mostly made of an approximate likelihood [Breslow, 
1974]: 
(8.4) 
In this formula m; (i = 1, ... ,k) denotes the number of patients who died at time t;, 
while S(Q (i = 1 •... ,k) denotes the sum of the covariate values for these m; individuals. 
This approximate likelihood will suffice in case the fraction of tied failure times is not 
too large. If there are no tied failure times, likelihood (8.4) reduces to likelillOod 
(8.3). Maximizing the likelihood leads to the estimates of the elements of the un-
known parameter vector II. The available likelihood procedures give rise to straight-
forward significance test about elements of II and the calculation of approximate 
coufidence limits [Tsiatis, 1981]. Using simulation, small sample properties were 
examined by Johnson et al (1982). It is worth mentioning that, in case Z is a covariate 
vector denoting group membership, the score test of the hypothesis 11=0, leads to the 
well-known logrank test. 
To estimate Ao(t) , Breslow (1974) has proposed a step function which has a constant 
value between the different failure times. In the interval (t;." t;]. with to taken to be 
zero, his estimator takes the fonn: 
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(8.5) 
jER(tJ 
Smooth estimates of I,,(t) are described by Whitmore and Keller (1986) and Ramlau-
Hansen (1983). The cumulative reference hazard function Ao(t)=i.\Ao(t)dt may be 
estimated by 
A.(t)=Lm,1 L e'iP (8.6) 
t/~t jER(t~ 
A slightly different estimate of the cumulative reference hazard function is proposed 
by Link (1984). The estimate of the baseline survival function S,(t) can be obtained by 
exponentiating the negative of ",(t). If all elements of /I are zero, i.e. the covariates 
considered have no prognostic value, the cumulative hazard rate estimator reduces to 
the step function: 
(8.7) 
where r, (i = 1, ... ,k)denotes the number of patients at risk at t,. The corresponding 
survival function estimator equals the Nelson estimator (equation 5.4) in this case. 
For illustration, the data of the renal carcinoma patients (chapter 3) are used here. 
Among various factors evaluated, the most important factors which were found to be 
related to survival after operation were the gender of patients (z, = 1 if male, z, =0 if 
female) whether or not there was renal vein invasion at pathological examination 
(z,=1 if yes, z,=0 if no) and the level of the erythrocyte sedimentation rate (z,=ESR 
(mmlhr». The resulting prognostic model could be written as 
(8.8) 
in which the prognostic index PI equals 0.79 z, +0.89 z,+0.018 z,. Larger values of PI 
indicate a worse prognosis. The estimate of the reference hazard rate function I,,(t) 
based on this model is shown in figure 5. Apart from some random variation, the 
estimated reference function does not seem to vary systematically along time. Fitting 
the model again, but now with I,,(t) taken to be a constant (1,,), thus in fact fitting the 
negative exponentional model (7.4), the resulting estimate of I" equals 0.0017 
(95% confidence interval:0.0013·0.0022) deaths/month. Fitting of the negative 
exponentional model did not lead to appreciable changes with respect to the estimates 
of the regression coefficients or their standard errors. 
The prognostic index alone is not sufficient to assess the impact on survival probabi-
lities for individual patients. In addition to the value of the prognostic index, the 
estimated reference survival function using equation (8.2) is needed. Figure 6 shows 
estimated 5- and lO-years survival probabilities according to values of the prognostic 
index for the renal carcinoma patients. 
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Figure 5. Estimated death rate function for operated renal cell carcinoma patients 
whose prognostic Index PI equals O. 
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Figure 6. Five years (solid curve) and ten years (dotted curve) survival probabilities 
according to prognostic index PI. 
Confidence limits for the survival probabilities S(t;z) at some fixed time t have been 
derived by Andersen et al (1983). Confidence bands for the whole curve S(t;z) for 
some fixed z have been derived by Lin and Fleming (1991). It is not possible to derive 
confidence limits for curves such as shown in figure 6. This is due to the fact that 
standard errors of the estimated survival probabilities do not only depend on the value 
of the prognostic index, but also depend on the precise values of the covariables 
resulting in a particular value of the prognostic index [Altman and Anderson, 1986). 
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9. Goodness-of-fit for the proportional hazards model 
Tests for goodness-of-fit are described by Schoenfeld (1980) and Andersen (1982). 
Because of their omnibus character these tests are not very powerful and are therefo-
re seldom used. Better suited are tests which are sensitive to particular aspects 
thought to be important. One such aspect is the stability of the resulting regression 
coefficients when the model is fitted to different intervals of the time-axis. By using 
IikelillOod ratio tests the significance of differences in outcomes between the various 
intervals can be assessed easily. Score-tests to be used with such a-priori determined 
intervals have been described by O'Quigley and Pessione (1989). Any relation 
between the values of II and time can also be investigated by introducing additional 
tenns in the model which are the product of one or more components of the covariate 
vector z and functions of time itself. This way smooth changes along time of the effect 
of covariates can be assessed [Cox, 1972]. 
Graphical procedures to evaluate various aspects of fit are also very useful. One such 
method is to stratify the patient group according to some covariate values. The basic 
model (equation 8.1 above) can be extended by allowing the reference hazard functi-
ons for these strata to differ from each other. If the covariates used in the fonnation 
of these strata have a multiplicative effect on a common baseline hazard function, the 
various estimated hazard functions should be proportional to each other. If this 
assumption is true, then the various cumulative hazard functions should run parallel 
on a logarithmic scale. 
As was the case with the parametric models discussed before, the assessment of fit by 
using generalized residuals can also be done for proportional hazard models [Kay, 
1977]. If the residual R; for the im patient with observation time t; is defined as -log 
S;(t;), the residual for that patient can be estimated by 
(9.3) 
If the model holds, the generalized residuals should follow a negative exponential 
distribution with mean one. A first step in the evaluation of fit using residuals is to 
plot the "survivor" function of the residuals with a logarithmically transformed vertical 
axis. The Kaplan-Meier representation should approximate a straight line then. For 
the kidney cancer survival data (chapter 3), in figure 7 the Kaplan-Meier curve is 
plotted of the generalized residuals obtained after fitting the proportional hazards 
model allowing for gender, renal vein involvement and ESR. Based on this graph the 
applied model seems to fit well because the curve does not greatly differ from its 
expectation. 
The residuals can also be investigated for groups of patients or plotted against particu-
lar covariates. For example, Damhuis and Blom (1995) found in a population based 
study that survival for renal carcinoma patients decreased with increasing age at 
diagnosis. No such relation was found, neither univariately nor multivariately, for the 
patients described in chapter 3 . Figure 8 shows the generalized residuals, after fitting 
the proportional hazards model taking account of gender, renal vein involvement and 
ESR, which are plotted against the age of patients at diagnosis. No relation between 
the residuals and age is apparent, indicating that in our patient group age is of no 
additional prognostic value during the follow-up period considered within the 
framework of the proportional hazards model. 
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Figure 7. Kaplan-Meier representation of distribution of generalized residuals. Dotted 
line denotes the standard exponential distribution. 
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Figure 8. Generalized residuals (circles: patients alive, triangles: dead patients) 
plotted against the age of patients at diagnosis. 
Various other type of residuals have been defined by Therneau et al (1990). Diagnos-
tic plots that are useful for assessing the effect of adding a variable, detecting non-
linearity, or identification of influential points, are described by Chen and Wang 
(1991). 
A noteworthy characteristic of the proportional hazards model is that if this model 
holds for a certain combination of cDvariates, the model does not apply any more if 
one or more relevant covariates are discarded from the model. This is true irres-
pective of the distribution of such omitted covariates. The effect of dropping a 
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balanced variable in the proportional hazards model is shown by example in the 
following. Assume that the proportional hazards model A(t;z"z,)=A,,(t)exp(0.693z, 
+0.693z,) holds. Here z, represents a binary (0, I) variable denoting treatment group, 
and Z, denotes a binary (0,1) indicator for some prognostic factor whose associated 
effect is to double the hazard rate. According to the model, the ratio of hazard rates 
for the two treatment groups also equals 2, both for z,=0 and z,=1. Taking A" equal 
to I, figure 9 is obtained. This figure shows at each point in time the resulting ratio of 
hazard rates of the two total treatment groups for varying fractions p of cases with 
z,=1 (p=O.I, 0.5 and 0.9). With increasing prevalence of the factor associated with the 
greater risk (z, = 1), the deviations from a constant hazard ratio of 2 become more 
pronounced. This example demonstrates that in comparing treatment groups the omis-
sion of an important covariate in a situation that the proportional hazard model ap-
plies, even when this covariate is balanced between the groups, will lead to a biased 
estimate of the treatment effect. This effect will then be underestimated, contrasting 
the situation in ordinary multiple linear regression. A quantitative study of this biasing 
effect was performed by Chastang et al (1988). The loss of power due to the omission 
of a balanced covariate was studied by Lagakos and Schoenfeld (1984). 
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Figure 9. Effect of an omitted balanced covariate in a proportional hazards model. 
The prevalence of the omitted prognostic factor is denoted by p. 
10. Discussion and introduction to chapters 3-6. 
With the increased use of controlled clinical trials, there has been a proliferation of 
statistical methodology for the analysis of survival data. Graphical representations of 
outcomes, e.g. using Kaplan-Meier curves, afe important components of analysis. The 
regression models described, either parametric or nonparametric, have proven useful 
in identifying factors which are strongly associated with survival in numerous studies. 
The parametric models are most useful in studies which have a relativelY small 
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number of patients or events, or when it is needed to extrapolate beyond the range of 
observed failure time data. An advantage of some of the parametric models may also 
be that their results are more easy to communicate because of their great similarity 
with the familiar multiple regression method in which the expected outcome is linearly 
related to a number of factors. With the possibility of allowing the effects of the 
baseline covariates to depend on time itself, and the possibility to allow for the 
inclusion of various baseline hazard functions which are related to different subgroups 
of patients, the Cox-regression method is an extremely flexible tool in analysing rates 
of occurrence of some well-defined event. An interesting application in a competing 
risk framework was made by Kay (1986) who studied various factors regarding their 
impact on different cause-specific death rates (cardiovascular, cancer or other causes) 
in patients with prostate cancer. In that study it was found that using Cox-regression it 
was well possible to describe each of the separate cause-specific death rates, but the 
proportional hazards assumption failed regarding the overall mortality. This example 
demonstrates that a judicious choice of a subtyping of events, when appropriate, may 
be advantageous in order to obtain a better understanding of the data. 
The proportional hazards regression model as described applies to continuous times, 
i.e. the times of the occurrence of the event can be observed (nearly) exactly. This 
requires an intensive observation of patients. In some instances patients arc only 
regularly seen after relatively long intervals . When at a particular follow-up visit it is 
evident that the event has occurred, e.g. a recurrence of disease, and it is only possible 
to conclude that the exact time-point of the recurrence lies between the previous visit 
and the current one, the method should be adapted [Prentice and Gloeckner, 1978]. A 
method suited for nonsynchronized follow-up intervals is described by Finkelstein 
(1986). 
Another situation may be that the follow-up proceeds in truly discrete units, e.g. the 
number of cycles women with fertility problems need treatment in order to achieve 
pregnancy. For such truly discrete situations, Cox (1972) has proposed an analogue of 
the proportional hazards model. With this method, the probability of the event 
studied, conditional on not having observed the event before, is written as a logistic 
regression equation [Cox, 1970]. 
Occasionaly it may occur that patients do not all enter the study at time flzero tl , but 
some time later. This will happen, for instance, when one studies survival from 
diagnosis in a particular hospital setting, and one wants to include also those patients 
who had a diagnosis elsewhere but were referred to the particular hospital a conside-
rable time thereafter. The inclusion of such late entries, without applying specific 
corrections for their late entry, will severely bias the resulting survival rates. A similar 
bias will occur when studying survival of patients diagnosed in a certain period, if one 
also wants to include the prevalent cases in the calculations. It is evident that, without 
adjustments in the calculations, the proportion of long-term survivors will then be 
over-estimated [Kurtzke, 1989]. Cnaan and Ryan (1989) have descibed methods which 
appropriately deal with such late entries. 
Similar adaptions are required when another choice of time-scale is indicated. For 
instance, in epidemiological studies regarding the incidence of a particular disease 
such as cancer, age will often be a more appropriate time-axis than the length of time 
since some more or less arbitrary time point which marks the beginning of the study. 
The time-axis most strongly related to the outcome studied is to be preferred [Breslow 
and Day, 1987]. In most clinical studies the basic time variable corresponds to the 
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duration of follow-up after diagnosis or start of treatment. However, in studying an 
untoward event during pregnancy, for instance, it may be more appropriate to use the 
gestational age as the time-axis instead of measuring time since the moment that 
women entered the study and came under observation. 
In the following three chapters clinical studies are described in which Cox-regression 
played an important role in the evaluation of baseline characteristics. 
In chapter 3 various baseline characteristics are evaluated regarding prognosis in 
operated kidney cancer patients. Some aspects of this study are already discussed 
above. One of the more important prognostic factors in that study appeared to be a 
very low-cost parameter, namely the erythrocyte sedimentation rate. The importance 
of ESR as prognostic factor in renal cell carcinoma was recently also found by Roosen 
et al (1994), Fossa et al (1994) and Lopez Hanninen et al (1996). 
Chapter 4 gives all accoullt of a randomized study ill colorectal cancer which evalua-
ted the potential benefit regarding prognosis of an autologous blood transfusion 
program as compared to standard allogeneic transfusions. The main goal of Cox-
regression in this application was to provide more precise estimates of transfusion 
effects. 
In chapter 5 various prognostic factors are evaluated for patients surgically treated for 
esophagus carcinoma. In an appendix to that article it is shown that ordinary Kaplan-
Meier curves are not suitable for obtaining absolute risk percentages of recurrent 
dysphagia. 
In the foregoing only methods to evaluate factors established at baseline are discus-
sed. In chapter 6 methods are discussed which allow evaluations of observations on 
patients made during follow-up, thereby providing means to update prognosis. 
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CHAPTER 3 
PROGNOSTIC INDEXES FOR RENAL CELL CARCINOMA 
This chapter was published in European Journal of Cancer 1980; 16: 833·840 
by W.C,J. Hop and B.H.P. van der Werf-Messing. 
Introduction 
As in many other malignant diseases, patients with adenocarcinoma of the kidney 
show a great variability in survival as the outcome of treatment. The identification of 
factors associated with the prognosis of these patients, and from which the variability 
in outcome can be substantially explained, may be of great importance. In this paper, 
results of a study to investigate the relative prognostic importance of a number of 
factors concerning nomnetastasized renal cell carcinoma by a multivariate statistical 
method are presented. Two analyses are performed. One is concerned with preopera-
tively assessable factors. In the second, tumour characteristics which become evident 
on histopathological examination of the nephrectomy specimen are also included. This 
distinction is useful, as the preoperative identification of groups of patients with diffe-
rent prognosis may facilitate treatment decisions. 
Postoperatively, emphasis is on explaining variability in treatment results by considera-
tion of possible mechanisms of the disease. 
The preoperative factors studied are (a) sex, (b) age, (c) erythrocyte sedimentation 
rate (ESR) and (d) radiodiagnostic extent of the tumour. Postoperative tumour 
characteristics analyzed are (e) histopathological extent of the tumour, (0 invasion of 
the renal vein, (g) degree of differentiation and (h) cell type. In both analyses, 
prognostic indexes from which the expected survival of individual patients can be 
derived are constructed. 
Material and methods 
During the years 1965-1977, 174 patients with nonmetastasized renal cell carcinoma 
who were considered suitable for sinlple nephrectomy entered a randomized clinical 
trial to investigate the value of preoperative irradiation'. Of these patients, 89 received 
preoperative irradiation (TD 3000-4000 rad/3-4 weeks) and 85 were directly nephrec-
tomized. 
The i. v. pyelographs and arteriographs performed for the preoperative assessment of 
the extent of the tumour, the T-category2, were reviewed by one diagnostic radiologist 
(R.C. Ledeboer). Renal vein invasion was assessed by histological examination of the 
nephrectomy specimen. The histological extent of the tumour is expressed by the P-
category (PI: tumour surrounded by renal parenchyma; P2: tumour extending to the 
capsule andlor invading the renal pelvis andlor calyces; P3: perinephric or hilar 
extension; P4: extension into neighbouring organs andlor fixed to the abdominal wall). 
Review of all histological specimens was done by one pathologist (R.O. van der Heul). 
Because of simple nephrectomy local node involvement was not assessed as a routine. 
At the time of this analysis, 87 patients had died and 87 were still continuing follow-
up. All patients had regular follow-up examinations. 
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Statistical methods 
Survival functions of groups of patients are estimated by survival curves according to 
Kaplan and Meier'. For the calculation of P-values in the comparison of survival 
curves, tbe log-rank test4 is used. Because of the limited number of patients and tbe 
existing relationships among several factors, tbe prognostic importanee of the factors 
can be simultaneously invesdgated by these methods to only a limited extent. A more 
promising way of making progress here is by adopting a multivariate statistical model. 
Moreover, sueh a model may be useful in deriving a mIe for prognostic predictions 
concerning future individual patients. The model which is used here is Cox's proporti-
onai hazards model'. With this model. a scoring function which relates the expected 
survival times of individual patients to the values of the prognostic variables caD be 
obtained. The value of the scoring function indicates how strongly the force of 
mortality (the instantaneous death ratel is related to these factors. 
If the number of patients is denoted by n and. if p is the number of prognostic 
variables, the scoring function for the i-th patient can be written: 
(I) 
Here aij is the value of the j-th prognostic variabie (j=I ..... p)for the i-th patient 
(i=I ..... n).The parameter ]3j denotes the difference in score of patients who differ by 
one unit in the j-th variabie. the other variables being at the same level. Factors with 
continuous levels sueh as ESR and discrete factors with two categories sueh as sex are 
represented by one variabie and one related parameter ft. A discrete factor with more 
than two categories generally needs a number of variables and parameters equal to its 
number of categories minus one. For instance, the four-categorical factor T-category 
needed three variables to represent all its levels. 
The score Sj is related to the survival outcome by: 
A.,(t) = exp (S,) 1co(t), 
where ),.,(t) denotes the force of mortality of the i-th patient at time I (rougbly 
speaking. A.,(t) gives the probability of dying at month I if the padent is known to be 
alive at month I-I). lco(t) denotes an arbitrary reference force of mortality function 
which is unknown. A high score indicates a high death rate and thus a (relatively) 
poor prognosis. Another interpretation of this scoring system can be obtained by 
considering its implication for the survival functions. It can be shown thai the survival 
function F,(t) to which the i-th patient is subjected can be written as: 
Here Fi(t) denotes a reference survival function, that is, the survival function for 
patients with a score s=o. 
The unknown parameters ]3j. ]32 ... · fJp and the function FJt) can be estimated from the 
clinical data by maximum likelihood procedures'. This fitting of the model has to be 
done by a process of successive approximation. Significance tests on subsets of less 
important prognostic factors can be obtained by comparisons of fits of models through 
likelihood ratios. 
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Results 
Extensive analysis of the data showed that the preoperative irradiation had little or no 
effect on histological variables or survival (5-year survivals for the preoperatively 
treated and the surgically treated only group were, respectively, 45 and 54%), This 
treatment factor is therefore omitted from further consideration. Preoperative factors 
were first analyzed for their prognostic value. 
Table 1. Survival according to preoperative factors. 
Factor Category No. of Survival (%) 
patients 3yr 5yr Log-rank test 
Sex female 75 66 57 
male 99 59 43 P=0.05 
Age (yr) < =55 60 65 60 
56-65 60 59 38 
>=66 54 61 50 P=0.2 
Sedimentation < =12 50 89 80 
rate (mmlhr) 13-29 39 76 57 
> =30 83 40 27 P<O.OOI 
T-category Tl 14 75 48 
T2 47 58 50 
T3 66 70 57 
T4 39 52 36 P=O.1 
combined Tl,2,3 127 66 52 
T4 39 54 36 P=0.02 
Missing data: sedimentation fate: 2, T-category: 8. 
In Table 1, 3-year and 5-year survival percentages are given for the preoperative 
assessable factors. Considered on its own, sedimentation rate seerns to be strongly 
associated with subsequent survival. Females have a bettef prognosis than males. 
Category T4 does more poorly than the lower T-categories. To analyse the effects of 
the factors sedimentation rate, sex and T-category simultaneously, model (I) is written 
as: 
Here aij allows for tbe factor sedimentation rate and ail for sex. The three variables 
ai]' ai4 • and aiJ represent the four categories of the T -c1assification. Further details on 
the coding of these variables and the resulting fit to !he data are given in Table 2. It 
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Table 2. Model including sedimentation rate, sex and T-category. 
Estimated Likelihood 
Factor Variable Jl Jl ratio test 
Sedimentation ail:::: ESR Jl 1 0.020 P<O.OOI 
rate (mm/br) 
Sex ao =1 if male Jl, 0.51 P=0.05 
=0 if female 
T-category ao=1 ifT! Jl, -0.26 P=O.OI 
=0 if otherwise 
a.=1 ifT2 Jl, -0.39 
=0 if otherwise 
a"=1 ifT3 Jl, -0.95 
=0 if otherwise 
appears that each of these tbree factors contributes significantly to the score. On 
further examination of the estimated parameters related to the T-category, however, it 
appears that category T3 has a more favourable prognosis than T2. In turn, T2 is 
estimated to be somewhat more favourable than Tl. As this ranking did not seem to 
be logical and the differences between the categories T!, T2 and T3 themselves were 
far from statistical significance, the model was fitted again to the data with T4 
contrasted to categories T!, T2 and T3 combined. After assuring that the factor age 
did not improve the fit of the model, the ultimate preoperative score could be written 
as: 
r 0.6 (male) 
S = 0.02 x ESR + I + 
L 0 (female) 
r 0.7 (T4) 
I 
L 0 (T!, T2 or T3) 
Now, for each patient, a score according to this prognostic index can be calculated 
and patients with a similar score can be grouped. After grouping patients with a score 
between 0 and I, between I and 2, etc., it is shown in Figure 1 that the observed 
survival curves of these groups of patients are in reasonably good agreement with the 
expected survival curves arising from the model. Groups with a relatively good, 
intermediate and poor prognosis can be clearly distinguished. 
Concerning postoperative factors, it appeared that category P4 (inoperable patients) 
had a very poor prognosis. All seven patients died within 2 yr, most of them within 1 
yr. Moreover, as no information was available concerning the histological variables of 
the tumour in the majority of these patients. they were omitted from the following 
analysis. In Table 3, survival percentages are given for the remaining operable 
patients. With increasing P-category, survival becomes worse. Renal vein involvement 
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Table 3. Survival according to histopathological factol's 
No. of Survival (%) 
Factor Category patients 3 yr 5 yr Log-rank test 
P-category PI 61 81 65 
P2 38 64 60 
P3 67 50 33 P=O.OOI 
Renal vein Yes 62 47 28 
invasion No 105 76 65 P<O.OOI 
Degree of Low 60 51 39 
differentiation Medium 81 73 57 
High 21 90 68 P=O.OI 
Cell type Clear 123 68 52 
Granular 17 67 52 
Mixed 22 54 54 P=0.8 
Missing data: P-category: I, degree of differentiation and cell type: 5. 
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Figure 1. Observed and expected survival curves according to preoperative score 
[=0.02 x ESR (mm/lir) + 0.6 (if male) + 0.7 (if T-category T4)]. 
leads to a considerably poorer prognosis than when no venous invasion is seen. Also 
with decreasing degree of differentiation of the tumour, survival becomes worse, while 
the different cell types show similar survival rates. To investigate the prognostic 
importance of the P-category, renal vein invasion and degree of differentiation 
simultaneously, the following scoring function, which also takes account of sex and 
sedimentation rate, was fitted to the data: 
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The various variables and results of fitting this model are given in Table 4. It appears 
that, onee tbe factors sex, sedimentation rate and renal vein involvement are known, 
!he factors P-category and degree of differentiation do not contribute significantly 10 
!he score. Extending the model with the factors age and cell type also did not improve 
the fit of !he model. The ultimate postoperative score, based on all operabie patients 
except two because of a missing sedimentation rate, can now be written as: 
r 0.8 (male) r 0.9 (renal vein invasion) 
S = 0.02 x ESR + I + I 
L 0 (female) L 0 (no renal vein invasion) 
After grouping patients with a similar score, Figure 2 is obtained. Good agreement 
between observed and expected survival curves is evident. 
Table 4. Model incIuding sedimentation rate, sex, P-category, renal vein invasion and 
degree of differentiation. 
Factor 
Sedimentation 
rate 
Sex 
P-category 
Renal vein 
invasion 
Degree of 
differentiation 
Variable 
a,,=ESR 
au = 1 if male 
=0 if female 
a,,=1 if PI 
= 0 if otherwise 
ai4=1 if P2 
=0 if otherwise 
3js=1 if yes 
=0 if no 
ai6 =1 if low 
=0 if otherwise 
ai7 = 1 if medium 
=0 if otherwise 
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Estimated Likelibood 
B B ratio test 
BI 0.018 P<O.OOI 
B2 0.87 P=O.OOI 
B3 -0.48 P=0.15 
B4 -0.53 
B, -0.95 P=0.002 
B6 0.25 P=0.3 
B, -0.14 
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Figure 2. Observed and expected survival curves according to postoperative score 
[=0.02 x ESR (mm/hr) + 0.8 (if male) + 0.9 (if renal vein involvement)]. 
DisCllssion 
The relatively poor prognosis of patients with invasion of the rerral vein IS m agree-
ment with general clinical experience7 . The risk of reoal vein involvement increases 
greatly with increasing P-category; see Table 5. It is conceivable that tbe prognostic 
importanee of P-categories is mainly derived from renal vein involvement. A similar 
phenomenon could be observed in the data of McDonald and Priestley'. who studied 
survival in relation to rerra} vein involvement and weight of the diseased kidney. 
Table 5. Numbers of patients according to renal vein invasion and P-category 
Renal vein invasion 
ehi-square test: P<O.OO1. 
P-category 
PI P2 P3 
Yes 8 (13%) 
No 53 
15 (39%) 39 (58%) 
23 28 
It has been known for a long time that renal celI carcinoma patients frequently show 
an elevated sedimentation rate9. The importanee of the sedimentation rate as a 
prognostic factor was already stated by BöttigerlO , Ochsner et al. II and recently by 
Juusela12 . In this study, a gradual worsening of prognosis was observed with increasing 
sedimentation rate. The sedimentation rate showed astrong correlation with the 
degree of differentiation. With a decreasing degree of differentiation, the sedimentati-
on rate increases. Cumulative frequency distributions of the sedimentation - rate are 
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given in Figure 3 (differences significant at P=O.OI by the Krukal-Wallis test). This 
correlation could explain why the degree of differentiation, while of prognostic value 
when considered alone (Table 3), is of less value in the postoperative score. 
% 
100 
80 
60 
40 
20 
high (n=20) 
medium (n=Bl 
low (n=60) 
01,--_,--_,--_,--_,------:,.,-_,--_,-
20 40 60 BO 
ESA (mmlhr) 
Figure 3. Cumulative frequency distributions of erythrocyte sedimentation rate by 
degree of differentiation. 
That females have a better prognosis than males was also noted by Meyers et al" and 
Juusela". The greater incidence of renal cell carcinoma among males" and the finding 
that, once metastases have become clinically evident, women respond less to hormonal 
treatment than men"·16 are also suggestive of the involvement of hormonal factors. 
The prognostic value of the T-classification was not impressive in this material. Only 
category T4 was an ominous sign. This observation could readily be explained by 
comparing T with P-categories. While T4 patients were mainly P3 or P4, there was a 
minor agreement between T and P-categories for the cases with a lower T-category. 
The prognostic indexes derived were broadly similar when a correction was made for 
the occurrence of intercurrent death. By considering patients (18) withdrawn from 
study at the moment of death from causes supposedly unrelated to renal cell carci-
noma, the estimated parameters in the multivariate models did not appreciably differ 
from those given. 
In comparing observed and expected survival curves (Figures 1 and 2), good agree-
ment was apparent. The validity of a prognostic index, however, should preferably be 
tested in another group of comparable patients. Dr. H. Juusela (Helsinki University 
Central Hospital) kindly evaluated the prognostic indexes by applying them to a 
comparable group of patients described in his thesis". For patients without evidence 
of disseminated disease and with a P-category less than 4, intercurrent death corrected 
survival curves according to postoperative score were obtained as given in Figure 4 
(one patient with a score of 4.4 dying 1 month after operation is not included in that 
figure). Despite the fact that the groups with the highest scores are less separated, the 
overall worsening of prognosis with increasing score is satisfactorily confirmed. For the 
preoperative index a similar validation was obtained. 
About uses of the indexes: the preoperative prognostic indicator may possibly be 
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Figure 4. Survival after extrafascial nephrectomy. Paticnts arc grouped according to 
postoperative score (courtesy of Dr. H. Juusela). 
useful as a complementary factor to facilitate making the decision of whether to 
operate or not in particular patients. Until now, no mode of chemotherapy has been 
found which can deel effectively with clinically established metastases. In studies of 
more aggressive hormonal of chemotherapy treatments, the indexes can be useful 
either as selection criteria or as single stratification factors. 
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CHAPTER4 
BLOOD TRANSFUSIONS AND PROGNOSIS IN COLORECTALCANCER 
This chapter was published in The New England Journal of Medicine 1993; 328: 1372~1376 
by O.R.e. Buseh, W.C.J. Hop, M.A.W. Hoynck van Papendrecht, R.L. Marquet and J. leekel. 
Introduction 
Perioperative blood transfusions may have a deleterious effect on the survival of 
patients with a variety of solid tumors,,2, possibly because of an irnmunosuppressive 
effee!'.'. This possibility is supported by studies in animals in which tumor growth was 
enhaneed after allogeneic transfusion,,6, although eonflieting results have also been 
reported"'. A poor prognosis after blood transfusions has been noted espeeially in 
patients with colorectal eaneer. 
In the studies of the effect of blood transfusions in patients with eaneer, the patients 
were given the transfusions either because of their disease or because transfusion was 
necessary during surgical treatment. Therefore, the question remains whether the 
relation between blood transfusion and pOOI prognosis is causalor coincidental9. The 
need for transfusion could be an indicator of other prognostic factors that are either 
unknown or diffieult to quantify, sueh as the extent of the tumor and the dissection, 
the skil! of the surgeon, and the nutritional state of the patient. 
A randomized trial is the only way in whieh possible bias in the selection of patients 
can be avoided. Randomization between transfusion and no transfusion is impossible, 
however, because giving patients transfusions when there is no medical indication and 
withholding transfusions that are indicated are ethically unaeeeptabie. Sinee autolo-
gous blood is the safest blood to use in transfusion, eomparing the effects of alloge-
nek and autologous blood transfusions would be a logical option. 
We therefore conducted a randomized multicenter trial in patients with colorectal 
cancer to detennine whether autologous blood transfusion would reduce the rate of 
recurrence of cancer and improve survival as compared with allogeneic transfusion. 
We previously reported that a notabie reduction in the number of allogeneic transfu-
sions can be achieved with a program of autologous blood transfusionlO • 
Methods 
The study was eondueted in 14 hospitals in the Netherlands and 1 hospital in England 
and was approved by the e!hies committees of all the participating hospitais. After 
written informed consent had been obtained, eligible patients were randomly assigned 
to either the allogeneic-transfusion group or the autologous-transfusion group, with 
stratifieation aeeording to the participating hospita!. Patients were eurolled from 
August 1986 to November 1991, when the planned enrollment was reaehed. 
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Eligibility of patients: 
Patients scheduled for a potentially curative resection of cancer of the colon or 
rectum were eligible for enrollment if they fulfilled the criteria of the American 
Association of Blood Banks for autologous blood donation in anticipation of surgery!!. 
These criteria required the absence of severe cardiovascular or respiratory disease, no 
history of epilepsy after infancy, and a hemoglobin concentration above 11. 3g per 
deciliter (7 mmol per liter). In addition, patients had to have no evidence of metasta-
tic disease, on the basis of chest radiography and ultrasonography of the liver, no 
other cancer except basal-cell carcinoma of the skin or in situ carcinoma of the cervix; 
no evidence of ulcerative colitis, familial polyposis, or a fixed rectal carcinoma 
requiring preoperative radiation therapy; and no history of blood transfusion during 
the three months before randomization. No adjuvant therapy was allowed except 
irradiation. If metastatic or recurrent disease developed in a patient during follow-up, 
all available therapies were allowed. 
Procedures for donation and transfusion: 
Patients randomly assigned to the autologous-transfusion group were required to 
donate blood twice. The minimal interval between the two donations was 72 hours, 
and the second donation had to occur not later than five days begore surgery. At each 
donation, 450 ml of blood was obtained by standard procedures. 
The patients were treated with oral iron supplementation immediately after randomi-
zation. 
The collected blood was separated into packed red cells and fresh-frozen plasma, 
except at one hospital, where autologous blood was given in transfusion as whole 
blood. The packed red cells and whole blood were stored at 4 'C. Allogeneic blood 
was always given in transfusion as packed red cells. Standard rules for transfusion 
were used for both groups. Packed red cells could be given only if the loss of blood 
exceeded 500 ml or if the hemoglobin concentration dropped below 1O.5g per 
deciliter (6.5 mmol per liter). If this hemoglobin concentration was not achieved after 
two autologous transfusions, additional allogeneic transfusions were made. In both 
groups fresh-frozen plasma was given when indicated. 
Surgery and histopathological assessment: 
Standard surgical procedures were used. The operative specimens were classified 
according to Dukes' classification as modified by Turnbull!'. A tumor confined to the 
bowel wall was classified as Dukes' stage A, a tumor extending through the serosa 
into the pericolic fat as Dukes' stage B, the presence of regional lymph nodes 
containing metastases as Dukes' stage C, and the presence of distant metastases or 
unresectable tumor as Dukes' stage D. All patients who had residual tumor evident 
only on microscopical examination received postoperative radiotherapy. These 
patients and those who had en bloc resection of adjacent organs were not considered 
as having Dukes' stage D disease, but rather as having Dukes' stage B or C disease. 
Follow-up and criteria for recurrent cancer: 
The patients were evaluated every three months during the first two years after 
surgery and every six months thereafter. Each evaluation consisted of a history, a 
physical examination, and blood tests (to measure the concentrations of hemoglobin 
and serum carcinoembryonic antigen). Ultrasonography of the liver was performed 
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every six months for three years and each year thereafter. Chest films and colonosco-
py were done yearly. 
Characteristic abnormalities detected on physical examination or on chest radiograp-
hy, liver ultrasonography, or abdominal computed tomography were accepted as 
evidence of metastatic or recurrent disease. If possible, the presence of metastatic or 
recurrent disease was confiruled by histologic or cytologic examination. Increased 
serum concentrations of carcinoembryonic antigen without evidence of recurrence at 
suspected anatomical sites were not considered to indicate metastatic or recurrent 
disease. 
Statistical analysis: 
Categorial data were compared by the chi-square test, and continuous data by the 
Mann-Whitney test. The major end points were disease-free survival and colorectal 
cancer-specific survival (defined to include all patients who did not die of colorectal 
cancer, without regard to other causes of death), both as determined from the time of 
surgery and calculated according to the Kaplan-Meier method. The log-rank test was 
used to compare these end points. Multivariate analysis was performed by proportio-
nal-hazards analysis" to obtain a higher level of precision in the comparison of the 
transfusion groups. Two-sided P values of 0.05 or less were considered statistically 
significant. P values calculated with adjustment for Dukes' stage are indicated as 
adjusted P values in the text. 
Patients in whom a second primary tumor developed outside the colon were conside-
red withdrawn from the study with regard to the calculation of disease-free survival. 
Metachronous tumors in the colon, however, were defined as representing recurrent 
disease. Postoperative deaths, defined as deaths occurring within 30 days after 
surgery, and deaths occurring more than 30 days after surgery due to postoperative 
complications were counted as deaths due to cancer. 
Because the analyses of overall survival and colorectal cancer-specific survival gave 
similar results, only the results for colorectal cancer-specific survival are reported. 
Except for the patients who did not have colorectal cancer at the time of surgery, all 
randomized patients were primarily evaluated according to the intention-to-treat 
principle. In addition, exploratory analyses were performed according to the number 
and type of transfusions received. 
Results 
Characteristics of the Patients: 
A total of 510 patients were enrolled in the study. Thirty-five patients (7 percent) 
were excluded because they did not have colorectal cancer at the time of surgery. The 
characteristics of the remaining 475 patients are shown in Table 1. None of the 
characteristics differed significantly between the two groups. Twenty-six of the 239 
patients in the autologous-transfusion group (II percent) did not donate blood; the 
majority of these were refused by the blood bank because they did not fulfil the 
criteria of the American Association of Blood Banks. These patients were included in 
all the analyses according to the intention-to-treat principle, as were all the patients 
with metastatic disease or unresectable tumors. The median follow-up period was 2.5 
years (range, 1 to 59 months), and no patient was lost to follow-up. 
The perioperative hematologic values and use of transfusions are shown in Table 2. 
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Table 1. Characteristics of the patients with colorectal cancel' in the two transfusion 
groups. 
Characteristic Allogeneic Trans- Autologous Trans-
fusion (N = 236) fusion (N = 239) 
Median age - yr (range) 68 (33-89) 66 (31-88) 
number (percent) number (percent) 
Sex 
Male 132 (56) 141 (59) 
Female 104 (44) 98 (41) 
Tumor location 
Ascending colon 24 (10) 16 (7) 
Flexures and transverse colon 12 (5) 16 (7) 
Descending colon and sigmoid 62 (26) 65 (27) 
Rectosigmoid and rectum 132 (56) 135 (56) 
Multiple primary tumors 6 (3) 7 (3) 
Dukes' classification* 
A 53 (23) 55 (23) 
B 85 (36) 80 (34) 
C 78 (33) 72 (31) 
D 18 (8) 29 (12) 
Histologic differentation 
Good 35 (15) 33 (14) 
Moderate 169 (72) 172 (72) 
Poor 29 (12) 29 (12) 
Unknown 3 (I) 5 (2) 
Adjacent-organ fixation° 15 (7) 17 (8) 
Adjuvant irradiation° 15 (7) 16 (8) 
'" Does not mclude pallents who did not undergo surgery (two III the allogeneic group and three m 
the autologous group) 
o Excludes patients with Dukes' stage D tumors. 
The number of patients in the autologous-transfusion group who received allogeneic 
blood was half the number in the allogeneic-transfusion group (28 percent vs. 56 
percent, respectively; P<O.OOI). 
Morbidity and Mortality: 
Five eligible patients (two in the allogeneic-transfusion group and three in the 
autologous-transfusion group) did not have surgery. Four had more advanced disease 
than expected, and one patient died before surgery. Eight patients (three in the 
allogeneic-transfusion group and five in the autologous-transfusion group) died of 
postoperative complications. Postoperative infectious complications occurred in 26 
percent of the patients (25 percent in the allogeneic-transfusion group and 27 percent 
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in the autologous-transfusion group). There were no statistically significant differences 
between the two groups with respect to postoperative mortality and infectious 
complications. 
Disease-free Survival: 
Of the 423 patients who underwent curative surgery (216 in the allogeneic-transfusion 
group and 207 in the autologous-transfusion group), 105 (54 in the allogeneic-
transfusion group and 51 in the autologous-transfusion group) had recurrent disease 
(including three metachronous tumors). The disease-free survival of these 423 patients 
is shown in Figure 1. The plots for the two groups were almost identical (P=0.93). 
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Figure 1. Disease-free survival of all 423 patients with colorectal cancer who under-
went curative surgery. The disease-free survival at four years was 66 percent in the 
allogeneic transfusion group and 63 percent in the autologous transfusion group 
(P=0.93). The 95 percent confidence interval for the difference between these 
percentages (autologous minus allogeneic) ranged from -16 percent to + 10 pel'cent. 
Also, there were no differences with regard to diseasefree survival in each of the 
Dukes' stages. After adjustment for various factors, the multivariate analysis also 
revealed no difference between the groups in disease-free survival (Table 3). Six 
patients (two in the allogeneic-transfusion group) had second primary tumors outside 
the colon during follow-up. 
To explore the relation between blood transfusions and disease-free survival, we 
grouped the patients who underwent curative surgery according to the number and 
type of transfusions they received. The disease-free survival in the 143 patients who 
received no transfusions was significantly better (adjusted P=O.OOI) than that in the 
280 who did receive transfusions; at four years, it was 73 percent and 59 percent, 
respectively. Among the 280 patients who had transfusions, 136 received only .lloge-
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Table 2. Hemoglobin concentrations, blood loss, and transfusions in patients with 
colorectal cancer, according to transfusion group. 
Variable Allogeneic Autologous 
Transfusion Transfusion P value 
median (range) 
Hemoglobin concentration (g/dl) 
At baseline 14.5 (15.0-18.0) 14.4 (10.7-18.5) NS' 
Immediately 
before surgery 14.1 (9.5-18.0) 12.5 (8.4-16.4) <0.001 
At discharge 12.5 (9.2-17.2) 12.2 (9.2-16.2) NS 
Blood loss (ml) 775 (100-II,500) 750 (100-6500) NS 
Transfusions 
None 103 (44) 61 (26) <0.001 
Autologous only - (-) II2 (47) 
Allogeneic 113 (56) 66 (28) <0.001 
'" NS denotes not significant. 
To convert values for hemoglobin to millimoles per liter, multiply by 0.62. 
neic transfusions, 102 only autologous transfusions, and 42 transfusions of both types. 
The disease-free survival at four years in these three groups was 56 percent, 62 
percent, and 66 percent, respectively (adjusted P=0.50). No significant difference was 
found between the 49 patients who received no transfusions in the autologous-trans-
fusion group and the 94 such patients in the allogeneic-transfusion group; the disease-
free survival in these patients at four years was 69 percent and 75 percent, respective-
ly. 
Because the number of autologous transfusions was limited to two, further compari-
sons were made between the 75 patients in the allogeneic-transfusion group who 
received one or two allogeneic transfusions and the 102 patients in the autologous-
transfusion group who received one or two autologous transfusions but no allogeneic 
transfusions. The disease-free survival was significantly worse in the patients in both 
groups who received transfusions than in the 143 patients who did not, whereas the 
disease-free survival of the patients who received transfusions in both groups did not 
differ significantly from each other (Table 4). Analysis of the results with respect to 
the use of fresh-frozen plasma revealed no relation between its use and disease-free 
survival. This was true whether the patients received blood transfusions or not. 
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Figure 2. Colorectal cancer-specific survival in all 475 patients with colorectal cancer. 
The colorectal cancer-specific survival at four years was 67 percent in the allogeneic 
transfusion group and 62 percent in the autologous transfusion group (p=0.39). The 
95 percent confidence interval for the difference between these percentages (autolo-
gOlls minus allogeneic) ranged from -18 percent to +7 percent. 
Colorectal Cancer-Specific Survival: 
During the study, 114 patients died of colorectal cancer (53 in the allogeneic-transfu-
sion group and 61 in the autologous-transfusion group). The survival of all 475 
eligible patients in the two groups was similar (P=0.39) (Fig. 2). 
In addition to the Dukes' stage, the patient's age was also significantly related to 
colorectal cancer-specific survival - i.e., older patients generally did worse than 
younger ones. The ratio of the death rate in the autologous-transfusion group to the 
death rate in the allogeneic-transfusion group, after adjustment for Dukes' stage and 
age, was 1.1 (95 percent confidence interval, 0.8 to 1.7; P=0.66). 
As was the case for disease-free survival, the colorectal cancer-specific survival in the 
423 patients who underwent curative surgery was significantly better (adjusted 
P <0.001) in the patients who did not receive transfusions than in those who did; the 
survival at four years was 88 percent and 65 percent, respectively. When the patients 
who received transfusions were subdivided according to the type of transfusions they 
received (allogeneic, autologous, or both), there were no significant differences 
(adjusted P=0.60) between the three subgroups; the survival at four years was 64 
percent, 68 percent, and 63 percent, respectively. The survival of patients who did not 
receive transfusions did not differ significantly (adjusted P = 0.86) between the two 
randomized groups; the survival of these patients at four years was 87 percent in the 
allogeneic-transfusion group and 88 percent in the autologous-transfusion group. 
When the analysis was restricted to patients who had one or two transfusions of the 
same type, the patients receiving autologous transfusions and those receiving alloge-
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neic transfusions both had worse survival rates than the patients without transfusions 
(Table 4).No relation was found between survival and the transfusion of fresh-frozen 
plasma. 
Table 3. Multivariate analysis of factors related to disease-free survival in 423 
patients with colorectal cancer who underwent curative surgery.' 
Factor 
Transfusion group 
Allogeneic" 
Autologous 
Dukes' classification 
A** 
B 
C 
Relative 
Recurrence 
Rate 
1 
1.1 
1 
4.0 
10.8 
95 percent 
Confidence 
Interval 
0.7-\.6 
1.7-9.5 
4.7-25.1 
P value 
0.74 
0.002 
<0.001 
* Olher factors investigated (age and sex of patients, tumor location, adjacent-organ fixation, degree 
of differentiation, and tumor size) had no significant additional predictive value with respect to 
disease-free survival, and the effect of randomization was not significantly influenced by any of 
these factors. 
** Reference category. 
Discussion 
The results of the retrospective studies of the influence of blood transfusions on 
survival and the recurrence rate in patients with colorectal cancer are conflicting. The 
studies in which the prognosis in patients receiving transfusions was poorer may have 
been biased by the selection of patients14•15 • One way to avoid such confounding by 
indication l6 is to conduct a randomized trial comparing the effects of autologous and 
allogeneic blood transfusions17•18 • The results of this study indicate that as compared 
with the use of allogeneic blood, the use of autologous blood either to avoid or to 
reduce exposure to allogeneic blood neither lowered the recurrence rate nor impro-
ved survival in patients who had undergone surgery for colorectal cancer. In accordan-
ce with some retrospective studies, the recurrence rate was higher in patients who had 
received transfusions than in those who had not. For patients given transfusions with 
allogeneic blood, the increase in the recurrence rate was similar to that in the 
patients who received only autologous blood. The same applied to the survival of the 
patients. 
Recently, Ness et al. 19 reported no difference in survival in a nonrandomized study in 
which the effects of allogeneic and autologous blood transfusions were compared in 
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Table 4. Disease-free survival and colorectal cancer-specific curvival, according to 
transfusion status and Dukes' classification, in patients with colorectal cancer who 
underwent curative surgery. 
Factor No. of Disease-
patients free 
survival 
at 4 yr 
No. of transfusions 
0*** 143 73% 
I or 2 
Allogeneic 75 59% 
Autologous 102 62% 
Dukes' classification 
A *** 78 93% 
B 130 73% 
c 112 39% 
* Obtained by multivariate analysis. 
** P<O.05for the comparison with the reference category. 
*** Reference category. 
Relative 
recur-
rence 
rate* 
I 
2.1 ** 
1.8**° 
4.3** 
15.5*' 
o Not significantly different (P>O.60)from the allogeneic-transfusion group. 
Survi- Relative 
val at death 
4 yr rate* 
88% 
67% 3.6** 
68% 2.8**° 
94% I 
85% 1.2 
50% 10.8*' 
patients undergoing radical surgery for prostate cancer. The results of a randomized 
study comparing both types of transfusion in patients with colorectal cancer were also 
presented recently". In that study, which included only 120 patients, there were fewer 
recurrences in the autologous-transfusion group, but on the basis of life-table analysis 
there were no statistically significant differences between the randomized groups. 
An explanation for our findings could be that autologous blood induces the same 
adverse reactions as allogeneic blood. In animals in which allogeneic transfusions had 
an adverse effect, no such effect was described for syngeneic blood transfusions. 21 ,22 
Since autologous blood transfusions in humans are comparable to syngeneic transfusi-
ons in animals, there is no experimental support for an effect of autologous transfusi-
ons on tumor growth. On the other hand, autologous transfusion requires the 
donation of blood. We have found in rats that the donation of blood can decrease 
natural-killer·cell activity and stimulate tumor growth."'" Therefore, the patients in 
the autologous-transfusion group could have had a lower natural·killer-cell activity 
than the patients in the allogeneic-transfusion group at the time of surgery. However, 
among the patients who did not receive transfusions) there was no difference in 
survival between the patients in the autologous-transfusion group, who donated blood, 
and those in the allogeneic-transfusion group. 
The most likely explanation for our findings is that there is no causal relation 
between blood transfusions and prognosis in patients with colorectal cancer. Thus, the 
findings in the retrospective studies in which blood transfusion was a detenninant of 
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prognosis were probably due to patient selection. We think it is not the blood 
transfusions themselves, but rather the circumstances necessitating the transfusions, 
that are the real detenninant of prognosis. The need to give patients transfusions 
during the perioperative period is obviously determined by a number of factors, such 
as blood loss, the extent of the tumor and the dissection, and the skill of the surgeon, 
although we found tumor size not to be a determinant of prognosis in the multivariate 
analysis. In some retrospective studies the groups receiving transfusions contained 
more patients with rectal tumors - who have a poorer prognosis than patients with 
colon cancer - than did the groups not receiving transfusions"'''. We found that the 
higher recurrence rates in both groups receiving transfusions, as compared with the 
rate in the group receiving no transfusions, were not affected by the location of the 
tumor. Because of our rules regarding transfusion, there was such a strong relation 
between blood loss and transfusion that it was impossible to separate these two 
factors. Other possible reasons for transfusion, such as the extent of the dissection 
and the skill of the surgeon, are difficult to assess. Although it seems beneficial to 
operate on patients with colorectal cancer in such a way that blood transfusions are 
either avoided or minimized, there is no reason, with respect to either cancer 
recurrence or survival, to use a program of transfusion with autologous blood in 
patients undergoing surgery for colorectal cancer. 
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CHAPTERS 
QUALITY OF PALLIATION AND POSSIBLE BENEFIT OF EXTRA-ANATOMIC 
RECONSTRUCTION IN RECURRENT DYSPHAGIA AFTER 
RESECTION OF CARCINOMA OF THE ESOPHAGUS 
This chapler was published in the Journal of the American College of Surgeons 1994; 179: 705-713 
by J,I.B. van Lanschot, w.e,]. Hop, M.H.J. Voormolen, R.A.J. van Deelen, J,G.A.M. Blomjous 
and H. W. THanus 
Introductiou 
After operative resection for carcinoma of the esophagus, even if performed with 
curative intent, most patients die either as a result of locoregional tumor recurrence 
or distant metastatic disease, or bothI .'. For these patients, the main advantage of the 
operation is the relief of severe dysphagia. Unfortunately, in a number of patients, 
dysphagia recurs early after the operation and is mainly the result of benign fibrotic 
stenosis at the site of the anastomosis. In most patients, this can be treated successful-
ly by repeated endoscopic dilatation'. When dysphagia recurs at a relatively long time 
after the operation, it almost invariably indicates locoregionai tumor recurrence. 
In the case of a thoracoabdominal esophagectomy with an intrathoracic anastomosis, 
the neoesophagus can only be placed in the prevertebral position, that is, in the bed 
of the tumor'·s. During the last few years, many institutions have changed from a 
thoracoabdominal to a cervicothoracoabdominal procedure with a cervical anastomo-
sis~8. Using this technique, there is the choice of different routes for reconstruction. 
The extra-anatomic retrosternal route is easy to create and has the advantage that 
intrathoracic prevertebral tumor recurrence cannot invade the neoesophagus. 
This study was done to determine the incidence of secondary dysphagia because of 
locoregional tumor recurrence after esophageal reseclion and prevertebral gastric tube 
reconstruction, and to determine in which patients the recurrent dysphagia could 
probably have been prevented by using an extra-anatomic reconstruction route. 
Patients and methods 
In a retrospective study, the records were reviewed of all patients who underwent 
resection of a malignant tumor of the esophagus or the gastroesophageal junction 
between 1983 and 1989 in the Department of General Surgery of the Erasmus 
University Hospital, Rotterdam, The Netherlands. Only patients who had transhiatal 
or transthoracic esophagectomy and proximal gastrectomy followed by prevertebral 
gastric tube reconstruction were induded. Patients who had reconstruction by colonic 
interposition or by retrosternal gastric tube were excluded. No defined lymph node 
dissection was performed. Only lymph nodes immediately adjacent to the primary 
tumor and lymph nodes along the lesser curvature were resected. Lymph nodes at the 
base of the left gastric artery were systematically investigated. 
All patients had an extensive preoperative examination, comprising esophagogastro-
scopy with histologic biopsy, indirect laryngoscopy, ultrasound examination of the 
abdomen and occasionally ultrasound of the neck, and computed tomograpy (CT) 
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scanning of the thorax and the abdomen. If the tumor was located in the proximal 
part of the intrathoracic esophagns, bronchoscopy was performed to exclude ingrowth 
of tumor in the trachea or bronchi. 
Patients were only operated upon with curative intent, that is, in the absence of 
distant metastatic disease and in the absence of signs of local irresectability. Positive 
nodes either at the celiac trunk or in the neck, or both, were considered to be distant 
metastases and therefore a contraindication for operative therapy. 
During the first part of the study period, all patients underwent preoperative radiothe-
rapy unless the tumor was limited to the cardia. Preoperative radiotherapy was given 
to tumor dose of 40 Gy (fractions of 2 Gy in four weeks). In 1987, preoperative 
radiotherapy was abandoned. 
Squamous cell carcinomas and adenocarcinomas of the esophagus were classified 
according to the pTNM-criteria for carcinoma of the esophagus established by the 
International Union Against Cancer (IUAC) in 1987. Classification of adenocarcino-
mas of the cardia was done according to the criteria for carcinoma of the stomach 
(Table 1)9. 
Table 1. The pTNM-classification for tumors of tbe esophagns and of the cardia 
according to the 1987 criteria of the international union against cancer. 
Carcinoma of the Esophagus 
T -primary tumor 
Tis Carcinoma in situ 
TI Tumor invades lamina propria or submucosa 
T2 Tumor invades muscularis propria 
T) Tumor invades adventitia 
T, Tumor invades adjacent structures 
N-regional lymph nodes 
No No regional lymph node metastasis 
N, Regional lymph node metastasis 
M-distant metastasis 
Mo No distant metastasis 
M, Distant metastasis (including cervical and celiac nodes) 
Stage grouping 
Stage 0 
Stage I 
Stage IIA 
Stage lIB 
Stage III 
Stage IV 
T. 
T, 
T, 
T, 
T, 
T, 
T, 
T, 
Any T 
No 
No 
No 
No 
N, 
Any N 
N, 
Any N 
Any N 
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Table 1 (continued). 
Carcinoma of the Cardia 
T-primary tumor 
To Carcinoma in situ: intraepithelial tumor without invasion of the 
lamina propria 
Tumor invades lamina propria or submucosa 
Tumor invades muscularis propria or subserosa 
Tumor penetrates the serosa (visceral peritoneum) without invasion 
of adjacent structures 
N-regional 
No 
Nt 
lymph nodes 
N, 
No regional lymph nodes 
Metastasis in perigastric lymph node(s) within 3 em of the edge 
of the primary tumor 
Metastasis in perigastric lymph node(s) more than 3 em from the 
edge of the primary tumor or in lymph nodes along the left gastric, 
common hepatic. spenic or celiac arteries 
M-distant metastasis 
Mo No distant metastasis 
Mt Distant metastasis 
Stage grouping 
Stage 0 Tii No Mo 
Stage IA T t No Mo 
Stage IB Tt Nt Mo 
T, No Mo 
Stage II T t N, Mo 
T, Nt Mo 
T, No Mo 
Stage IlIA T, N, Mo 
T, Nt Mo 
T, No Mo 
Stage IlIB T, N, Mo 
T, Nt Mo 
Stage IV T, N, Mo 
Any T Any N Mt 
Radicality of the resection was scored as RO in cases of a microscopically radical 
resection, as Rl in cases of microscopic tumor residue, and as R2 in cases of macro-
scopic tumor residue. 
Frozen section analysis of the proximal and distal resection margins was not routinely 
performed. Patients had follow-up evaluation to January I, 1991, or until death. 
During the follow-up period, special attention was given to evidence of locoregional 
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tumor recurrence. 
For the pTNM-classification of the primary tumor, positive cervical nodes were scored 
as distant metastases according to the criteria of the lUAC. During the follow-up 
period, the cervical metastases were classified as locoregional recurrence because the 
symptoms were frequently similar to those of intrathoracic tumor. 
In cases of secondary dysphagia as a result of tumor recurrence, the exact localization 
of the recurrence (cervical or intrathoracic) was assessed and whether or not the 
recurrence originated intramurally near the anastomosis (so-called central recurrence) 
or invaded the neoesophagus from outside (peripheral recurrence) was determined. 
Only in cases of peripheral, intrathoracic tumor recurrence causing upper gastrointes-
tinal symptoms (especially dysphagia) for at least one month was it concluded that the 
extra-anatomic route would have been beneficial. 
The overall survival and local recurrence-free survival rates were calculated according 
to the Kaplan-Meier method. Comparisons were done with the log-rank test. Cox 
regression was used to evaluate the prognostic value of various factors simultaneously 
with respect to locoregional recurrence (p=0.05 [two-sided] was considered the limit 
of significance)lO. An adapted Kaplan-Meier method was used to determine the 
absolute risk of secondary dysphagia as a result of locoregional tumor recurrence. As 
this method is not well known, details are given in the Appendix. 
Results 
Two hundred nine patients fulfilled the selection criteria. The age of the patients at 
the time of the operation ranged from 31 to 84 years, with a mean age of 61.3 years. 
The male to female ration was 5:2. Of the 209 patients, 143 received preoperative 
radiotherapy. Ninety-five patients had squamous-cell carcinoma of the esophagus 
(group 1) and 57 patients had adenocarcinoma of the esophagus, almost invariably 
arising in Barrett mucosa (group 2). In 57 patients, the tumor originated from the 
cardia (group 3). The main tumor characteristics are summarized in Table 2. 
Twelve patients died postoperatively, eight patients with squamous-cell carcinoma, 
three patients with adenocarcinoma of the esophagus, and one patient with adenocar-
cinoma of the cardia, resulting in an in-hospital mortality rate of 8, 5 and 2 percent, 
respectively. Follow-up evaluation was complete in 208 patients (one patient left the 
country three years after resection, without signs of recurrent disease). The mean total 
follow-up period postoperatively was 2.2 years (range of 0.1 month to 7.9 years). The 
mean follow-up period of the survivors was 4.9 years (range of 2.3 to 7.9 years). The 
overall five-year survival rate for the three groups is illustrated in Figure I. 
During the follow-up period, 73 patients showed various symptoms of locoregional 
tumor recurrence, cervical nodes included (Table 3). The diagnostic procedures, which 
were performed to confinn and to localize the recurrent tumor mass, are sununarized 
in Table 4. In 52 (71 percent) of the 73 patients, locoregional tumor recurrence was 
confirmed histocytologically. 
The results of the multivariate analysis of various risk factors with respect to locoregi-
onal recurrence are given in Table 5. The most important prognostic factors were the 
Nl and Ml category (positive celiac nodes). No significant additional predictive value 
was found for deep local invasion (T3.4 versus T1.2) or macroscopic tumor residue 
(R2 versus RO.l), although both factors significantly correlated with locoregional 
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Table 2. Main tumor characteristics of 209 patients who had operative therapy for a 
malignant tumor of the esophagus or gastroesophageal jUllction. 
Group 1: Squamous cell carcinoma, 11=95 
Group 2: Adenocarcinoma of the esophagus, 11=57 
Group 3: Adenocarcinoma of the cardia. 1l=57 
Tumor characteristics Group 1 Group 2 Group 3 
pTNM stage 
1 14 8 11 
2 66 33 19 
3 9 9 25 
4 6 7 2 
Differentiation 
Good 9 3 2 
Moderate 50 36 21 
Poor 31 17 32 
Undifferentiated 5 1 2 
Microscopic tumor residue (R,) 
Only proximal margin positive 0 1 2 
Only distal margin positive 0 0 3 
Proximal and distal margins 
positive 0 0 1 
Only tangential margin 
positive 2 3 
Macroscopic tumor residue (R,) 16 6 1 
recurrence when evaluated univariately. Locoregional recurrence-free survival 
according to pT, pN, pM, and R category for the three tumor groups combined are 
iIIustrated in Figure 2. 
No significant prognostic value was found for the tumor type (squamous, Barrett, 
cardia). The same applied to age and gender of the patients, location of the primary 
tumor (upper, middle or lower third), degree of differentiation, and preoperative 
irradiation. 
Locoregional tumor recurrence caused upper gastrointestinal symptoms in 46 patients 
(22 percent), For these patients, the operation did not give definite palliation with 
respect to nonnal food intake (Tables 3 and 6), The median time between operation 
and the occurrence of recurrent dysphagia as a result of locoregional metastases was 
24 months (range of two to 42 months), The absolute risk of malignant secondary 
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Table 3. Locoreglonal tumor recurrence according to symptoms of 209 patients who 
had operative therapy for a malignant tumor of the esophagus or gastroesophageal 
junction. 
Group 1: 
Group 2: 
Group 3: 
Squamous cell carcinoma, 11=95 
Adenocarcinoma of the esophagus, 11 =57 
Adenocarcinoma of the cardia, 11=57 
Recurrence and symptoms Group 1 Group 2 
Locoregional recurrence 34 (36) 22 (39) 
Symptoms' related to 
upper gastrointestinal tract 
Dysphagia/vomiting 21 (22) 11 (19) 
Aspiration due to fistula 2 (2) 1 (2) 
Hematemesis 1 (1) 1 (2) 
Other symptoms' 
Pain 14 (15) 12 (21) 
Respiratory obstruction 14 (15) 5 (9) 
Hemoptysis 3 (3) 1 (2) 
Hoarseness 13 (14) 7 (12) 
Group 3 Total 
17 (30) 73 (35) 
14 (25) 46 (22) 
3 (1) 
2 (1) 
12 (21) 38 (18) 
7 (12) 26 (12) 
1 (2) 5 (2) 
1 (2) 21 (10) 
'" Patients can have more Ihan one symptom. Numbers in parentheses are percentages. 
Table 4. Number of additional diagnostic procedures to confirm and to localize the 
recurrent tUlllor. 
All Group Group 2 Group 3 
patients' 
11=73 11=34 11=22 11=17 
None 3 2 1 0 
Chest roentgenogram 33 24 7 2 
Endoscopy 48 20 13 15 
Ultrasound 28 18 2 8 
CT-scan 25 15 6 4 
Histology, cytology 52 20 16 16 
* Many patients had more than one test, 
eT: computed tomography. 
dysphagia amounted to 18 and 22 percent at two and five years, respectively, for the 
three tumor groups combined (Figure 3). By the conclusion of the study period, all 
patients with recurrent malignant dysphagia had died. Recurrent dysphagia lasted. an 
average 5.3 months (Range of 0.3 to 21.5 months), before the patients died (Table 6). 
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Table 5. Multivariate analysis of locoregional tumor recurrence in relation with the 
histopathologic factors of 209 patients who had operative therapy for a malignant 
tumor of the esophagus or gastroesophageal junction. 
Group I: 
Group 2: 
Group 3: 
Squamous cell carcinoma 
Adenocarcinoma of the esophagus 
Adenocarcinoma of the cardia 
Tumor type 
Group I 
Group 2 
Group 3 
pT·category 
T1•2 
T3,4 
pN·category 
No 
N, 
pM·category 
Mo 
M, 
R·category 
Ro., 
R, 
Total. 
n=209 
95 
57 
57 
78 
131 
146 
63 
195 
14 
186 
23 
Recurrence 
at 5 yr 
(percent)* 
44 
53 
53 
37 
51 
39 
74 
45 
>90 
45 
69 
*' Actuarial percentage (univariate), 
** FOf comparison with the reference category. 
o I.Odenotes the reference category. 
Relative 
recurrence 
rateO 
1.0 
0.9 
0.8 
1.0 
1.5 
1.0 
2.3 
1.0 
5.2 
1.0 
1.8 
p 
value** 
0.79 
0.42 
0.15 
0.002 
<0.001 
0.10 
In 27 of the 46 patients with malignant secondary dysphagia, the recurrent tumor mass 
was localized within the chest and invaded the neoesophagus from outside. Only for 
this subgroup of patients with intrathoracic peripheral tumor recurrence could the 
upper gastrointestinal symptoms have been prevented by using an extra·anatomic 
reconstruction route. The mean duration of this probable advantage was 4.4 months 
(range of one to 15.6 months) (Table 6). Analysis of the various risk factors related to 
this specific type of recurrence showed similar results, as described for the whole 
group of patients with locoregional recurrence (Figure 4). Six of the 27 patients with a 
symptomatic, peripheral, intrathoracic recurrence had an R2 resection. In the 
univariate analysis, the most important prognostic factors were the Nl and Ml 
category and the presence of macroscopic tumor residue (R2 compared with RO.l). 
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Figure 1. The overall survival rate of 209 patients who had operative therapy for a 
malignant tumor of the esophagus 01' gastroesophageal junction. Group I, squamous 
cell carcinoma; group II, adenocarcinoma of the esophagus, and group III, adenocar-
cinoma of the cardia. Number of patients at risk are indicated at the bottom. The 
difference between group I and group III is significant (P=0.02). 
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Figure 2. Locoregional recurrence-free survival rate for the three tumor groups 
combined (n=209) according to pT-category, pN-category, pM category and R-
category. P-values refer to univariate compal'isons. 
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recurrence in 209 patients who had operative therapy for a malignant tumor of the 
esophagus or gastroesophageal junction. Group I, squamous cell carcinoma; group II, 
adenocarcinoma of the esophagus, and group III, adenocarcinoma of the cardia. 
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Figure 4. Peripheral, intrathoracic recurrence-free survival rate for the three tumor 
groups combined (n=209) according to pT-category, pN-category, pM-category and R-
category. P-values refer to univariate comparisons. 
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Table 6. Locoregional tUl110r recurrence in relation to a possible benefit of an extra-
antomic reconstruction route in 209 patients who had operative therapy for a 
malignant tumor of the esophagns or gastroesophageal junction 
Group I: 
Group 2: 
Group 3: 
Squamous cell carcinoma, 11=95 
Adenocarcinoma of the esophagus, 11=57 
Adenocarcinoma of the cardia, 11=57 
(Duration from onset up to death) 
Group Group 
I 2 
Locoregional recurrence 34 (36) 22 (39) 
Locoregional recurrence 
plus upper GI symptoms 21 (22) 11 (19) 
Mean duration upper 
GI symptoms' 5.4 4.8 
Median and range duration' 
3.1 4.8 
0.3-21.5 1.2-15.4 
Benefit extra-anatomic 
reconstruction 11 (I2) 9 (16) 
Mean duration 
extra-anatomic benefit,;. 4.4 3.7 
Median and range 
duration benefit* 2.8 1.2 
1.0-9.5 1.0-11.4 
Numbers in parentheses are percentages. 
GI: gastrointestinal tract. 
* Months. 
Discussion 
Group Total 
3 
17 (30) 73 (35) 
14 (25) 46 (22) 
5.6 5.3 
3.7 3.5 
1.0-15.6 0.3-21.5 
7 (12) 27 (13) 
6.0 4.4 
13.0 2.7 
1.0-15.6 1.0-15.6 
After operative therapy for carcinoma of the esophagus or the gastroesophageal 
junction with curative intent, about one-third of the patients had locoregional tumor 
recurrence. In most patients, this resulted in disabling upper gastrointestinal tract 
symptoms, especially in recurrent dysphagia. For these patients, operative therapy 
provided neither definite cure nor permanent palliation of dysphagia. When evaluating 
the quality of palliation by operative therapy compared with other treatment modali-
ties for carcinoma of the esophagus, one should not only consider the in-hospital 
morbidity and mortality rates, but also the early and the late recurrence of dysphagi-
all. Early dysphagia is almost always caused by benign stricture fOlmation at the site 
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of the anastomosis and can effectively be treated by endoscopic dilatation". 
If dysphagia recurs relatively late postoperatively, it almost invariably indicates tumor 
recurrence. Forty-six patients (22 percent) had secondary dysphagia as a result of 
locoregional tumor recurrence (positive cervical nodes included), The operative 
therapy for these patients must be considered as failures, both with respect to 
definitive cure and to permanent palliation. Given these circumstances, additional 
palliative measures, such as radiotherapy and pertubation, are indicated, depending on 
the general condition of the patient, the localization and the extension of the recur-
rent tumor, and the presence of distant metastases. In 27 (59 percent) of these 46 
patients, the recurrent tumor mass was localized within the chest and invaded the 
neoesophagus from outside. For this subgroup of patients, an extra-anatomic reCOIl-
struction route would probably have prevented the upper gastrointestinal tract 
symptoms. This advantage would have lasted on an average for 4.4 months, before the 
patients died. 
The risk of locoregional tumor recurrence is clearly affected by the regional dissemi-
nation and the radicality of the resection. The presence of positive lymph nodes (NI), 
especially at the celiac trunk (MI) and a macroscopically nonradical R2 resection, 
seem to be important risk factors. Although all patients had lymph nodes present in 
the resected specimens, the number of nodes was limited. This might explain the 
relatively high percentage of patients with NO disease when compared with patients 
with an extended lymphadenectomy. 
The minimal follow-up period of the patients was two years. Although a substantial 
number of patients were still alive without disease by the end of the study period, and 
therefore still at risk for tumor recurrence, we know from earlier studies that most 
tumor-related events occur within two years postoperatively2. This can explain why the 
absolute risk of having malignant secondary dysphagia hardly rises after the second 
year (Figure 3). 
What is the price to be paid for the advantage of an extra-anatomic reconstruction? 
The closure of the hiatus and the creation of a retrosternal tunnel are simple and take 
only a few minutes. A rare but serious perioperative complication is retrosternal 
(venous) bleeding, for which a sternotomy is sometimes necessary to control the 
hemorrhage. If the whole stomach is brought up to the neck, it can be necessary to 
remove a portion of the manubrium and the medial portion of the left clavicle to 
avoid compression of the gastric conduit. If a narrow gastric tube is used (2 to 3 cm), 
this is hardly ever indicated. The retrosternal route is 2 to 3 cm longer than the 
prevertebral route, which might induce traction and relative ischemia at the site of the 
anastomosisl 3,14 • This might explain the increased risk of anatomic leakage that has 
been reported for palliative retrosternal gastric bypass procedures of the excluded 
esophagus 1s• However, it is unclear from these uncontrolled data to what extent the 
high leakage rate must be attributed to the poor general condition of these patients 
with advanced malignancy. 
No data are available on the functional aspects of a gastric tube in an extra-anatomic 
position. In case of a retrosternal reconstruction, the neoesophagus follows the 
manubrium in a curved course, which might hamper the nonnal passage of food and 
liquids. Furthermore, endoscopic dilatation of a benign stricture might be more 
complicated because of this curved course, Institutions at which the extra-anatomic 
route is always used after "curative" resection, do not report a high incidence of 
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technical complications J functional complications, or both16, 
APPENDIX 
The Kaplan-Meier method (Kaplan EL, P Meier: Nonparametric estimation from 
incomplete observations. J Am Statist Assoc 1958, 53: 457-481) has proved to be 
useful for providing iuformation about the pattern of events, for example death or 
tumor recurrence, along time. Essentially, the method adjusts for the duration of 
follow-up, which, in nearly all cases, varies from patient to patient. The Kaplan-Meier 
method gives an estimate of the risk of an event within a certain period for an event 
bound to occur in each patient, provided that the follow-up period is sufficiently long, 
for example J death irrespective of cause. Such an interpretation in term of risks is, in 
general, not possible for events that do not invariably occur in each patient, for 
instance, local tumor recurrence (Pepe MS, M Mori: Kaplan-Meier, marginal or 
conditional probability in summarizing competing risk failure time data? Stat Med 
1993; 12: 737-751). Patients who die, possibly as the result of distant metastases or 
intercurrent disease before a local tumor recurrence becomes manifest, are handled 
by the Kaplan-Meier method as if they left the study at the moment of that death. 
Thereafter, however, these patients are imaginary still considered to be at risk for 
tumor recurrence. This is based on the assumption that if such deaths could be 
avoided, such patients would have the same future risk of having a recurrence, 
Because it is impossible to prevent death without tumor recurrence, the Kaplan-Meier 
curve will not depict the true risk, along time, for patients to develop a local recurren-
ce, but will give an over-estimate of that risk. This is especially the case in studies on 
patients with a high mortality from other causes. 
This phenomenon can be demonstrated by a hypothetical example. Suppose that 75 of 
a group of 100 patients die within one year without local tumor recurrence, and the 
remaining 25 patients have local recurrence during the second year of follow-up. The 
Kaplan-Meier method will then show a percentage of 100 without local recurrence in 
the first year of follow-up study. This percentage will decrease to zero in the second 
year of follow-up study, suggesting that the "risk" of local tumor recurrence for the 
total group of patients equals 100 percent. This 100 percent risk, however, applies only 
to the subgroup of patients who survive the first year. Because only 25 of the 100 
patients actually have local recurrence during their life, the risk for the total group is 
25 of 100 (25 percent) instead of 100 percent. The discrepancy occurs because the 
patients who died without local recurrence should no longer be considered as being at 
risk for recurrence. 
A method is described to estimate the true (absolute) risk of an event to occur during 
a certain period of time (T months) after entering the study. The event to be conside-
red we derive from this article and concerns secondary dysphagia as a result of 
locoregional tumor recurrence in patients. operated upon for carcinoma of the 
esophagus. The method is presented in two steps. The probability needs to be 
estimated that patients have secondary dysphagia in a particular month. This probabi-
lity equals the probability that patients are alive in that same month without a 
previous dysphagia, multiplied with the probability that patients have secondary 
dysphagia in the mentioned month. In this multiplication, the first probability is 
estimated by the standard Kaplan-Meier estimate, the second is estimated by the 
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proportion of patients who have secondary dysphagia among those who are still at risk 
in that particular month. That is, with exclusion of the patients who experienced the 
event before, had died or had left the study for other reasons. The first step has to be 
repeated for each month preceding the time T. 
The second step concerns addition of all the calculated probabilities for the months 
preceding the month T. The sum thus obtained gives the estimate of the risk of 
secondary dysphagia before the time T. If all the patients have follow-up evaluation at 
least to the time T, in case they did not die before that time, this method simply 
reduces to the calculation of the proportion of patients who did experience the event 
before the time T, with the total number of the group as denominator. 
According to this method, the risk for the total group of patients, reported in the 
present study to have secondary dysphagia within two years (T=24 months) or five 
years (T=60 months) postoperatively, seemed to be 18 and 22 percent, respectively. In 
contrast, with the original Kaplan-Meier method, these percentages were calculated as 
23 percent within two years and 32 percent within five years, thereby considerable 
over-estimating the absolute risks. It is likely that some of the patients who died 
during the early follow-up period "escaped" from dysphagia. This has obviously 
influenced the risk of dysphagia itself, but should not result in adjustments of the 
estimate of the risk. 
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CHAPTER 6 
EVALUATION OF CHANGES IN PROGNOSTIC STATUS 
This chapter was published in shorter form in Computers in Biology and Medicine 1989; 
19: 181-188 by W.e,J. Hop and H.R. van Buuren 
6.1 Introduction 
The methodology of fixed factors, that is factors which have a fixed level throughout 
the study and which were determined at the time of entry into the study is reviewed 
in Chapter 2. Basic elements in the evaluation of such factors is the grouping of 
patients according to the levels of the factors, and comparing the groups thus 
obtained using Kaplan-Meier survival curves and significance tests. Another approach 
in the evaluation of such fixed factors would be to model the hazard rate, e.g. by 
using Cox-regression [Cox, 1972]. These approaches often lead investigators errone-
ously to apply the same techniques to evaluate factors which are time-dependent, i.e. 
factors which manifest themselves during follow-up. As an example one may consider 
the prognostic impact of a recurrence of disease regarding the ultimate survival, or 
some other event observed during follow-up. By grouping the patients according to 
whether or not the recurrence had occurred, and comparing the two groups thus 
obtained regarding their survival taken from entry into study, a severely biased 
outcome may result. This bias arises from the fact that the length of survival itself will 
influence the chance of a patient to be classified into one group or the other. A late 
recurrence necessarily implies a long survival from entry. A preferable strategy is to 
investigate the survival pattern following the event studied. But then the problem is 
how the contrast to such a survival curve is to be defined. The survival curve of the 
total patient group is often used for comparison, but one can easily construct 
examples in which the patterns of occurrence of the event and death are such that 
misleading conclusions about the effect of the event may be reached. In the field of 
clinical oncology, where responders to chemotherapy often are compared with 
nonresponders regarding survival, such so called response-time bias is well recognized 
[Anderson et aI, 1985]. Each patient starts in the non-response category and can only 
move to the responder status after sufficient time. Patients with an early death thus 
will not have the opportunity to enter the responder group. If it is required to 
compare survival according to response category, proper adjustments for the response 
time are needed. Of course, such analyses can not discriminate between the situation 
in which survival is affected by the response and the one in which response is only a 
marker of better prognosis. Also the presence of already known prognostic markers at 
baseline has to be taken into account [Oye et aI, 1984]. Similar problems occur when 
one wants to correlate retrospectively with survival the amount or duration of chemo-
therapy received [Redmond et aI, 1983]. 
A partial solution to the problem of response-time bias is provided by the so-called 
"Iandmarktl-method. 
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6,2 The Landmark Method 
A way to avoid the phenomenon of response-time bias is to select some "landmark" 
time point [Anderson et ai, 1983]. Only patients are considered who survive the 
chosen landmark time tL , and these are classified according to the history of the 
factor, e.g. a response, whose prognostic impact is to be evaluated. The choice of the 
time-point tL is arbitrary but may be based on some natural time of clinical signi-
ficance. Also the number of patients available may give some guidance in the choice 
of tL. For the analysis, all methods described in chapter 2 are available to assess the 
prognostic impact of the factor considered. This landmark method was used by 
Ettinger and Lagakos (1982) to evaluate the prognostic impact of tumour response in 
lungcancer patients treated with chemotherapy. 
The method is illustrated for patients with inoperable breast carcinoma without 
evidence of distant metastases who had been treated with rildiotherapy [Treurniet-
Donker et ai, 1980]. It was investigated whether a local tumour recurrence was 
predictive for a worse survival. For the chosen landmark-time tL =20 months after 
start of treatment this is shown in Figure 1. 
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Figure 1. Survival past 20 months after treatment, Patients are grouped according to 
whether or not the tumour had recurred before 20 months after treatment. 
For those patients surviving 20 months it appeared that it was an ominous sign if a 
local recurrence had developed before that time. Similar findings applied to other 
choices of tL. 
A major advantage of the landmark method is its conceptual simplicity. A great disad-
vantage, however, is the neglect of the information about the time behaviour of the 
factor studied after the landmark time tL• Also any relation between the prognostic 
factor and death rates before tL is not considered. A preferable method therefore is 
the so-called "transient-stateH method. 
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6.3 The transient state method 
Much interest of various biostatisticians in the problems discussed here was raised by 
the early heart-transplantation studies. Randomized studies in this field are lacking 
because it is clinically considered not valid to perform these. Therefore problems 
arise regarding a fully valid evaluation of the efficacy of the procedure. If one 
considers the group of patients who entered the program, and compares survival of 
those who actually received a heart transplant with those patients who did not, it is 
evident that such a comparison will be severely biased [Gail, 1972]. A transplanted 
patient must have lived long enough while being on the waiting list before a donor 
heart would become available. No such requirement applies to the non-transplanted 
patients. There is a real possibility that the instantaneous risk of dying, i.e. the hazard 
rate for the group as a whole, is decreasing while being on the waiting list due to 
heterogeneity among the patients, although for individual patients this risk may 
increase in time. Mantel and Byar [1974] showed that a pseudo control group for 
transplanted patients could be formed. This is shown in Figure 2 for a number of 
hypothetical patients. Basically, Mantel and Byar's method is reduced to a comparison 
of death rates between transplanted patients and their "proper" controls at all possible 
points in time. Their statistic is very similar to the logrank-statistic, except that group-
membership is not fixed but may change along time 
[Crowley, 1974]. 
d : dead 
> : alive 
x : transplant 
--------~-------------------> 
------r-~------------d 
time 
Figure 2. Dynamics of live hypothetical patients. Between time-points tl and t, 
patients 3, 4 and 5 serve as controls for patient 2. After t, patient 5 acts as control 
for both patients 2 and 4. 
A graphical procedure to accompany the method is described by Simon and Makuch 
(1984). From some chosen time-point x, which should at least be equal to the smallest 
observed time at which both prognostic states are present, they suggest to estimate 
the cumulative hazards 1;).,,(1)d1 and I;A,(1)dT. Here ).,,(t) and A,(t) denote, respecti-
vely, the death rates while patients are in the prognostic states 0 (e.g. non-transplan-
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ted) and 1 (transplanted). Simon and Makuch (1984) further suggest to convert these 
cumulative hazards into Kaplan-Meier type curves because the latter might be more 
easy to communicate. 
Figure 3 shows the cumulative hazard rates thus obtained for the breast cancer 
patients as described before. The figure shows that the cumulative hazard associated 
with recurrences has about twofold increased as compared with patients without a 
local recurrence. In the following a method is described in which relations between 
time-dependent factors and survival can be quantified in a more rigorous manner. 
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Figure 3, Estimated cumulative death rates according to recurrence status, Note the 
logarithmically transformed vertical axis, 
6,4 Cox-regression with time-dependent covariates 
The proportional hazards model (chapter 2, equation 8.1) can be extended to include 
time-dependent covariates by using 
A(t;Z(t» = Ao(t)eZ(t)P (6.1) 
Here Z(t) contains elements whose levels depend on time, e.g. Z(t)=O and Z(t)= 1 
denote the two prognostic states as descibed in the previous section. Factors with 
fixed levels may additionally be represented in Z(t). This model has been used in the 
evaluation of heart transplantations [Crowley and Hu, 1977J. If the time-dependent 
covariate Z(t) takes the value 1 as soon as the patient is transplanted, and Z(t)=O 
corresponds to the situation before that time, the model then states that at time t 
after entry into the program, the mortality rate among transplanted patients equals 
the constant e' times the mortality rate among patients waiting for a transplant. If it 
appears that e' is smaller than one, i.e. J3 < 0, such finding would indicate that 
transplantation is beneficial with respect to survival prognosis. A similar approach was 
used in an evaluation of allogeneic and autologous bone marrow transplantation in 
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acute myelogenous leukemia [Hermans et aI, 1989]. The procedure is graphically 
displayed in figure 4. 
A 
---
0'-r----------tc------
o " time 
Figure 4. Death rates according to two prognostic states. At time t, a transition 
occurs from A to a more favourable prognostic status B. 
Mauger et al (1995) modelled both a short-term and long-term effect associated with 
the transition to another prognostic state. 111e effect of such a transition is modelled 
as 
(6.2) 
In this formula w denotes the time point at which the transition takes place; I(t-w) 
equals zero for values of t less than w, and equals 1 if t is equal or greater than w. 
Before the transition, the death rate equals A,,(t). The death rate immediately after 
the transition equals exp(Il, + 1l,)A,,(t), whereas the death rate corresponding to the 
long-term effect of the transition equals exp(Il,)A,,(t). The parameter Il, «0) determi-
nes the rate at which the ultimate hazard rate exp(ll,)A,,(t) will be reached. A 
graphical display of the model is shown in figure 5. 
Applying this method for patients who had received a kidney-transplant, Mauger et al 
(1995) found that such patients initially experienced a somewhat higher death rate as 
compared to those who remained on dialysis. In the long run, however, their mortality 
was less. 
Kalbfleisch and Prentice (1980) make a distinction between internal time-dependent 
covariates and external time-dependent covariates. An internal time-dependent 
covariate is a variable whose level is generated by the individual under study. This 
level can ordy be observed as long as the patient is alive and under observation. An 
external time dependent covariate is one whose level is determined by some external 
process, i.e. a process not under the control of the individual under study. A donor 
organ becoming available in the examples above can be considered to be of the latter 
type. Also the cumulative exposure to particular agents in cohort studies of the inci-
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Figure 5, At time t. the death rate initially increases from A to a higher value, 
Ultimately a more favourable death rate is reached at B, The rapidity at which B is 
reached depends on the third beta-parameter, 
dence of particular diseases in occupational epidemiology, can be considered to be of 
the external type. Factors studied in clinical medicine in most cases are of the internal 
type. The study of the value of certain biochemical tumour markers in relation to the 
relapse rate in cancer patients [Gail, 1981] is an example. Another example is the 
evaluation of the anti-leukemic effect of graft-versus-host disease in patients who have 
recieved a bone marrow transplant [Prentice et ai, 1978]. For such studies the varia-
ble Z(t), which may represent not only the value of a particular factor at time t, but 
may also include aspects about the behaviour of the factor before time t, need to be 
quantified. An adequate functional choice for Z(t) may be obtained using clinical 
guidance but is not always easy. For the tumour marker study, Gail (1981) considered 
some variants of representation of the marker history for an individual up to time t, 
the most simple one being the level of the tumour marker itself at time t without 
consideration of previous values. Another aspect of the tumour marker behaviour 
would be to ascertain whether in the interval from 0 to t one or more elevated values 
of the marker were observed. In the latter situation the time-dependent covariate for 
an individual would be a step-function which equals 0 before any elevation is 
observed. It takes the value 1 after the first occcurrence of an elevated value. In this 
case Z(t) reduces to a status-indicator as described before. Also the rate of increase 
of the tumour marker might be a proper choice. 
Sometimes a graph of levels of the variable studied after grouping of patients 
according to the time-point at which the event occurred may be useful. This is 
demonstrated by the following example. For asthmatic children it was investigated 
whether the measurement of transcutaneous oxygen tension could be used as a sub-
stitute for the measurement of the PDw [Broekhoven et ai, 1991]. The PDw denotes 
the dose of the provocative agent Metacholine which causes a decrease of 20 percent 
of the forced expiratory flow in one second (FEV,). Starting from an initial dose of 
Metacholine, each time the dose was doubled up to the moment that the PD20 was 
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reached. After grouping the patients studied according to the dose at which the PD20 
was reached, figure 6 is obtained. At the highest dose tested (dosestep 10), two 
children stiIl did not respond. The figure shows that the oxygen tension behaves 
relatively stable prior to achieving the required FEY, response. At the dose-step at 
which the PD20 was reached, a large decrease of the oxygen tension had taken place. 
Analysis of the data using the discrete-time version of Cox-regression (there is no 
continuous time involved here, but discrete dose-steps; chapter 2) showed that the 
current level of the decrease from baseline of the transcutaneous oxygen tension was 
to a high degree significantly related to the probability of having reached the PD20• 
% 
'0 
20 
,., 
10 
° L,--Y-~---'--'--''--r--'---'--c 2 3 4 5 6 8 9 10 
dosestep 
Figure 6. Mean decrease from baseline (percent) of transcutaneous oxygen tension. 
Patients are grouped according to the dose-step at which the PD20 was reached. 
To estimate the components of n, the approximate likelihood (chapter 2, equation 
8.4) is generally used, but now with the values of Z in the various risk sets as determi-
ned at the time of failure to which the risk sets correspond. For the case with only 
one status indicator (Z(t) equals 0 or 1), it was shown by Crowley (1974) that the 
score test of Jl~O reduces to the two-groups logrank test with group membership 
varying with time [Mantel and Byar, 1974]. Special programming using the method of 
profile likelihood [McCullagh and Neider, 1990] is required for the case concerning 
the separate short-term and long-term effects discussed (equation 6.2 above) 
Model (6.1) was applied in the case of the irradiated breast cancer patients discussed 
above. The parameter 13, which represents the effect of a local recurrence on the 
death rate, was estimated to be 0.58 with a standard error of 0.25. For patients 
developing a local recurrence the death rate therefore seems to increase by a factor 
eO." ( ~ 1.8). 
The baseline hazard function can be estimated in a similar way as for fixed covariates, 
with the time-dependent covariates taking the observed values at the different failure 
times. 
Since in clinical practice the covariate values will often not be monitored continuous-
ly, but only at fixed intervals, some kind of interpolation will be necessary to obtain 
the values of the time-dependent covariates at the different failure times for the 
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various individuals. Simple interpolation rules, such as linear interpolation or carrying 
forward the last observation, generally will suffice. Some of the goodness-of-fit 
procedures which are applicable in the fixed-covariate case (chapter 2) can also be 
used in case time-dependent covariates are present. For instance, the stability of the 
regression coefficients when the model is fitted in adjacent intervals of the time-axis 
can be investigated. It will also be possible to investigate whether regression-coeffi-
cients vary smoothly along time by incorporating terms representing functions of time 
itself in the regression model. Stratification on fixed covariates and estimating the 
cumulative baseline hazard functions, will allow assessment of the proportionality 
assumption by graphical means. The comparison of observed survival curves with 
estimated survival curves based on grouping of patients according to covariates does 
not apply here. These depend on past and future values of the time-dependent 
covariates which are unknown. By taking succesive short inteIvals, however, in which 
the covariate vector Z(t) is assumed to be constant during each interval, short term 
survival probabilities can be calculated [Hughes, 1992]. The probability of surviving 
time t + h conditional on being alive at time t can be approximated by 
exp {ez(t)~ [-Ao (t+h) + Ao (t) J) (6.3) 
Here 1Io(t) denotes the estimated cumulative baseline hazard function. For groupings 
of the covariate vector at time t, the short term observed survival probabilities can be 
compared with the estimated short term survival probabilities for each interval. 
Also the plotting of residuals as defined by Barlow and Prentice (1988) may be useful. 
These residuals are computed for each subject separately for each variable and focus 
on the discrepancy between the covariate values at the failure time of the subject who 
dies and the covariate means of the corresponding risk set. These residuals can be 
plotted against the observation times. Although the plots are difficult to interpret, any 
trends or changes in variability are indicative of violations of the proportional hazards 
assumption [Altman and De Stavola, 1994]. 
6.5 Discussion and introduction to chapters 7-11 
A key clinical question at diagnosis is that of prognosis. A means of updating 
prognosis on the basis of the latest observations on a patient would be extremely 
valuable in many situations. Also an assessment of factors related to the drop-out rate 
in clinical studies might be useful [Macera et ai, 1988]. The proportional hazards 
model with updated covariates may be a useful tool for such analyses. The method 
allows the investigation of the history of covariates regarding their association with 
the instantaneous hazard rate. Its main use therefore lies in the description of the 
evolution of disease. Short-term predictions, that is predictions over periods of time in 
which the time-dependent factors do not vary greatly, are possible. Long-term 
predictions however are not possible. This would require an additional modelling of 
the time-path that the various covariates will follow [Mulder, 1993]. 
If the effect of treatment is of primary importance, as in the analysis of clinical trial 
data, it is extremely hazardous in general to allow for time dependent factors in the 
model. Because then there is a real danger that effects of treatment will be "adjusted 
away" by the inclusion of such factors. Similar difficulties regarding the interpretation 
will arise when other baseline covariates are evaluated regarding their prognostic 
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value while the statistical model also includes time-dependent covariates_ For instan-
ce, a model relating various baseline characteristics in oncology to survival, at the 
same time allowing for metastases which may be found during follow-up of patients, 
will be hard to interpret. In exceptional cases, however, both the inclusion of treat-
ment and time dependent variables in the same model may give useful results by 
illucidating the mode of action of the treatment. This is shown in one of the following 
chapters where data arising from a randomized clinical trial evaluating selective 
decontatnination in acute pancreatitis are presented_ In that study it was found that 
survival of patients was improved when using adjuvant selective decontamination_ It 
was also found that in patients of the selective decontamination group less gram-
negative infections of pancreatic necrosis occurred_ Using time-dependent Cox-regres-
sion, allowing for both treatment and whether or not gram-negative infected necrosis 
had developed, it was found that a gram-negative infection of pancreatic necrosis was 
an ominous sign, while, taking account of this, no significant difference between the 
selective decontamination group and the control group remained regarding mortality_ 
In the following chapters various clinical studies are described in which the interest 
focussed on the assocation between factors as determined during follow-up and the 
OCCllrrence of some endpoint. The above mentioned effect of a gram-negative 
infected pancreatic necrosis on mortality in acute pancreatitis is described in chapter 
7_ 
It is often thought that transabdominal chorionic villus sampling during pregnancy 
may induce abortions_ It goes without saying that sllch an effect can only be assessed 
be means of observational studies_ In chapter 8 a study is described where the rate of 
spontaneous abortions is studied among women who were scheduled for such an 
examination. At the various gestational ages, the women who were stiB waiting for the 
procedure served as controls for the women who already had undergone the examina-
tion_ Using Cox-regression the procedure related abortion risk was assessed_ 
In chapters 9, 10 and 11 (respective fields: cardiology, obstretics and oncology), 
clinical longitudinal studies are described in which monitoring measurements were 
evaluated regarding their ability to predict a defined endpoint. 
References 
Altman DG, BL de Stavola. Practical problems in fitting a proportional hazards model to data with 
updated measurements of the covariates. Statist Medic 1994; 13: 301-341. 
Anderson JR, KC Cain, RD Gelber. Analysis of survival by tumor response. J Clio Oneol 1983, 1: 710-
719_ 
Barlow WE, RL Prentice. RcsiduaJs for relative risk regression, Biometrika 1988; 75: 65-74. 
Broekhoven P van, WCJ Hop, B Rassec, Je de Jongstc, KF Kerrebijn. Comparison of FEV, and 
transcutaneous oxygen tension in the measurement of airway responsiveness to Metacholine. Pedr Pulm 
1991; 11: 254-258_ 
Cox DR. Regression models and life tables (with discussion). J Roy Statist Soc 1972; B34: 187·220. 
Crowley J. Asymptotic normality of a new nonparamctric statistic for use in organ transplant studies. J 
73 
Am Stat Assoc 1974; 69: 1006·1011. 
Crowley J, M Hu. Covariance analysis of heart transplant survival data. J Am Stat Assoc 1977; 72: 27-36. 
Ettinger DS, S Lagakos. Phase III study of CCNU, cyclophosphamide, adriamycine, vincristine and VP-16 
in small-cell carcinoma of the lung. Cancer 1982; 49: 1544-1554. 
Gail MH. Does cardiac transplantation prolong life? A reassessment. Ann Int Medic 1972; 76: 815-817. 
Gail MH. Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 
1981; 37: 67·78. 
Hermans J, S Suciu, T Stijnen, P Aegerter, NC Gorin, A Gralwohl, M Hayat, P Stryckmans, R ZiUoun. 
FE Zwaan. Treatment of acute myelogenous leukemia. An BBMT-EORTC restrospective analysis of 
chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Oncol 1989; 
25: 545·550. 
Hughes MDt CL Raskino, SJ Pocock, MR Biagini, AK Burroughs. Prediction of short-term survival \vith 
an application in primary biliary cirrhosis. Statist Medic 1992; 11: 1731-1745. 
Kalbfleisch JOt RL Prentice. The statistical analysis of failure time data. Wiley, New York, 1980. 
Mantel N, DP Byar. Evaluation of response-time data involving transient states: an illustration using 
heart-transplant data. J Am Stat Assoc 1974; 69: 81-86. 
Mauger EAt RA Wolfe, FK Port. Transient effects in the Cox proportional hazards regression model. 
Statist Medic 1995; 14: 1553-1565. 
Macera CAl KL Jackson, C Farach, RR Pate. The use of proportional hazards regression in investigating 
dropout rates in a longitudinal study. J Clin Epid 1988; 41: 1175-1180. 
McCullagh P, JA Neider. Generalized linear models. Chapman and Hall, New York. 1989. 
Mulder PGH. The simultaneous processes of ageing and mortality. Statistica Neerlandica 1993; 47: 253-
268. 
Dye RK, MF Shapiro. Reporting results from chemotherapy trials. Does response make a difference in 
patient survival. J Am Med Assoc 1984; 252: 2722-2725. 
Prentice RL, JD Kalbfleisch, A V Peterson, N Flournoy, VT Farewell, NE Breslow. The analysis of 
failure times in the presence of competing risks. Biometrics 1978; 34: 541-554. 
Redmond C, B Fisher, HS Wieand. The methodological dilemma in retrospectively correlating the 
amount of chemothearpy received in adjuvant therapy protocols with disease-free survival. Cancer 
Treatm Rep 1983; 67: 519-529. 
Simon R, RW Makuch. A non-parametric graphical representation of the relationship between survival 
and the occurence of an event: application to responder versus non-responder bias. Statist Medic 1984; 3: 
35·44. 
Treurniet-Donker AD, WCJ Hop, S den Hoed-Sijtsema. Radiation treatment of stage III mammary 
carcinoma; a review of 129 patients. Int J Radiat Oncol Bioi Phys 1980; 6: 1477·1482. 
74 
CHAPTER 7 
DIFFERENTIAL PROGNOSIS OF GRAM-NEGATIVE VERSUS GRAM-POSITIVE 
INFECTED AND STERILE NECROSIS IN ACUTE PANCREATITIS 
This chapter is submitted for publication by 
H.I.T. Luilen, W.C.I. Hop, I.F. Lange and H.A. Bruining 
Introduction 
As infectious complications have become the leading cause of mortality and morbidity 
in acute necrotizing pancreatitis, patients in whom devitalized pancreatic and 
peripancreatic tissues remain sterile have to be distinguished from others in whom 
secondary infection of pancreatic necrosis develops (Le. sterile vs. infected necrosis). 
Sterile pancreatic necrosis, especially in the absence of systemic complications, has a 
favourable prognosis with a reported mortality rate of 0 - 11 %.14 Mortality, which 
increases sharply with increasing Ranson or Imrie score on admission, is related to 
systemic complications resulting in multiple organ failure occurring most frequently 
during the first two weeks of illness. 5•10 
Infected necrosis on the other hand, occurring later during the course of the disease, 
often proves fatal and is generally agreed to represent an absolute indication for 
surgery in an effort to reduce mortality. 2.11·" 
Cultures of infected necrosis yield most frequently a polymicrobial flora with 
preponderance of gram-negative aerobic bacteria in 50 - 70 % suggesting an enteric 
origin. 2•5•12•15." Gram-positive aerobes (mainly Enterococci and StaphylococcI) are 
isolated in only 5 - 20 % .'.5.12.15.19 
Patients with severe acute pancreatitis in whom infected necrosis exists are usually 
dealt with as one group irrespective of the specific flora cultured. However due to a 
different intrinsic pathogenic potential, the prognosis of patients with infected 
pancreatic necrosis may differ according to the bacteria cultured. In accordance with 
results of bacteriological analyses of infected pancreatic necrosis two major groups of 
patients can be distinguished: gram-positive infected necrosis versus gram-negative 
infected necrosis. This distinction between patients with infected pancreatic necrosis 
has not been studied prospectively to date. 
In a recent controlled clinical trial selective decontamination has been shown to 
effectively reduce mortality in patients with objective signs of severe acute 
pancreatitis. S Selective decontamination (SD) however does not prevent against gram-
positive infection. Subsequent intestinal overgrowth with EnterococcllS resulting in 
increasing gram-positive infections has been suggested to be a limitation of SD.20 
The present prospective controlled clinical study was undertaken to evaluate for both 
treatment groups, Le. SD group and C (= control) group, a possible difference 
concerning mortality between patients with either gram-positive infected necrosis or 
gram-negative pancreatic infection during the course of the disease, as compared to 
patients in whom pancreatic necrosis remained sterile. 
Patients and methods 
Between April 22, 1990 and April 19, 1993, 102 patients with objective signs of severe 
75 
acute pancreatitis were admitted to 16 participating hospitals. The diagnosis of acute 
pancreatitis had been established on the basis of clinical examination and elevated 
plasma levels of serum amylase (> 1000 IU per liter, normal range 0 - 300 lUll 
(Phadebas», or at diagnostic laparotomy (10 patients). All patients suffered from 
severe acute pancreatitis according to a multiple laboratory criteria score (Imrie score 
L 3) andlor grade D or E disease severity (Balthazar grades) using contrast-
enhanced computerized tomography.'-'1 Bacteriologically proven infected necrosis at 
the time of randomization was defined as an exclusion criterium. The patients were 
randomly assigned to receive standard treatment (C group : n = 52 pts.) or the same 
treatment plus selective decontamination (SD group : n = 50 pts.). A more elaborate 
outline has been reported previously. 5 
Microbiology: 
The microbial flora of all patients was carefully monitored. Cultures from oropharynx, 
gastric content and rectum were taken on admission and repeated twice per week 
(surveillance cultures) until discharge. If fever ~ 39°C) was present blood cultures 
were taken. An US- or CT-guided fine needle aspiration with subsequent culture was 
performed if there was clinical suspicion of infected pancreatic necrosis. II Cultures of 
pancreatic and peripancreatic devitalized tissues (Le. necrosis) were obtained at every 
laparotomy. Drainage from the pancreatic bed was also cultured twice per week. 
Samples from oropharynx, stomach and rectum were taken with a moistered sterile 
cotton-tipped swab and cultured semi-quantitatively. Specimens from the pancreatic 
necrosis were sent directly to the laboratory and cultured semi-quantitatively. 
Identification was done following routine microbiological procedures. Pancreatic 
necrosis, peripancreatic devitalized tissues and fluid collections were considered 
sterile in those patients pursuing a nonseptic course and in patients with negative 
cultures. 
Surgery: 
Surgery was perfomled if aspiration cultures demonstrated development of infected 
necrosis or if the condition of the patient was rapidly deteriorating towards a multiple 
organ failure resistant to exhaustive intensive treatment. Access towards the pancreas 
was obtained through a median or (preferably) transverse laparotomy. If repeated 
laparotomies were foreseen, a laparostomy, i.e. ventral open packing of the 
abdominal cavity, was created ensuring a rapid and easy access towards the upper 
abdominal cavity. 12 Removal of necrotic tissue was mainly performed by means of 
finger or clamp fraction, i.e. necrosectomy. 
Statistical Analysis: 
Percentages and continuous data were compared between groups by using Fisher's 
exact test and Mann-Whitney's test respectively. Cumulative percentages of patients 
developing gram-negative or gram-positive infected necrosis, taking account of the 
length of survival, were assessed by the actuarial Kaplan-Meier method and logrank-
test. Cox regression was used to evaluate various factors simultaneously regarding 
mortality.22 This method was also used to assess the relation between the occurrence 
of pancreatic infections (only gram-negative, only gram-positive or mixed gram-
negative I gram-positive) and mortality." P-values given are two-sided, and p = 0.05 
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was considered the limit of significance. 
Results 
Of 102 patients with objective signs of severe acute pancreatitis (Imrie score .2. 3 
and/or Balthazar CT score grade D or E) 50 patients were assigned to the SD group 
and 52 to the C group. The groups were well matched regarding Imrie score (both : 
mean 3.2) and Balthazar grade.' 
Microbiology: twenty-nine of 102 patients (28 %) developed infected pancreatic 
necrosis. Pseudoll/ollas aerugillosa (13 pts.), Escherichia coli (13 pts.), Staphylococcus 
epidenllidis (21 pts.) and Enterococci (19 pts.) were most frequently isolated. Infected 
necrosis occurred in 9 of 50 patients (18 %) of the SD group in comparison to 20 of 
52 patients (37 %) of the control group (p~0.03) due to a significant reduction of 
gram negative infected necrosis (SD : 4/50 patients (8 %); Control : 17/52 patients 
(33 %». Figure 1 shows the increasing percentage of patients with time developing 
gram-negative pancreatic infection. The incidence of gram-positive infection of 
pancreatic necrosis did not significantly differ between treatment groups (SD : 9/50 
patients (18 %); C : 16/52 patients (31 %» (figure 1). 
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Figure 1. Cumulative (actuarial) percentage with time of patients with gram-negative 
infection (left panel) and with gram-positive infection of pancreatic necrosis (right 
panel) according to treatment group (Control (C) and SD). Numbers along curves 
indicate patients at risk. 
The Imrie score at entry into the study appeared to correlate very strongly with the 
incidence of gram-negative pancreatic necrosis with time, especially in the control 
group (p<O.OOI) (figure 2). The Balthazar grade at entry into the study also 
correlated with the incidence of gram-negative pancreatic infection, although less 
pronounced (Grade C/D : 6/48 pts. (12 %) versus Grade E : 14/53 pts. (26 %» 
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(adjusted for treatment group: p=0.03). 
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Figure 2. Cumulative (actuarial) percentage with time of patients with gram-negative 
infection of pancreatic necrosis in the C group (left panel) and SD group (right 
panel) according to Imrie score (I : 0-2 ; II : 3-4 ; III : > 4) at entry into the study. 
Mortality: mortality is significantly reduced in patients treated with adjuvant SD.' In 
patients who survived (n = 73), the percentage of cases in whom infected necrosis 
had occurred was 19 % (14 pts.), which is significantly (p = 0.002) lower than the 52 
% (15 pts.) of non-survivors (n = 29) (table 1). 
Table 1: Bacteriological results of pancreatic necrosis during the course of the 
disease. Data given are numbers of patients. 
Sterile 
Only gram-positive 
Only gram-negative 
gram-positive/negative 
Survivors 
(n = 73) 
59 
6 
8 
(81 %) 
(8 %) 
(-) 
(11 %) 
Non-survivors 
(n = 29) 
14 
2 
4 
9 
(48 %) 
(7 %) 
(14 %) 
(31 %) 
To evaluate the impact on mortality of infected pancreatic necrosis developing during 
treatment, patients were classified each day according to whether pancreatic necrosis 
was still sterile, or whether only a gram-positive, only a gram-negative or a mixed 
gram-negative/gram-positive pancreatic infection had occurred. All patients started in 
the sterile condition in accordance with the entry criteria. 
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Table 2: Multivariate analysis of mortality in relation to the development of infection 
of pancreatic necrosis during treatment, baseline Imrie-score, baseline Balthazar 
grade and randomized treatment. 
Data given between parentheses denote results when no allowance was made for the factor infections. All 
patients start in the sterile category in accordance with the entry criteria. 
Factor Deathsl 
number· 
Relative 
Death Rate 
Significance+ 95 % confidence 
limits of relative 
death rate 
Infected pancreatic necrosis 
Sterile [14/5209] 1+ 
Only G+ [21615] 1.2 
Only G- [4/103] 8.0§ 
Mixed G+/G- [9/508] 7.0i 
Imrie score 
0-2 
3-4 
5-7 
Balthazar Grade 
CID 
E 
Treatment 
[1/36] 
[9/41] 
[19125] 
[9148] 
[20153] 
Control [18/52] 
SD [11150] 
(0+: gram-positive; G-: gram-negative) 
1'10 
7.4 
31.2 
1+ 
0.9 
1+ 
0.8 
(1) 
0.86 
0.001 
0.002 
(10.6) 0.06 
(56.8) 0.001 
(1) 
(1.3) 0.76 
(1) 
(0.4) 0.56 
(-) 
(0.03) 
(0.001) 
(-) 
(0.38) 
(-) 
(0.03) 
0.2.5.5 
2.4,27 
2.1.24.5 
0.9,60.3 
3.9, > 100 
0.3,2.3 
0.3, 1.8 
*: number denotes the number of patient-days (up to day 80, i.e. the day number of the last 
t. 
.. 
.. 
death) after the first occurrence of the infection specified, or the number of patients for Imrie 
score, Balthazar grade or treatment. 
comparison with reference category 
reference category 
not significantly different from each other, but both significantly greater in comparison with 
Only G + category 
{Missing data: BaJthazar grade (n = I)} 
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Using Cox-regression for both groups it emerged that, compared to patients with 
sterile necrosis, those who only acquired a gram-positive pancreatic infection had a 
1.6 fold increased death rate (p=0.52) . Patients who developed only gram-negative 
pancreatic infection had a 14.4 fold increased death rate (p<O.OOI)compared to 
those with sterile necrosis. A similar increased mortality of 15.8 (p <0.001) was found 
in those with a mixed gram-negative/gram-posiHve infected necrosis. 
Table 2 shows the results of the multivariate analysis of the relation between 
mortality and the type of pancreatic infection, taking into account the Imrie score, 
Balthazar grade and randomized treatment. This analysis demonstrates that 
development of a gram-negative infection of pancreatic necrosis during the course of 
the disease is both an important and ominous sign, while there was no significant 
increased mortality due to gram-positive pancreatic infection. Taking into account 
these infections, there is still an increased death rate of patients with a higher Imrie 
multifactorial initial assessment. No additional prognostic value was found for the 
Balthazar grade. The data between parentheses (table 2) also show that SD decreases 
mortality when analyzed without consideration of infectious status. There was no 
mortality difference between treatment groups for patients without gram-negative 
infected necrosis (i.e. sterile or only gram-positive) as demonstrated in figure 3 (left 
panel). After the occurrence of a gram-negative pancreatic infection mortality was 
high (13/21 pts. = 62 %). As shown in figure 3 (right panel) survival in these patients 
did not significantly differ between treatment groups. However a gram-negative 
pancreatic infection occurred in only 4 patients in the SD group. 
Hospital stay: the average hospital stay in survivors with gram-negative necrosis (n=8 
pts.) was 135 days (range 56-241 days), which is significantly higher than the mean 
value of 55 days (range 26-82 days) (p=O.OI) as well as 30 days (range 10 - 71 days) 
(p<O.OOI)of survivors with only gram-positive (n=6 pts.) or sterile necrosis (n=59 
pts.) respectively. Although smaller, the difference between hospital stay of survivors 
with only gram-positive infected and sterile necrosis is also significant (p=0.004). 
These results were similar in both treatment groups (SD or C group). 
Discussion 
This study demonstrates that mortality increases dramatically once gram-negative 
infection of pancreatic necrosis occurs in patients with severe acute pancreatitis. 
However if pancreatic necrosis becomes infected with only gram-positive aerobic 
bacteria mortality is not significantly increased and is comparable with patients in 
whom pancreatic necrosis remains sterile throughout the course of the disease, 
probably because Staphylococcus epiderlllidis or Enterococci, most frequently isolated 
in case of solitary gram-positive infected necrosis, are less pathogenic in these 
patients. 
The overall incidence of secondary infection of pancreatic necrosis is 28 %. In the 
Control group 38 % infected necrosis occurred, which has also been described by 
others.'·I5·24 In patients treated with SD the overall incidence of infected necrosis (18 
%) is significantly reduced due to a marked reduction of gram-negative infected 
necrosis of only 8 % in contrast to 33 % in the C group. The occurrence of a gram-
negative infection of pancreatic necrosis is an ominous sign. Mortality in these 
patients increases significantly irrespective of coexistence of a gram-positive infection 
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as shown in this study. Mortality with regard to the bacteriological status of pancreatic 
necrosis is comparable for the SD group and the C group, i.e. once gram-negative 
infection of pancreatic necrosis has occurred mortalily increases considerably in both 
treatment groups. However mortality in the treatment group is significantly reduced in 
patients treated with adjuvant SD (table 2) as has also been published previously.' 
Consequently, SD reduces mortality in patients with severe acute pancreatitis due to a 
significant reduction in the development of gram-negative infection of pancreatic 
necrosis. This is accomplished by reduction of gram-negative intestinal colonization 
leading to reduced gram-negative bacterial translocation into the pancreatic necrosis. 
However SD is not useful in patients in whom gram-negative pancreatic infection 
already exists before or in whom gram-negative infection develops during SD 
administration as is demonstrated in this study. 
It has been suggested that overgrowth and translocation of gram-positive bacteria, i.e. 
Elllerococc; or Staphylococci, may be a draw back of SD.20,,, Our results do not 
support this hypothesis. Neither intestinal overgrowth nor increased incidence of 
gram-positive infected necrosis has been found in our study. Mortality due to 
unexplained gram-positive sepsis with positive blood cultures in two patients and 
otherwise documented sterile necrosis at time of death, was equally divided among 
the SD and the C group. However these possible hazards demand strict indications 
and careful bacteriological surveillance as is the case for any kind of antibiotic 
regimen. 
The development of gram-negative infection of devitalized tissues in and around the 
pancreas is, apart from the Imrie score, the most important parameter determining 
outcome. Gram-negative pancreatic infection can be minimized with adjuvant SD 
thereby reducing mortality in patients with severe acute pancreatitis. 
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Figure 3. Left panel: Actuarial survival from entry into the study counting only 
deaths with sterile or only gram-positive infected pancreatic necrosis according to 
treatment group. Tick marks denote patients dying after a gram-negative infection of 
pancreatic necrosis. Right panel:Survival after the occurence of gram-negative 
infection of pancreatic necrosis according to treatment group. 
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CHAPTERS 
SPONTANEOUS ABORTION RATES AND ADVANCED MATERNAL AGE: 
CONSEQUENCES FOR PRENATAL DIAGNOSIS 
This chapter was published in The Lancet 1990; 336: 27-29 
by T.E. Cohen-Overbeck. W.C.J, Hop, M. den Ouden, L. Pijpers, M.G,J. Jahoda and 
J.W. Wladimiroff. 
Introduction 
The primary indication for first-trimester prenatal chromosome analysis is advanced 
maternal age. 12 Jahoda et ai' found that transcervical chorionic villus sampling (TC-
CVS) at 9-11 weeks of gestation was associated with a significantly higher spontaneous 
abortion rate in women aged 36 and older (7·2 %) than in women aged under 36 
(2·6%). Whether this higher abortion rate is procedure related or due primarily to a 
higher baseline rate of fetal loss at advanced maternal age is uncertain. The objective 
of the present study was to determine maternal age related and procedure related 
fetal abortion rates in older women scheduled for transabdominal chorionic villus 
sampling (TA-CVS) at 12-14 weeks of gestation. 
Patients and methods 
384 pregnant women requesting prenatal diagnosis between January and October, 
1988, were included in the study. 
Admission criteria were: (i) maternal age 36 years or older at 20 weeks of gestation 
(ii) a viable singleton pregnancy; (iii) gestational age not beyond 76 days; (iv) no 
indication for prenatal diagnosis apart from advanced maternal age. TA-CVS was 
scheduled as an outpatient procedure between 12 and 14 weeks of gestation.' After 
reconfirmation of fetal viability by ultrasound, the skin was disinfected and a 20 
gauge needle without stylet was introduced into the chorion frondosum under continu-
ous ultrasound guidance. No local anaesthetic was used. The needle was aUached to a 
20 ml syringe filled with 5 ml saline. Chorionic tissue was obtained by moving the 
needle under continuous suction in a vertical and oblique direction. During each 
procedure the number of aUempts and the amount of tissue collected were recorded. 
Non-attenders were contacted personally in order to establish the reason for failing 
their appointment. 
In the event of a spontaneous abortion the gestational age at which this had occurred 
was documented. Continuing pregnancies were followed up by means of a questionnai-
re about short-term and long-term complications. 
Statistics: 
Cumulative percentages of women having a spontaneous abortion while being 
scheduled for TA-CVS were calculated with life-table methods'. The log-rank test was 
used to compare percentages between the different classes of gestational age and 
maternal age. In this analysis. women were considered removed from the study as 
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soon as TA-CVS had been completed. 
To assess the effect of the TA-CVS procedure on the spontaneous abortion rate, 
patients themselves partially served as controls. The composition of the control group 
depended on the variable interval between intake and the TA-CVS procedure. For 
example, if 2 patients, matched for maternal and gestational age at intake, waited 15 
and 20 days, respectively, then the interval between day 16 and day 20 for patient 2 
would serve as the control period for patient 1, who by then had already undergone 
TA-CVS. Cox regression6 was used to compare abortion rates between those still 
waiting and those who had already undergone TA-CVS at various points of time. In 
this analysis the day of gestation at intake was considered the day of entrance into the 
study. Relative (post versus pre TA-CVS) abortion rates, adjusted for maternal age, 
were calculated.' p values given are two-sided. The limit of statistical significance was 
set at p<0·05. 
Results 
Maternal age of the 384 women ranged from 35 to 49 years (median 37 years) and 
maternal parity from 0 to 6 (median 1). Women were subdivided into five gestational 
age classes, 42-48 days (n=IO), 49-55 days (n=68), 56-62 days (n=I72), 63-70 days 
(n=98), and 71-76 days (n=36), and three maternal age classes, 35-36 years (n=106), 
37-39 years (n=213), and 40 years or older (n=65). 5 women decided against prenatal 
diagnosis and 7 women did not undergo TA-CVS for technical reasons (retrochorionic 
haematoma, posterior placenta in a retroverted uterus, vaginal blood loss, HBAg 
positive). These women remained in the study up to the moment of withdrawal or 
cancellation. 
There were 26 spontaneous abortions before TA-CVS. The percentage of women 
aborting while waiting for TA-CVS increased with advancing maternal age (figure, A). 
The percentage of women who aborted within 30 days after intake rose from 1·9% in 
the 35-36 years group to 10·9% in the group aged 40 and older (trend test:p < 0·05). 
Women entering the study between day 42 and 48 of gestation had a greater probabi-
lity of aborting before TA-CVS than those entering beyond day 48 (p<0·05; figure, 
B). The same observation was made when the comparison was adjusted for maternal 
age (p <0·01). No correlation could be established between the incidence of sponta-
neous abortion and reproductive performance. 
TA-CVS was carried out in 346 women, 6-54 days (median 26 days) after intake. 
Spontaneous abortion occurred in 6 women between 15 and 29 days after TA-CVS 
and in 2 women at 66 and 81 days. 11 pregnancies were terminated because of trisomy 
21 (n=6), trisomy 18 (n=2), 47, XXY (n=2), or 47, XXX (n=I). The remaining 327 
pregnancies progressed uneventfully up to 28 weeks. Subsequently, 1 woman suffered 
unexplained intrauterine death near term and 2 women were lost to follow~up. 
The table shows the numbers of spontaneous and induced abortions before and after 
TA-CVS for each week of gestation in relation to maternal age. The women appeared 
to have a smaller risk of spontaneous abortion after than before TA-CVS, resulting in 
a maternal-age-adjusted relative abortion rate (post versus pre TA-CVS) of 0.10. This 
result, however, is severely biased because of the removal from the study of all 
chromosomally abnormal fetuses after TA-CVS. If all 19 abortions after TA-CVS are 
considered to have occurred spontaneously, the procedure led to a maternal-age-
adjusted relative abortion rate of 1·66 (not statistically significant). Additional 
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adjustment for gestational age at intake resulted in a relative abortion rate of l.56. 
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Cumulative percentages of women aborting spontaneously while awaiting TA-CVS 
according to (A) matel'llal age and (B) gestational age at intake. Numbers in 
parentheses denote number of women still being scheduled for TA-CVS on days 0, 10, 
20, alld 30 after intake. 
Chorionic villus tissue was obtained after one sampling attempt in 307 women, 
including the 8 with spontaneous abortion after TA-CVS. In 1 woman the procedure 
was abandoned after one attempt, and a successful amniocentesis was carried out at 
16 weeks. Two samplings were carried out in the remaining 38 women. 
Discussion 
The safety of first-trimester invasive procedures has been assessed against the back-
ground risk of spontaneous abortion. Incidences of 2·1 % and 3·3% have been repor-
ted. 8,9 However, the percentage of women of advanced maternal age in these studies 
was always less than 9%. 
Maternal age groups were differentiated in one study, 9 but the number of older 
women (over 40 years) was too small to allow any definite conclusions. The increase 
in chromosomal anomalies with advancing maternal age is more pronounced in 
populations undergoing CVS than in populations referred for amniocentesis. to This 
strongly suggests a maternal age dependent rise in fetal loss rate between 9 and 16 
weeks of gestation. Moreover, the incidence of chromosomally normal abortions also 
rises with advancing maternal age. with a steep increase after 36 years. II 
The present study confirms that there is a steady increase in early loss of a previously 
viable pregnancy with advancing maternal age. This must be taken into consideration 
when planning first-trimester chorionic villus sampling in older women. 
Our study suggests that at advanced maternal age the risk of spontaneous abortion of 
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Table. Cumulated no of days patients were followed and no of abortions before and 
after TA-CVS for each week of gestation. 
Age 35-36 Age 37-39 Age> =40 
(n=106) (n=213) (n=65) 
Before After Before After Before After 
TA-CVS TA-CVS TA-CVS TA-CVS TA-CVS TA-CVS 
Week R A R A R A R A R A R A 
6 13 0 14 0 
7 95 1 191 0 49 1 
8 354 0 743 3 201 0 
9 630 0 1186 1 358 1 
10 705 1 6 0 14023 4 0 411 4 2 0 
11 615 1 93 2' 1264 5 161 0 370 1 40 0 
12 260 0 433 l' 500 3 882 2' .157 0 231 3' 
13 59 0 621 1 125 0 12322' 46 0 332 0 
14 8 0 659 1+1'35 1 1300 1 27 0 351 0 
15 658 0 25 0 1299 1 11 0 357 0 
16 658 0 8 0 1299 1 357 0 
17 658 0 1291 1 357 0 
18 658 0 12880 357 0 
19 658 0 12880 357 0 
20 658 0 1284 1 357 0 
21 658 0 1281 0 357 0 
22 658 0 1281 1 357 0 
23 658 0 1274 0 357 0 
24 658 0 1274 0 357 0 
Total abortions 
3 2+4' 16 6+4' 7 3' 
R=tolal number of days patients were monitored during a particular week of gestation. 
A=no of abortions. 'induced abortions after TA+CVS 
a previously viable fetus in the first 12 weeks of gestation is greater than the chance of 
live birth of an infant with a chromosomal anomaly. The decline in abortion rate is 
more pronounced between 6 and 7 weeks of gestation than later. The increased 
abortion risk for women entering the study in week 6 could be explained by the 
apparently high initial abortion risk for these women during weeks 7 and 8. At that 
time the abortion rate was 0·024(3/124) abortions per day, whereas during the same 
period the abortion rate for women entering the study during week 7-8 was 0·001 
(2/1509) abortions per day. This reduction in abortion rate is probably influenced by 
the ultrasound examination carried out at the intake visit. The exclusion, at that stage, 
of all non-viable pregnancies would explain the low abortion rate in patients entering 
during week 7-8. 
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A relation between gestational age at intake and abortion rate has also been observed 
in other studies in which early fetal viability was documented by ultrasound. 12•13 The 
only maternal age dependent data on fetal loss rates at given gestational periods 
presented in life-table style l ' were based on a cross-sectional study design and are 
therefore difficulty apply to a cohort under observation at a given stage of pregnancy. 
Moreover, in that study fetal viability was not verified by ultrasound. From the present 
study it has also become evident that a considerable number of pregnancy losses 
before TA-CVS occurred at 10-12 weeks of gestation. 
This coincides with the period surrounding the TC-CVS procedure and explains the 
relatively high spontaneous fetal loss rate after TC-CVS in the advanced maternal age 
group.' 
In contrast to Regan,15 we were unable to establish any relation between spontaneous 
abortion rate and past reproductive performance. This may be because non-viable 
pregnancies were disregarded in the present study; 50% of the spontaneous abortions 
in Regan's study would have fallen into this category. 
We found no evidence for any adverse effect of TA-CVS on the abortion rate. The 
abortion rate after TA-CVS was not significantly higher than that before the procedu-
re, even if it is assumed that all abortions would have occurred spontaneously. 
However, when all diagnosed chromosomal anomalies were excluded, the spontaneous 
abortion rate before TA-CVS was considerably higher than that observed after the 
procedure. 
We suggest that these findings justify late first-trimester chronic villus sampling in 
women of advanced maternal age because the spontaneous abortion rate and the 
procedure related abortion risk do not exceed the risk of fetal chromosomal abnorma-
lity. At 12 weeks of gestation termination is still feasible as an outpatient procedure. 
This approach will also be more cost effective, since a number of affected fetuses 
diagnosed early in the first trimester most likely would have aborted spontaneously by 
this time. 
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CHAPTER 9 
CYTOIMMUNOLOGICALMONITORING OF HEART TRANSPLANT RECIPIENTS 
This chapter was published in Clinical Transplantation 1990; 4: 297~300 by 
N.H.P.M.Jutle, w.e,J. Hop. R. Daane, C.B. Essed, W. Weimar, M.L. Simoons and E. Bos 
Introduction 
Monitoring of rejection after clinical heart transplantation is generally perfonned by 
judging histological sections of endomyocardial biopsies (EMB) which are taken via 
the jugular vein I . Reports have appeared describing a method by which rejection crises 
could be observed in peripheral blood. The advantages of a non-invasive method for 
the patient are clear. In addition. this method, called cytoimmunological monitoring 
(CIM), was reported to be very sensitive so that rejection in the CIM could be 
observed 2-3 days before signs of rejection were observed in the EMBs'. The positive 
results obtained'·3 prompted us to investigate the value of CIM for the population of 
heart recipients in Rotterdam, although negative results of CIM have also been 
published' . 
In the present study we investigated the prognostic value of CIM with respect to the 
first rejection episode during the first 3 months after transplantation. A randomized 
clinical trial evaluating prophylactic immunosuppression with either OKT3 or cyclos-
porin was started during the period of investigation. CIM results within each of these 
groups were also evaluated. 
Patients and methods 
Seventy patients transplanted between January 1985 and December 1988 were 
included in the study. 
The prophylactic immunosuppressive therapy consisted of either cyclosporin or the 
monoclonal antibody OKT3 (Orthoclone 5 mgfd i. v. for 7 d) together with 50 mg 
azathioprine per d, both with 60 mg prednisone per d, decreasing to 10 mg at 7 weeks 
posttransplantation, starting immediately after transplantation, followed by cyclosporin 
and low-dose steroids. Many of the patients (45) participated in randomized clinical 
trial to evaluate both regimens. EMBs were taken once a week until 6 wk postoperati-
vely, once every 2 wk until 3 months after transplantation, once a month until 6 
months posttransplantation, once every 6 wk until 9 months posttransplantation, once 
every 8 wk until 12 months and once every 4 months thereafter. CIMs were made 
concurrent with EMB during 3 months after transplantation. 
At the day of EMB, peripheral blood was separated over a Picoll-isopaque gradient to 
obtain a concentrate of mononuclear cells. The cells were washed, a cytospin slide was 
made and stained with May-Grunwald Giemsa according to standard methods. The 
cells were counted, differentiating between lymphoblasts, activated lymphocytes, 
normal lymphocytes, large granular lymphocytes, juvenile granulocytes, juvenile 
neutrophil leucocytes ("rod-like") and plasma cells based on morphological appearan-
ce. Three-hundred cells of the above cell types were counted on at least 3 different 
sites in the cytospot. The number of lymphoblasts and activated lymphocytes was 
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calculated as percentage of the total amount of lymphocytes. The slides were counted 
without knowledge of the histological score of EMB. 
A rejection episode was defined as moderate rejection according tot the criteria of 
Billingham', i.e. when infiltrates and myocyte necrosis were observed. Only the first 
rejection episode of each patient was analyzed in this study as subsequent rejection 
therapy might influence the results thereafter. In the present group of patients a 
severe rejection episode, described as myocyte necrosis and interstitial bleeding, was 
not observed. All patients were considered evaluable for CIM. Excluded were patients 
who died within 2 wk posttransplantation or who were transplanted elsewhere 
although being monitored at our center. 
Statistical methods: 
The relation between immunological parameters and the risk of first rejection as 
demonstrated by EMB was investigated by Cox-regression' with CIM data as time-
dependent variables. p-values given in these analyses are derived from likelihood-ratio 
tests. Parameters within patients were also compared using Wilcoxon's test. Five 
percent (two-sided) was considered the limit of statistical significance. 
Results 
A total of 371 CIMs were made from 70 patients concurrently with EMB within a 
period of 3 months after transplantation or, if a rejection occurred within this period, 
up to the date of rejection. During this period 35 patients showed an episode of 
rejection concurrent with investigation by CIM. An additional 5 patients rejected 
within 90 d posttransplantation but no CIM was available at the day of rejection. CIM 
data of these 5 patients were included in the evaluation up to the latest measurement 
at the day of EMB preceding the day of rejection. Fourteen of the 35 CIM-monitored 
rejections occurred within 1 month after operation. Nine patients had a first rejection 
episode after 90 d post-transplant. Twenty-one patients did not have a rejection 
episode within the first 3 months nor in the follow-up period of at least 6 months 
thereafter, although 1 of these patients died of causes not related to rejection at 5 
months post-transplant. 
The median values of all CIMs counted concurrent with EMBs indicating no rejection 
were 0.5% (range: 0-13.4) lymphoblasts, 2.7% (range: 0-51.8) activated lymphocytes 
and 3.2% (range: 0-55.2) for the sum of both counts (n=336). Similar values were 
obtained for CIMs counted concurrently with EMBs indicating rejection within 90 d. 
For this group, median values were 0.5% (range: 0-2.9) lymphoblasts, 2.4% (range: 0-
17.2) activated lymphocytes and 3.5% (range: 0-17.2) for both counts summed (n=35). 
Figure 1 shows, for each posttransplantation day at which rejection was observed, the 
counts of lymphoblasts and activated lymphocytes for patients with rejection in 
comparison to counts for patients in whom elM was made at exactly the same post-
transplant day but in whom no rejection was found. Cox-regression with time-depen-
dent variables of the data given in this figure did not show an increased risk of rejecti-
on when larger percentages of lymphoblasts or activated lymphocytes were observed, 
either considered separately or in combination. 
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Figure 1. Percentages of lymphoblasts (A) (upper panel) and activated lymphocytes 
(B) (lower panel) in peripheral blood of heart transplant recipients according to time 
after transplantation. Represented are valnes of all individual patients who were 
measured on the day posttransplant at which 1 or more patients experienced 
rejection. 
The estimate of the relative risk of rejection associated with an increase of the 
percentage of lymphoblasts with 1 % was 0.88 which, however, is far from statistical 
significance (p=0.6) as compared to 1 (i.e. no relation). The relative risk associated 
with an increase of the percentage of activated lymphocytes with 1 % was estimated to 
be 0.96 (compared to 1: p=OA). Both estimates of the relative rejection risk did not 
significantly differ between the first period of I month after transplantation and the 
period thereafter. 
Any correlation of elM and rejection was also not apparent when analyses were 
performed separately for each immunosuppresive regimen used. All findings applied 
equally when the number of control-observations for each day at which rejection was 
observed was increased by using interpolated values of the counted immunological 
parameters of patients without rejection (data not shown in Figure I). 
When, instead of comparing elM values between patients or groups of slides, changes 
in values within individual patients are considered, a different evaluation can be made. 
Figure 2 shows counts of Iymphoblasts and activated lymphocytes in individual 
patients at the time of rejection in comparison to the counts at the latest elM 
preceding the rejection. The median time interval between both elMs was 8 d. Both 
parameters, and their sum, were not significantly increased at rejection as compared 
91 
to the previous measurement. In only 1 patient was a large increase in Iymphoblasts 
observed at rejection. In another patient the percentage of activated lymphocytes had 
increased greatly (Figure 2). When time posttransplantation was included in evaluating 
these data by applying Cox-regression to study the pattern of increasesldecreases 
within patients with time, no relation with rejection was apparent. This was also the 
case for each immunosuppressive regimen separately. 
Discussion 
The present results show that in our hands CIM is not useful in replacing EMB for 
diaguosis of rejection. The results are in contrast with previous claims that CIM is a 
help in detecting rejection at an early stage'" and that the amount of Iymphoblasts is 
most significant in this respects. Differences in immunosuppression regimens, inciden· 
ce or severity of rejection may cause the different results. In the present study no 
prognostic value of CIM could be found for two different inmlUnosuppression 
regimens. 
The first rejection episode appears to be most apt for evaluation since no interference 
from anti-rejection therapies can occur in the comparison of the EMB and the CIM. 
In addition, patients who reject more than once should not weigh more in the analysis. 
Therefore, in the present study only the first rejection in our group of patients were 
analyzed. Because most first rejections take place within 3 months after transplanta-
tion, we analyzed in the present study the CIMs obtained within this period of 90 d. 
As in other studies7,8 activation of the immune system by bacterial or viral infections 
was not excluded. 
Different CIM studies appear not be directly comparable since either the concentra-
tions of activated cells were given2.),7 or percentages of activated lymphocytes were 
usects. It was demonstrated that use of concentration or percentage did show similar 
results with respect to detection of rejection'·9.JO. In the present study analysis was 
based on the amount of activated cells as percentage of the amount of lymphocytes as 
has been done previously by the Munchen group'. 
The percentages of activated cells in our studies are low as compared to the findings 
of others. The level of 6% Iymphoblasts (as percentage of the amount of lymphocytes) 
which was reported as a limit for discrimination between non-rejection and rejection8 
was hardly ever reached in our material. In the present group of patients a severe 
rejection was never observed as judged by EMB, either in the first 
rejection or in later rejection episodes. In groups of patients studied by others, the 
rejecting group appeared to include both moderate and severe rejection"'. Thus the 
difference between rejecting and non-rejecting patients may be larger in other studies 
since more severe rejections appeared to be observed. As shown in the present results, 
higher amounts of activated cells were observed incidentally. 
It has been reported that the greatest sensitivity of the method is reached during the 
1st month following operation? However, our present data do not support these 
findings. 
In conclusion, monitoring of rejection of heart transplant recipients by morphological 
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analysis of peripheral blood by elM was not useful for the group of patients trans-
planted in Rotterdam. 
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Figure 2. Percentages of lymphoblasts (A) or activated lymphocytes (B) in individual 
patients at the day of rejection as compared to the last preceding measurement 
(hefore rejection). Pairs of values for each patient are conneeted, except for one 
patient (x) who showed rejection in the first biopsy after transplantation. One line 
(7x) represents seven patients. 
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CHAPTER 10 
THE PREDICTIVE VALUE OF DOPPLER FLOW VELOCITYWA VEFORMSIN 
THE DEVELOPEMENT OF ABNORMAL FETAL HEART RATE TRACES IN 
INTRAUTERINE GROWTH RETARDATION; 
A LONGITUDINAL STUDY 
This chapter was published in Early Human Developement 1993; 32: 151-159 by 
I.A.L.Groenenberg, W.C.I. Hop, J.W. Bogers, 1,0. Santema and J.W. Wladimiroff 
Introduction 
Less than 40% of pregnancies complicated by intrauterine growth retardation (IUGR) 
are recognized by maternal signs or symptoms which prompt the clinician to suspect 
IUGR". Serial biometric measurements by ultrasound have improved the pick-up rate 
of IUGR. However. not all those small fetuses are necessarily at risk of becoming 
hypoxaemic. Doppler flow velocity wavefono studies in the fetus have provided 
characteristic changes in various fetal vessels relative to IUGR 7 ••• 17.19. Comparative 
studies between umbilical artery flow velocity wavefono recordings and standard 
antepartum fetal heart rate testing suggest the fonoer technique to be a valuable 
adjunct in the antepartum fetal surveillance in high-risk pregnancies". Despite its 
limitations. most centres still consider fetal heart rate monitoring as the method of 
choice in the assessment of fetal compromise. No studies are known in which the 
time-relationship between these two methods of fetal surveillance was detenoined in 
a longitudinal blinded study design. The objective of the present study was to assess 
the predictive value of serial cardiac and extra-cardiac blood flow velocity waveform 
recording in the prediction of an abnonoal fetal heart rate (FHR) trace in IUGR. 
Materials and methods 
Forty-two out of 43 women with a singleton pregnancy admitted for IUGR consented 
to participate in the study. The study protocol was approved by the Hospital Ethics 
Review Board. IUGR was defined as a fundal growth delay of more than 2 weeks and 
a deviation of the sonographic fetal upper abdominal circumference to beneath the 
10th centile of the reference curve. Pregnancy duration was detenoined from the last 
menstrual period and confinoed by sonographic measurement of the fetal biparietal 
diameter at 14-20 weeks gestation. In 33 women pregnancy was further complicated 
by pregnancy-induced hypertension. All women were entered into the study within 
one to 2 days of hospital admission. Gestational age at the entry to the study varied 
between 26 and 35 weeks of gestation (median 31 weeks). Clinical management 
consisted of bedrest and treatment of hypertension. The appropriate time of delivery 
was detenoined by daily monitoring of fetal heart rate and maternal condition 
thereby taking into account gestational age. 
Doppler flow velocity wavefono recordings were made by an independent observer 
(IALG) on the day of entry into the study (day 1) and subsequently at 2-3 day 
intervals until delivery. Maximum flow velocity waveforms were recorded at both 
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cardiac and peripheral level, using a combined mechanical sector and pulsed Doppler 
system (Diasonics CV 400). Flow velocity wavefonns from the fetal ascending aorta 
(AO) were obtained from the five chamber view'. Fetal pulmonary artery (PA) flow 
velocity wavefonns were recorded from the conventional echocardiographic short axis 
view'. Doppler sample volumes were placed in the great vessels immediately distal to 
the semilunar valves. The angle between the Doppler cursor and the assumed 
direction of flow was always 10 degrees or less. Sample volume length was between 
0.2 and 0.4 cm. Peak systolic velocity (PSV, cmls) and time-averaged velocity (AV, 
cmls) were calculated. Flow velocity analysis consisted of tracing the outer border of 
the densest part of the Doppler spectrum envelope. For both parameters a good 
reproducibility was previously established'. Peripheral arterial Doppler studies were 
focused on the fetal umbilical artery (UA) and the fetal internal carotid artery (ICA). 
For both vessels, the pulsatiiity index (PI) was calculated through dividing the 
difference between the peak systolic velocity and end-diastolic velocity by the time-
averaged velocity. 
All flow velocity wavefonns were recorded on hard copies for analysis after delivery 
by a microcomputer (Olivetti M24) linked to a graphics tablet. An average of four 
consecutive flow velocity wavefonns of good quality was used to establish each value. 
Fetal cardiotocograms were recorded daily at a median duration of 35 minutes (range 
25-60 minutes). In case of a flat FHR trace, recordings were made up to 60 minutes 
to exclude the "non-reactive" FHR pattern inherent to fetal rest-activity cycles. After 
delivery, all FHR traces were classified by two experienced independent observers 
(JWB and JS), who had no knowledge of the Doppler outcomes, according to the 
Fischer score'. This score is detennined by five variables each being classified as good 
(2 points), moderate (I poinO or poor (0 points). These variables are: (i) heart rate, 
(Ii) heart rate band width, (iii) number of zero-crossings per minute of baseline fetal 
heart rate, (Iv) heart rate accelerations, and (v) heart rate decelerations. When the 
scoring difference between the two observers was 3 points or more, the FHR trace 
was evaluated by a third independent observer, whereby the median value was 
detennined (13 recordings). In case of cyclic activity, assessments were only made 
during the active sleep state". An FHR trace was considered abnonnal when the 
Fischer score totaled 6 or less. Considering that Doppler flow measurements cannot 
predict an abnonnal FHR trace when the latter is related to an obstetric intervention 
(n=3), in the analysis, the Doppler data of these three patients were only evaluated 
up to the day of cervical priming. 
All Doppler parameters were expressed as standard deviation scores. This score is 
obtained by taking the difference between the observed value and the mean reference 
value according to the gestational age and dividing the result by the standard 
deviation of the reference values lO•20• Logistic regression) was used to investigate the 
relationship between Doppler parameters and the presence of an abnonnal FHR 
trace on the day of entry into the study (day I). For patients who did not show an 
abnormal FHR trace on day I, Cox-regression with time-dependent variables was 
used to investigate the relation between the Doppler parameters and the first 
occurrence of an abnonnal FHR trace during follow-up'. Gestational age served as 
the time-axis in this analysis. Cumulative percentages of an abnonnal FHR trace 
during follow-up were determined by actuarial methodsll • 
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Results 
The number of Doppler sessions per subject varied between 1 and 20 (median 8), 
totaling 247 Doppler sessions and 988 Doppler measurements. The success rate in 
obtaining technically acceptable Doppler flow velocity waveforms in the umbilical 
artery, internal carotid artery, pulmonary artery and ascending aorta was 100%, 96%, 
94% and 87%, respectively. One woman dropped out two weeks after hospital 
admission, due to referral to another hospital. Doppler and heart rate data obtained 
during these weeks were included in the analysis. Fetal birth weight varied between 
p<2.3and p25 (median p5) according to Kloosterman's Tables corrected for maternal 
parity and fetal sex". Caesarean section was performed in 36 women, vaginal delivery 
took place in the remaining 6 women (including one intrauterine death). Umbilical 
artery pH after delivery ranged between 6.82 and 7.33 (median 7.20). Umbilical artery 
BE ranged between -0.9 and -24.2 (median -7.0). 
Fifteen out of 42 patients displayed an abnormal FHR trace on day 1 (day of entry 
into the study). The presence of an abnormal FHR trace on day 1 correlated 
significantly with gestational age: patients with an abnormal FHR trace were of a 
significantly (Mann-Whitney's test: p~0.03) lower gestational age than those with a 
normal FHR trace (mean 29.8 weekS, SD 1.8 versus mean 31.3 weeks, SD 2.5). Table 
r presents data on the various Doppler parameters, expressed as standard deviation 
scores according to whether or not abnormal FHR traces were present on day 1. 
When taking into account gestational age, PIUA and PSVAO scores separately 
showed a significant correlation with the occurrence of an abnormal FHR trace on 
day I. Simultaneous evaluation of these flow parameters, however, demonstrated that 
only the PIUA score remained significantly correlated. The risk for an abnormal FHR 
trace was increased by 20% (P <0.01) for an increase in prUA of one standard 
deviation score. 
Longitudinal data from the remammg 27 patients (788 Doppler measurements) who 
had a normal FHR trace on day 1, were used to establish the predictive value of 
Doppler recordings for the development of an abnormal FHR trace during the course 
of pregnancy. Fourteen patients developed abnormal FHR traces, 13 patients did not. 
All 14 patients developing abnormal FHR traces were delivered by caesarean section, 
whereby the time delay between the occurrence of an abnormal FHR trace and 
delivery ranged between 0 and 15 days (in 71 % of cases this interval was less than or 
equal to 2 days). Five out of 13 patients who did not develop abnormal FHR traces 
were delivered vaginally. In the remaining eight women caesarean section was 
performed because of partial abruptio placentae (n~2), severe pre-eclampsia (n~4) 
or gestational age of 36 weeks or more in the presence of non-optimal FHR traces 
(n=2). Cox-regression revealed that the PIUA, PlICA, PSVAO and AVAO scores 
were significantly correlated with the incidence of an abnormal FHR trace. However, 
when each parameter was evaluated separately from simultaneous assessment of these 
variables, it appeared that the correlation only remained signifcant for the PIUA and 
PlICA scores. Relative rates of an abnormal FHR trace for both parameters are 
given in Table II. 
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Table I. Mean scores of Doppler parameters in the presence or absence of an 
abnormal FHR trace on the day of entry into study. 
abnormal FHR trace 
present absent 
Doppler sd sd 
, 
mean n mean n p 
parameter 
PIUA 12.0 11.0 15 3.7 4.0 27 .001 
PlICA -2.9 1.1 15 -2.4 1.5 26 .09 
PSVAO -1.6 0.9 14 -0.9 1.4 22 .04 
AVAO -1.4 1.0 14 -O.S 1.1 22 .OS 
PSVPA -2.S I.S 14 -2.2 1.5 23 .16 
AVPA -2.2 1.7 14 -1.S 1.3 23 .21 
(*) significance, adjusted for gestational age (logistic regression). Total number of patients not 
always 42 due to different success rates for various Doppler measurements. PIUA, PlICA = 
pu)satility index in the umbilical artery and internal carotid artery. PSVAO, A VAO ""'peak systolic 
and time-averaged velocity in ascending aorta. PSVPA, AVPA = peak systolic and time-averaged 
velocity in pulmonary artery. 
Table II. Multivariate analysis of PIUA and PlICA scores with respect to the 
incidence of an abnormal FHR trace. 
Variable 
PIUA 
PlICA 
relative rate of 
developing an 
abnormal FHR 
trace 
1.5' 
2.6' 
P-value 
.01 
.05 
confidence 
limits (90%) 
1.2-1.9 
1.3-5.4 
As compared with fetuses who dispay values 1 standard deviation score lower for PIUA (a), or 1 
standard deviation score higher for PlICA (b), 
The multivariate assessment of the PIUA and PlICA scores resulted in a prognostic 
index for the development of an abnormal FHR trace during follow-up: 0.43 x PIUA 
score - 0.96 x PlICA score. Figure 1 depicts the values of this index for the 27 
patients during follow-up. Data points for the 14 patients developing an abnormal 
FHR trace are interconnected, with the last data point representing the Doppler 
measurement obtained within 24 hours prior to the occurrence of an abnormal FHR 
trace. As can be seen, the prognostic index values of patients developing an abnormal 
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FHR trace tend to be higher than those who did not. The prognostic index appears to 
increase with advancing gestational age. By fitting a least-squares regression tine (A) 
through the data points of patients who did not develop an abnonnal FHR trace, the 
rising trend of the prognostic index was characterized. The prognostic value of the 
index was evaluated for two arbitrary chosen cut-off levels, drawn 1 SD (B) and 2 SD 
(C) above the regression tine, respectively (Fig 1). 
The actuarial cumulative percentage of patients who developed an abnormal FHR 
trace was detennined I) according to the number of days past the day on which 
prognostic index values from patients were situated for the first time above the 
chosen cut-off levels, B (+lSD) and C (+2SD) respectively, and II) according to the 
number of days past the day of entry into the study prognostic index values remained 
below the chosen cut-off levels. Figure 2 displays the actuarial percentages for these 
two cut-off levels. For the + ISD cut-off level, the cumulative percentage of patients 
who had developed an abnonnal FHR trace amounted to 47% within 1 week and to 
77 % within 4 weeks after the day the prognostic index value was first found to be 
situated above this level (curve II, upper panel, based on n= 18 patients). As for the 
+2SD cut-off level, within 3 weeks after the first measurement was situated above 
this level the cumulative percentage of patients developing an abnonnal FHR trace 
rose to 100% (curve II, lower panel). 
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Figure 1. Prognostic index values against gestational age. Data points of patients 
(n=14) developing an abnormal FHR trace are interconnected. Data points of 
patients (n = 13) who never developed an abnormal FHR trace are given as individual 
data points. (A) Least-squares regression tine through prognostic index values of 
patients with normal FHR traces. (B) Cut-off level positioned 1 SD above regression 
tine A. (C) Cut-offtevel positioned 2 SD above regresioll Iille A. 
In contrast, as long as the prognostic index values remained situated below the +2SD 
cut-off level, within 4 weeks 50% developed an abnormal FHR trace (curve I, lower 
panel). 
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In comparing for each patient the last obtained prognostic index value before delivery 
with umbilical artery pH, it appeared that both variables were significantly correlated 
(r= -0.35, p=O.03; n=40). The index also significantly correlated with BE (r= +0.35, 
p=0.03; n=39). 
To validate the derived prognostic index, Doppler data of 25 IUGR cases from a 
previous cross-sectional study' were reviewed. This comparison was permitted as it 
concerns a similar growth-retarded population. Data from 18 patients, who were not 
displaying an abnormal FHR trace on the day at which the fetal Doppler recording 
was obtained, were available for this evaluation. Fifteen out of 18 patients 
subsequently developed an abnormal FHR trace, all but one of which displayed a 
prognostic index value above both the + ISD and +2SD cut-off level depicted in 
Figure I. In the remaining three women, the prognostic index was situated below the 
+ ISD level. 
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Figure 2. Cumulative percentages of patients developing an abnormal FHR trace. 
Upper panel shows the results for the + 1 SD cut-off level; lower panel refers to the 
+2 SD cut-off level. For curve I (upper and lower panel) the horizontal axis repre-
sents the number of days following the day of entry into the study during which the 
prognostic index always remained below the + 1 SD cut-off level and + 2 SD cut-off 
level, respectively. For curve II (upper and lower panel) the horizontal axis 
represents the number of days following the day that the prognostic index was first 
situated above the + 1 SD cut-off level and + 2 SD cut-off level, respectively. 
Numbers between parentheses denote number of patients still at risk of developing 
an abnormal FHR trace 
Discussion 
Previous studies in high risk pregnancies have related Doppler flow velocity 
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wavefonns to neonatal outcome, thereby comparing Doppler data with that of fetal 
heart rate monitoring"". Unlike these reports, the present study describes the use of 
Doppler flow measurements as a monitoring tool in predicting abnonnal FHR traces. 
Standardization was achieved by classifying them retrospectively according to the 
Fischer score which is a comprehensive scoring system. 
Our finding of Fischer scores being significantly related to gestational age on the day 
of entry into the study, is likely to be a consequence of patient selection, since 
particularly cases of early developing IUGR are referred from district hospitals to 
academic centres for close fetal monitoring. Taking into account the gestational age, 
both the PIUA scores and PSVAO scores appeared to have a predictive value 
regarding the presence of an abnormal FHR trace on the day of entry into the study. 
However, no additional infonnation is provided by the PSVAO score when the PIUA 
score is known. The risk of an abnonnal FHR trace went up sharply with increasing 
PIUA. 
Of particular interest is the course of pregnancy during hospitalization. Several studies 
have shown that changes in Doppler parameters may precede deterioration in fetal 
heart rate patterns'·t6. This is the first study to demonstrate that PIUA, PlICA, 
PSV AO and A V AO scores are related to the development of an abnormal FHR 
trace. Also here, the cardiac parameters do not contribute to the assessment of fetal 
well-being when the combined PIUA and PlICA scores are known. The derived 
prognostic index, therefore, only includes the PIUA and PlICA scores. The inclusion 
of the PlICA emphasises the pathophysiological importance of a reduced cerebral 
vascular resistance (so-called brain-sparing) in intrauterine growth retardation. 
Validation of the derived prognostic index in a second group of growth-retarded 
fetuses confirmed its predictive value. 
With the introduction of Doppler flow measurements, a number of reports have 
appeared regarding its value as a secondary test for identifying the compromised 
fetus. Lowery et al" consider these Doppler recordings to have a significant 
complementary value to traditional antepartnm heart rate testing. However, its value 
as to the timing of delivery is questioned by others'. In this context the time-
relationship observed in the present study between the development of abnonnal 
Doppler flow velocity waveforms resulting in a raised prognostic index value and the 
development of abnonnal FHR trace is of particular importance. Nearly 50% of 
women with a raised prognostic index above the + ISD level developed an abnonnal 
FHR trace within a period of one week, whereas none of the patients who remained 
below the + ISD level developed abnonnal FHR traces within 11 days. For clinical 
application the +2SD cut-off level may possess a more discriminitive power since 
54 % of patients with a prognostic index value once above this level develop abnonnal 
FHR traces within I week and all patients within 3 weeks. However, 37% of cases 
developed abnonnal FHR traces within 3 weeks although their prognostic index value 
continuously remained below the +2SD cut-off level (fig.2). The time-relationship we 
found is much weaker than that reported by Bekedam et al'. On the other hand, 
Arduini et aI' reported significant changes in peripheral and umbilical vessels close to 
the onset of late FHR decelerations, but a nadir of cerebral vasodilatation two weeks 
before the appearance of these abnonnal heart rate patterns. 
The established correlation between the prognostic index and umbilical cord pH and 
BE suggests that Doppler flow measurements may reflect fetal well-being. Further 
prospective studies are needed to obtain guidelines for optimal incorporation of 
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Doppler measurements in obstetric management. It can be concluded that the PI in 
the umbilical artery and internal carotid artery are predictive for the developement of 
an abnormal FHR trace. 
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CHAPTER 11 
PROGNOSIS AND PROST A TIC VOLUME CHANGES 
DURING ENDOCRINE MANAGEMENT OF PROSTATE CANCER: 
A LONGITUDINAL STUDY 
This chapter was published in Journal of Urology 1992; 147: 962-966 by 
Z.W. Sneller, W,e,l. Hop, P.I. Carpentier, F.H. SchrOder. 
Introduction 
Endocrine therapy is the standard palliative treatment of prostate cancer at least in 
those patients with symptomatic metastatic disease. Although initial objective response 
occurs in about 40% of all patients, which is associated with a symptomatic response 
in 70 to 80% of all cases, relapse to the hormone independent state of this disease is 
inevitable. I Few parameters exist that allow the prediction of progression under 
endocrine treatment. In previous reports we have shown that the degree of prostatic 
volume reduction under endocrine treatment after a 3-month period correlated well 
with the occurrence of progressive disease. 24 If there was a volume reduction of 50% 
or more early distant progression was unlikely. Another purpose of these early studies 
was to identify patients with local progression, and to investigate the relationship 
between progression of the primary tumor and the incidence of distant progression. 
The previous report was hampered by a relatively small number of patients and an 
observation period that was limited to 24 months. During the subsequent years the 
prospective study was continued, thereby increasing the period of observation and 
recruiting more patients under various forms of endocrine management. The accumu-
lated material of 102 patients with an average followup of 3 years warrants a new 
review and report. The purpose of the present analysis is, while considering other 
prognostic factors, to reassess the relationship between prognosis and early (at 3 and 6 
months after start of treatment) volume changes of the primary tumor, and to investi-
gate the correlation between progression of the primary tumor and distant progressi-
on. 
Materials and methods 
This study was initiated in May 1979 and recruitment of patients continued through 
December 31, 1987. Patients were included in this prospective study if they had 
histopathologically verified adenocarcinoma of the prostate, were not eligible for 
potentially curative treatment and presented with an indication for endocrine manage-
ment. Furthermore, patients had to give consent to the study protocol, including 
repeated transrectal ultrasound examinations, and they had to be previously untreated. 
A total of 42 patients was not eligible to participate in this study, in addition to those 
who had undergone previous transurethral resection. Ultrasonography on day 0 was 
not available in 7 patients, crucial ultrasound studies at 3 and 6 months were missing 
in 15 and ultrasound studies were not sufficiently evaluable in 4. The follow-up period 
was too short for clinical evaluation in 3 cases. Six patients had to be treated by other 
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means shortly after entering the study, including radical prostatectomy (3), transur-
ethral resection of the prostate (2) and radiotherapy to the primary tumor before a 3 
month ultrasound was performed (1). Seven patients were omitted from the study for 
other reasons. 
Of the 102 patients 58 were treated by intracapsular orchiectomy immediately after 
the initial evaluation was completed. Most cases in the MON + category had undergo-
ne staging lymphadenectomy. The remaining 44 patients were treated with luteinizing 
hormone-releasing hormone in 3 different forms of application, including 14 who 
received cyproterone acetate during the first months of therapy. These forms of 
treatment are generally considered equivalent. Patients were seen every 3 months. 
After longer periods of stability of the disease process follow-up was extended to 6 
months. Follow-up studies included transrectal ultrasonography, markers available at 
various times and other routine laboratory studies. Bone scans and bone x-rays were 
done yearly of when indicated. Ultrasound findings had no influence on installing 
other diagnostic procedures. 
Patients left the ultrasound protocol when distant progression or death occurred. 
Local progression was not a reason to discontinue the study. The criteria of the 
European Organization for Research on Treatment of Cancer Genitourinary group 
were used to determine progression.5 Death from prostatic cancer was defined as 
death in the presence of a heavy metastatic load with no other obvious cause. Local 
progression was considered to have occurred when a series of 3 consecutive measure-
ments showed an increase of at least 20% in volume after which the increase was 
noted. The time of local progression of the primary tumor was considered the time of 
the second measurement in the consecutive series. 
During the initial period of this study a 3.5 MHz. rotating ultrasound probe was used, 
which was replaced in 1983 by a 7.5 MHz. probe. Both probes were mounted on the 
Aloka chair allowing axial transverse sections at fixed distances. A specially trained 
nurse performed all measurements. Prostatic volumes were calculated as described 
previously.3 The surface of transverse sections taken at 1 em. distances was calculated 
on a planimeter and prostatic volumes were calculated by totalling the surfaces of all 
transverse sections. 
Table 1 gives the tumors, nodes and metastases categories (International Union 
Agairu;t Cancer 1982), age, pretreatment prostate volume and grade according to 
primary treatment. The grade of differentiation of the primary tumor was determined 
by review of routine pathology reports according to the system of Mostofl. 6 In case of 
pleomorphism the worst formation was judged as being representative and was 
included as a parameter in this study. All cases in the MO group except for 3 T4NOMO 
cases had lymph node metastases. 
Survival and time until distant progression were calculated on an actuarial basis using 
Kaplan-Meier curves. Comparison of these curves was done by logrank tests. Intercur-
rent death corrected survival was calculated by considering patients withdrawn from 
study at the moment patients died of causes not related to prostatic carcinoma. The 
same applied to the calculation of survival without distant progression. Multivariate 
analysis Was done using Cox regression.7 This method with a time-dependent covariate 
was applied to evaluate the prognostic value of local progression with respect to 
distant progression.' P values are 2-sided, with 0.05 taken as the limit of statistical 
significance. 
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Table 1. Various characteristics at entry into the study according to primary treat-
ment. Data given are numbers of patients or medians (with 10 to 90 percentile range), 
Treatment 
Luteinizing Hormone- Orchi- Total 
Releasing Hormone ectomy 
T category: TO-2 10 13 23 
T3 19 26 45 
T4 15 16 31 
TX 0 3 3 
N category: NO 7 18 25 
Nl 4 13 17 
N2 9 6 15 
N3 4 6 10 
N4 14 4 18 
NX 6 11 17 
M category: MO 11 24 35 
M1 33 34 67 
Grade: G1 2 3 5 
G2 22 28 50 
G3 19 23 42 
GX 1 4 5 
Prostate Vol (cm'): 29 (17-50) 34 (22-59) 33 (19-58) 
Age (yrs): 67 (53-77) 69 (56-79) 68 (54-78) 
Results 
Of the 102 patients 70 patients died during the study period, including 53 of prostate 
cancer at an average of 28.7 months (range 3 to 78) after initiation of treatment and 
17 of other causes after 34.2 months (range 8 to 84). The remaining 32 patients are 
alive at the end of the study with a follow-up period of 47.1 months (range 12 to 92). 
The follow-up period of all 102 patients averaged 53.2 months (range 3 to 92). During 
the study period distant progression developed in 61 patients. Time to distant 
progression averaged 18.0 months (range 1 to 73). Distant progression was noted 
during year 1 in 28 cases, year 2 in 20, year 3 in 6 and thereafter in 7. Median 
survival, median intercurrent death corrected survival and the median period until 
distant progression, when calculated on an actuarial basis, were 34, 52 and 24 months, 
respectively. 
Not counting occasional measurements at month 1 and 2 , a total of 594 ultrasound 
studies was performed. At 3 months the prostatic volume had decreased to a mean of 
58% of the pretreatment volume in the orchiectomy group. The mean decrease was 
significantly (Mann-Whitney's test, p = 0.02) greater compared to the luteinizing 
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honnone-releasing hormone treated group (mean percentage of pretreatment volume 
69%). At 6 months these figures were 56% and 64%, respectively (p = 0.08). It is 
noteworthy that only 2 patients did not show a volume decrease at 6 months, while 99 
did (97.1 %). A volume decrease of at least 50% at 3 months was noted in 33% of the 
orchiectomy cases compared to 21 % of the luteinizing hormone-releasing hormone 
group (Fisher's exact test, p = 0.19). 
, ,. 
...... 
''''''''' .... '' 
~ ;"" 
• 
.. 
, 
, .. 
.................. 
.. 
···iI.·· .... ·il ........ .. 
..... '01,,\ '01.-.:.1 
"'\"'t~"'I'" 
.. 
.. 
• 
.. 'n .......... . 
. .... 
.. 
·,i .. • .. • .. ;1 
fUrt 
, 
, . 
.. 
n .••... , ••• " " ,. 
» 
w···,',·j;,···· .. ·j\··· .. · .. ll 
.. 
» 
Figure 1. Total survival, intercurrent death corrected survival and survival without 
progression for patients whose prostate had regressed by at least 50% at 3 lIlonths 
(solid curve) 01' less than 50 % (dotted curve). Curves are obtained by yearly inter-
polation of Kaplan-Meier estimates. Numbers along curves denote numbers of 
patients at risk. 
At 6 months these percentages were 47% and 31 % (p = 0.18), respectively. Grade 
was analyzed separately in the MO group: Gx in 1 case, Gl in 2, G2 18 and G3 in 14. 
The volume reductions in the 3 groups amounted to 38.0%, 40.6% and 34.4%, 
respectively, and did not differ statistically. Considering the small numbers and similar 
volume reductions at 3 months a separate analysis of time to progression per subgroup 
was not considered useful. 
Figure 1 shows survival, intercurrent death corrected survival and survival without 
distant progression according to whether the prostate had regressed to at least 50% of 
the pretreatment volume at month 3. Survival was better in cases of such a large 
decrease. This finding applied also to the distant progression rate, although it is just 
above statistical significance (p = 0.06). Similar results were obtained when patients 
were grouped according to whether the volume decrease was at least 50% at month 6. 
However, multivariate analysis of each end point showed that a volume reduction of 
50% or more was not of great importance as a prognosticator when the degree of 
differentiation and M category were considered. This findings applied to the 3 and 6-
month ultrasound studies. Table 2 gives outcomes of the multivariate analysis with 
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respect to the ultrasound measurement at month 3. From both ultrasound examinati-
ons no prognostic value could be found by multivariate analysis when other groupings 
of the measured volume were analyzed. Also age, T and N categories were not 
significantly related to survival and distant progression. The same applied to the type 
of treatment. 
Table 2. Multivariate analysis of endpoints sUl'Vival, intercurrent death corrected 
Sln'vival and distant progression. Data given are relative death, c.q. relative progressi-
on rates. Number of patients 95 (missing data: volume reduction 2, grade 5). 
Factor Death Death Distant 
(all causes) (Ca) progression 
Grade: 
GI-2 I I I 
G3 2.5 (p < .001) 2.3 (p< .01) 1.8 (p < .05) 
M category: 
MO I I I 
MI 3.0 (p< .001) 2.9(p<.001) 2.7 (p< .001) 
Vol. reduction': 
50% or greater I I I 
Less than 50% 1.3( p=.3) 1.5 (p=.2) 1.3 (F.3) 
(#) Ultrasound finding at month 3. 
Survival and distant progression rates according to the 2 most important prognostic 
factors in this study are given in figures 2 and 3. 
According to the ultrasound findings, regrowth of the primary tumor was observed 
during the follow-up period in 10 (luteinizing hormone-releasing hormone) and in 14 
orchiectomy cases. Regular follow-up ultrasound examinations were done in all 
patients before distant progression. The interval from treatment to regrowth for these 
cases varied from 3 months (a case that did not show regression of the primary tumor 
after treatment) to 60 months (median 18 months). In 15 of the 24 patients distant 
progression was observed at a median interval after the regrowth of 5 months (range a 
to 30 months). Of the 102 patients, 57 were still in follow-up at 18 months without 
distant progression, including 10 with local progression at or before month 18, and 47 
without progression. After month 18 subsequent distant progression was noted in 7 of 
the 10 and in 17 of the 47 patients. The actuarial cumulative percentage of cases 
having distant progression after month 18 was significantly (p < 0.01) greater in the 10 
patients compared to the 47 patients. After 2 years these percentages were 77% and 
24 %, respectively. Using Cox regression, local regrowth correlated significantly with 
the rate of distant progression, and after regrowth the risk of distant progression was 
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Figure 2. Overall sUn'ival and progression-free survival according to G category. 
2.7 times higher (p<O.OI).' 
Local regrowth also appeared to be a prognostic factor for distant progression when 
the degree of differentiation and M category were considered (table 3). 
Table 3. Multivariate analysis of distant progression according to grade, M category 
and local progression. Data given are relative rates of distant progression. 
Factor Relative rate Significance 
Grade: Gl-2 I 
G3 1.7 p~.06 
M category: MO I 
MI 2.4 p< .005 
Local Progression: No I 
Yes 2.4 p< .01 
Discussion 
This longitudinal study of 102 patients with prostate cancer confinns only partiaUy the 
previous findings of a significant correlation between the change of overall prostatic 
volume and its value in predicting progressive disease. In the previous study, which did 
not include a multivariate analysis, prostatic volume reduction under endocrine 
treatment was described as being a prognostic factor. Although a volume reduction of 
at least 50% at 3 months in this study was significantly related to survival (aU causes 
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Figure 3, Overall survival and progression-free survival according to M-category. 
and death from prostate carcinoma) and almost significantly to distant progression, 
the value of this observation is limited by the fact that grade of malignancy and M 
status together are of overmling prognostic significance. After adjustment for both of 
these factors, no significant relation between the volume reduction and prognosis was 
present, which could be explained by the findings that there were relativelY more 
patients with a favourable grade and M category in the group with a greater volume 
decrease. Of 69 cases with Gl-2MO disease 12 (17%) had a volume reduction of less 
than 50% at month 3, whereas 8 of 26 (31 %) had a greater prostate volume reducti-
on. 
In the previous report distant progression was seen in 20 of 55 patients during a 24-
month interval. At the same time local progression occurred in only 2 instances 
(10%). In this report with an average follow-up of 53.2 months systemic progression 
was seen in 61 patients, while local progression occurred in 24. 
Although there appears to be a statistical association between local progression and 
an increased risk of subsequent distant progression, the clinical value of monitoring 
the prostate volume for this purpose seems slight. Many cases that show local 
progression do not develop distant progression. while also there are many cases with 
distant progression without prior local progression. The risk of local volume increase 
overall cannot reliably be assessed because patients went off protocol at the time of 
distant progression. Nevertheless 6 patients had shown- local progression after distant 
progression but this was not systematically investigated. Micturition problems requi-
ring treatment were seen in 9 patients (9%) (some with and some without local 
progression). The fact that 99 of 102 patients showed at least some volume reduction 
indicates the responsiveness of the primary tumor but it may also be related to 
associated prostatic hyperplasia. The study by Ryan et al represents the only other 
report in the literature that has pursued the same approach as we did. 9 They have not 
been able to find in 84 men treated by subcapsular orchiectomy or with goserelin 
acetate depot a correlation between prostatic volume reduction and progression 
observed in 20 patients during a period of 12 months. 
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Obviously, it would be advantageous to be able to measure prostatic cancer volume 
rather than prostatic volume. Lee et al,lO and Frentzel-Beyme and Ledwa ll clearly 
showed that many if not most prostate cancers can be identified as hypoechogenic 
areas within the remainder of the prostate gland. However, Rifkin et al believe that a 
substantial proportion of prostate carcinomas present as hyperechogenic and isoecho-
genic lesions. 12 When Carter et al used transrectal ultrasonography studies that were 
obtained before radical prostatectomy to identify prostate cancer in apparently normal 
contralateral lobes of cancerous prostates in comparison to the histological findings, a 
sensitivity and specificity of only 52% and 68% resulted." Especially the low specifici-
ty indicating the large proportion of false positive ultrasound studies makes it difficult 
to follow hypoechogenic lesions as a parameter for volume change unless these 
individual lesions are identified by biopsy as representing carcinoma of the prostate. 
Considering the inaccuracy of digital rectal examination in identifying correctly the 
volume of the prostate or the volume of prostatic cancer within the gland, it seems 
reasonable to obtain volume determinations before treatment and again during 
treatment as soon as there is suspicion of a prostatic volume increase or if serum 
markers increase. A volume increase of more than 20% in our study seems to indicate 
early which patients tend to have a higher risk for distant progression. 
Esrly transurethral resection even for palliative reasons or palliative radiotherapy may 
be applicable to such patients to prevent the difficulties arising from a large pelvic 
tumor. 
Of the 102 patients 58 were treated by castration, 30 with luteinizing hormone-
releasing hormone alone and 14 with luteinizing hormone releasing hormone plus 150 
mg. cyproterone acetate daily for 1 month. When the prostatic volume reduction seen 
at 3 months in the 58 castrated patients was compared to the volume change in the 
remaining endocrine treatment group a significant difference in favour of a more 
pronounced volume reduction in the castration group was seen. Also, the only 2 
patients in whom no volume decrease was observed after treatment had received 
luteinizing hormone-releasing hormone. At 6 months and thereafter no significant 
differences in mean prostate volume were present. This finding suggests that it takes 
longer with luteinizing hormone~releasing hormone treatment to reach a maximum 
response of the target cells and that in this respect castration may be superior. The 
ultrasound studies were well tolerated and accepted by the patients. No side effects 
occurred and few refusals of further studies were encountered. 
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CHAPTER 12 
GENERAL DISCUSSION 
Diseases develop in time and the same will apply to their progress. Important aspects 
in the characterization of a particular disease are the effects of therapy and the 
prognosis of the patients. In view of the vast growing amount of literature, these 
aspects receive much attention. A search in the literature database MEDLINE, 
covering the period 1992 up to mid 1996, resulted in a number of more than 25000 
articles in which the keywords prognosis or prognostic had been used. For breast 
cancer, a disease with a high incidence, Klein et al (1993) have compiled a list of 
prognostic factors, mostly of biochemical origin, which amounts to about one hundred. 
Also in the statistical Iitterature there has been a growth of papers dealing with the 
statistical methodology of the subject. A milestone was the pioneering paper of Cox 
(1972) in which the innovation of the proportional hazards model was described. 
Besides the more elementary methods such as the Kaplan-Meier curve and the 
logrank-test, the proportional hazards model is probably the most widely used statisti-
cal tool in investigations regarding the prognostic value of patient characteristics and 
the effects of therapy (it can be siad that Kaplan-Meier curves and logrank-tests can 
even be considered to be special elaborations of the Cox-regression method). The 
method has gained great popularity to evaluate baseline charateristics. Due to its 
flexibility, it may also be extremely valuable in deriving rules for updating prognosis 
for patients according to the history observed during the course of the disease. 
To sort out the most important prognostic factors, usually a step-wise approach is 
chosen. The most logical option is to perform a backward elimination approach by 
eliminating factors from the model which have the least significant contribution to the 
model (forward selection is less appropriate due to the fact that the model cannot fit 
fully in the initial stages of the building of a model). In this process, however, the 
correlation structure of the various prognostic factors has to be taken into account. If 
two variables are strongly correlated, it will be difficult to assess their separate 
prognostic value. Also factors may need to be retained because of prior knowledge or 
because there is special interest in the factor possibly due to its putative causal effect. 
The selection procedure will result in a predictive rule which will tend to perform less 
when it is applied to a new set of patients as compared to the performance of the rule 
when it is applied to the group of patients from which the prognostic index was 
derived (Phillips et ai, 1990). With a very large dataset, the effect of this phenomenon 
can be investigated by randomly splitting the dataset in two halves. One half is used to 
determine the prognostic index, while the other half is used for verification of the 
prognostic performance of the rule. In practice. however, this is not a realistic option 
due to the large number of patients required. Using the data on which the predictive 
rule is based, Verweij and Van Houwelingen (1993) have proposed the method of 
cross-validation to assess the ability of the proportional hazards model to predict 
future data. The method of choice, however, is the testing of the clinical prediction 
lUle in another group of similar patients. These new patients can come from the 
clinical setting from which the prognostic index was derived, but a different clinical 
envirolmlent is to be preferred (Wasson et ai, 1985). Such a prospective validation 
generally will be costly and time consuming, but it is essential in order to obtain a 
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wider acceptancy of any prognostic index. 
Sometimes there are treatments for life threatening diseases for which there appears 
to be so much evidence about their efficacy from uncontrolled studies, that it is 
considered not clinically valid to initiate randomized studies to prove their efficacy. 
Heart and liver transplantations are examples. Cox-regression with time-dependent 
variables, using only concurrent controls from the waiting list for transplantation and 
allowing for important prognostic determinants, is an option to evaluate the efficacy of 
such transplantations. Another option which remains in such circumstances is to prove 
that the outcome for patients treated that way is better than the outcome for similar 
patients before the introduction of the treatment. Bonsel et al (1990) thus compared 
the survival of patients with primary biliary cirrhosis after transplantation with 
expected survival, the latter being determined according to various published prognos-
tic indices which all had been derived using Cox-regression. 
The successful application of Cox-regression in many publications is no guarantee that 
it will work satisfactorily in all situations. The information contents of any dataset are 
limited. It is impossible to assess the independent association of factors with prognosis 
from material in which the number of potential predictors approaches the number of 
patients studied. This applies to Cox-regression as well as to any other statistical 
method. The number of patients (actually, the number of events present in the 
dataset) should be large in comparison with the number of factors studied. It is 
advocated, as a rule of thumb, that a minimum of 10 patients who experienced the 
event are required for each factor studied [Harrell et ai, 1985]. (There are good 
reasons to count a categorical factor with k levels even as a number of k-l factors in 
this calculation). No thoroughly based rules for the number of patients required, 
however, are available in multivariate situations. The difficulty in deriving such rules is 
caused by the fact that the correlation structure of the various predictors need to be 
known, which will not be the case. 
Publications in which the prognostic effect is evaluated of factors as observed during 
follow-up are relatively rare, in contrast to evaluations of baseline characteristics. In 
publications of the first type, however, often inappropriate methods have been used. 
There seems to be much room for improvement here, although the situation improves 
in the last few years. 
There are occasions in which time does not play an important role in evaluating 
prognosis, e.g. in assessing which factors are predictive for a successful operation. For 
such short-term prognostic evaluations, logistic regreSSion has become the preferred 
method [Cox, 1970]. 
In most situations, however, the method of Cox-regression has become the method of 
choice. It is likely that the method will keep that status for a very long time. 
References 
Donsel GJ, IJ Klompmaker, F van 't Veer, JDF Habbema. MJH Slaoff. Use of prognostic models for 
assessment of value of liver transplantation in primary biliary cirrhosis. Lancet 1990; 335: 493-497. 
Cox DR. The analysis of binary data. 1970. Melhuan, London. 
Cox DR. Regression models and life tables (with discussion). J Roy Slat Soc 1972; B34: 187-220. 
112 
Harrell FE, KL Lee. DB Matchar, TA Reichert. Regression models for prognostic prediction: advantages, 
problems, and suggested solutions. Cancer Treatm Rep 1985;69: 1071-1077. 
Phillips AN. SG Thompson, SJ Pocock. Prognostic scores for detecting a high risk group: estimating the 
sensitivity when applied to new data. Stat Med 1990; 9: 1189-1198. 
Klijn JGM. EMJJ Berns. JA Pockens. Prognostic factors and response to therapy in breast cancer. Cancer 
Surveys 1993; 18: 165-198. 
Verweij PJM. JC van Houwelingen. Cross-validation in survival analysis. Statist Medic 1993; 12: 2305-
2314. 
Wasson JH, HC Sox. RK Neff. L Goldman. Clinical prediction rules; applications and methodological 
standards. New Eng J Med 1985; 313: 793-799. 
113 

Summary 
The various roles which knowledge about prognostic factors may play in clinical 
medicine are discussed in Chapter 1. Some well-known prognostic staging systems for 
a few specific diseases are described briefly. 
Some important theoretical statistical developments of what is usually referred to as 
Survival Analysis are reviewed in Chapter 2. Emphasis is placed on the concept of 
Hazard Rate Function. In many instances this function is better suited to assess the 
role of patient or disease characteristics andlor interventions regarding their impact 
on prognosis than the more traditional Survival Function. The flexibility of the method 
of Cox-regression, by which the prognostic value of various factors can be assessed 
simultaneously, is emphasized. 
A case study in patients with kidney carcinoma is presented in Chapter 3. Using Cox-
regression the role of various baseline factors regarding their impact on survival 
prognosis of operated patients was evaluated. Besides gender and tumour invasion of 
the renal vein, it was found that a very low-cost parameter, namely the level of the 
erythrocyte sedimentation rate, was an important indicator of prognosis. 
Cox-regression played an important role in the analysis of possible adverse effects of 
blood transfusions regarding prognosis in patients operated for colorectal cancer as 
described in Chapter 4. The main finding in a randomized clinical trial was that there 
were no significant differences regarding recurrence rates and survival between 
patients who had donated blood before the operation and those who had to receive 
allogeneic blood if required. It was also found that patients who needed blood 
transfusions had a worse prognosis as compared to those who did not need transfusi-
ons. This applied equally to both types of blood transfused. 
Another case study is described in Chapter 5. Various prognostic factors were evalua-
ted using Cox-regression regarding their impact on prognosis in patients operated for 
esophageal carcinoma. The calculation of the life-time risk of dysphagia due to 
recurrent disease is described in an appendix to this chapter. 
Chapter 6 discusses some pitfalls regarding the assessment of the prognostic value of 
factors whose level may change during follow-up. Theoretical developments of various 
relevant methods, among which Cox-regression with time-dependent variables, to 
perform such assessments reliably are described. 
In Chapter 7 a case study is presented which shows an analysis using time-dependent 
covariates. It was found that the occurrence of a Gram-negative infected pancreatic 
necrosis in patients with severe acute pancreatitis is a very severe ominous sign. Using 
Cox-regression, with type of infection of the necrosis as a time-dependent factor, it 
turned out that the observed smaller mortality using Adjuvant Selective Deconta-
mination could be explained by a reduced incidence of such Gram-negative infections. 
Chapter 8 gives an account of an investigation of factors related to the risk of a 
spontaneous abortion among pregnant women scheduled for transabdominal chorionic 
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villus sampling. The risk of the procedure itself was assessed by considering patients 
who were still scheduled for the test to act as controls for those women who already 
underwent the procedure. An increased risk could not be demonstrated. 
The prognostic value of cytoimmunological monitoring of peripheral blood from 
patients who had received a heart transplant was investigated using Cox-regression 
with time-dependent variables as described in Chapter 9. The critical event considered 
was the first occurrence of a rejection episode. It is concluded that the method is not 
able to replace the currently required invasive method of taking a biopsy. 
In Chapter 10 the monitoring value of various Doppler measurements in growth 
retarded fetusses in relation to the occurrence of abnormal Fetal Heart Rate traces is 
discussed. Using Cox-regression with the time-dependent serial Doppler measure-
ments, it was possible to derive a prognostic index regarding the risk of abnormal 
fertal heart rate traces. 
In Chapter II the prognostic value of serially performed ultrasound measurements of 
the prostate, in addition to other factors, was investigated in prostatic cancer patients 
who received endocrine treatment. 
A general discussion of the statistical methodology of the assessment of prognostic 
factors in clinical medicine is presented in Chapter 12. 
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Samenvatting 
De verschillende IVijzen IVaarop kennis omtrent prognostische factoren in de k1inische 
geneeskunde van belang kan zijn worden besproken in Hoofdstuk 1. Enkele bekende 
prognostische stadieringssystemen voor enkele specifieke ziekten worden toegeIicht. 
Enige belangrijke theoretische statistische ontlVikkelingen op het gebied van IVat 
gebruikelijk wordt aangeduid met Overlevingsanalyse worden besproken in Hoofdstuk 
2. De nadruk is gelegd op het concept Uitvalstempofunctie (Hazard Rate Function). 
In vele gevallen is deze functie beter geschikt om het belang van patienten- of 
ziektekarakteristieken en/of interventies na te gaan dan de meer gebruikelijke 
Overlevingsfunctie. De flexibiliteit van Cox-regressie, door middel waarvan de 
prognostische waarde van meerdere factoren kan worden nagegaan, wordt benadrukt. 
Een studie over patienten met nierkanker wordt gepresenteerd in Hoofdstuk 3. 
Gebruikmakend van Cox-regressie werd het belang van diverse uitgangsvariabelen met 
betrekking tot de overleving van geopereerde patienten nagegaan. Naast geslacht en 
het gegeven of de vena renalis was aangetast door de tumor, bleek het niveau van de 
bloedbezinking een belangrijke indicator voor de prognose te zijn. 
Cox-regressie speelde een belangrijke rol bij de analyse van mogelijke nadelige 
effecten van bloedtransfusies met betrekking tot de prognase bij patienten die 
geopereerd werden voor dikke darm of rectum kanker zaals beschreven in Hoofdstuk 
4. De voornaamste bevinding in cen gerandomiseerde klinische studie was dat er geen 
significante verschillen waren wat betreft recidiefkansen en overleving tussen patien-
ten die voor de operatie bloed hadden afgestaan en patienten die op de gebruikelijke 
wijze allogeen bloed kregen indien nadig. Er werd ook gevonden dat patienten die 
bloedtransfusies nodig hadden een slechtere prognase hebben dan zij die geen 
bloedtransfusies nadig hadden. Dit gold in gelijke mate voar beide typen bloedtransfu-
sics. 
Een andere studie is beschreven in Hoofdstuk 5. Verschillende variabelen werden 
geevalueerd met Cox-regressie betreffende hun prognostisch belang bij patienten die 
geopereerd waren voor slokdarmkanker. De berekening van het absolute nSlco op 
slikklachten ten gevolge van een recidief van de ziekte is besproken in een appendix 
van dit hoofdstuk. 
Hoofdstuk 6 bespreekt enkele voetangels en klemmen met betrekking tot de evaluatie 
van factoren waarvan het niveau kan veranderen gedurende de follow-up. Theoreti-
sche ontwikkelingen van diverse relevante methoden, waaronder Cox-regressie met 
tijds-afhankelijke variabelen, om dergelijke evaluaties betrouwbaar uit te kunnen 
vaereD, worden besproken. 
In Hoofdstuk 7 wordt een studie gepresenteerd welke een analyse taont gebruikma-
kend van tijds-afllankelijke varia belen. Er werd gevonden dat het optreden van gram-
negatieve infecties van alvleeskliernecrose bij patienten met acute pancreatitis een 
ongunstig voorteken is. Met Cox-regressie, waarbij type infectie van de alvleesklier-
necrose de rol van tijds-afllankelijke variabele vervulde, bleek dat de gevonden lagere 
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mortaliteit bij het gebruik van Selectieve Darm Decontaminatie verklaard kan worden 
door een lagere incidentie van zulke gram-negatieve infecties. 
Hoofdstuk 8 geeft een bespreking van een onderzoek naar factoren die gerelateerd 
zijn aan het risico op spontane abortus onder zwangere vrouwen die een transabdomi-
nale vlokkentest zouden ondergaan. Het risico van de procedure zelf werd nagegaan 
door die vrouwen die een afspraak hadden staan voor het onderzoek te beschouwen 
als controlepatienten voor diegenen die de test reeds ondergaan hadden. Een 
verhoogd risico ten gevolge van de procedure kon niet worden aangetoond. 
De prognostisehe waarde van cytoinununologische testen van perifeer bloed bij 
patienten die een harttransplantatie hadden ondergaan werd met behulp van Cox-
regressie met tijdsafllankelijke variabelen onderzoeht zoals besehreven in Hoofdstuk 9. 
De concIusie luidt dat de methode niet geschikt is om als vervanging te dienen voor 
de huidige invasieve methode van het nemen van biopten uit het hart om een 
afstoting te kunnen vaststellen. 
In Hoofdstuk 10 wordt de waarde van diverse Doppler metingen bij groeivertraagde 
foetussen onderzocht wat betreft hun vennogen om het optreden van faetale nood te 
vQorspellen. Door middel van Cox-regressie, met de seritHe Doppler metingen als 
tijds-afllankelijke variabelen, was het mogelijk een prognostische index te ontwikkelen 
met betrekking tot het optreden van foetale nood. 
In Hoofdstuk 11 werd, additioneel op andere faetoren, de prognostische waarde van 
seriele eehografisehe metingen van de prostaat onderzoeht bij prostaatkanker 
patienten die honnonaal behandeld werden. 
Een algemene besehouwing van de statistisehe methoden die relevant zijn voor het 
evalueren van prognostische factoreD in de klinische geneeskunde wordt gegeven in 
Hoofdstuk 12. 
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